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Abstract 
 
Lentiviruses  stably  integrate  their  genome  into  the  host  genome.  Although  this 
feature can be advantageous for long term transgene expression, it also has the potential to 
cause mutagenesis and cell transformation. To address this problem, thereby improving the 
safety  of  lentiviral  gene  therapy,  non-integrating  lentiviral  vectors  (NILVs)  were 
developed. 
NILVs  were  generated  by  mutating  the  cis-acting  sequences  that  interact  with 
integrase  (att  sites)  or  by  mutating  specific  residues  in  integrase  in  different  domains 
(catalysis - D64V, strand transfer – Q148A, K264R, K266R, K273R, DNA or chromatin 
binding -  N120L, W235E). Relevant mutations were then combined in order to improve 
the safety of these vectors. 
It was shown that all mutant vectors were efficiently produced and mutations did 
not affect infectivity. In contrast to dividing cells, differentiated muscle cells infected with 
NILVs show stable transgene expression over time without degradation of episomal viral 
DNA. The vectors were also tested in vivo by intramuscular injection in neonate mice. 
Transgene  expression  from  muscle  cells  was  maintained  for  8  months  using  both 
integrating and NILVs.  
The vectors were then tested in a haemophilia B disease model. It was shown that 
plasma levels of FIX produced by muscle cells infected with integrating lentiviral vectors 
were above the therapeutic threshold. However, expression from NILVs was lower. This 
was  studied  in  detail  and  it  was  found  that  integrating  lentiviral  vectors  are 
transcriptionally more active than NILVs. A comparison of expression levels revealed that 
integrated lentivectors express more transgene protein per vector copy than NILVs and 
AAV vectors, but both episomal vectors display similar levels of transgene expression per 
vector copy. 
In conclusion, NILVs have the potential to be used as tools for prolonged transgene 
expression in non-dividing muscle cells or transient expression in dividing cells. However, 
vectors may need to be optimised if high expression levels are required. 
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1 – Introduction 
 
  The understanding of molecular pathologies and the development of vectors that 
can mediate transfer of DNA into cells created a new approach in the treatment of diseases 
(Friedman and Roblin, 1972). Thus, gene therapy can be defined as a technique used for 
the delivery of genetic material into cells. Translation of this technology to clinic was 
initially disappointing but gene therapy became accepted as a new tool in medicine when 
reports  of  clinical  trials  showed  that  a  clear  clinical  benefit  was  achieved  using  this 
technique (Aiuti et al., 2002; Cavazzana-Calvo et al., 2000; Gaspar et al., 2004; Ott et al., 
2006). 
The first clinical trial was initiated in 1989 in the United States. The aim was the 
treatment  of  patients  with  advanced  cancer  with  autologous  tumour  infiltrating 
lymphocytes modified  with  a retroviral  vector. This  study demonstrated the  successful 
introduction of a gene coding for the resistance to Neomycin by retroviral transduction 
(Rosenberg et al., 1990). Over the last 20 years, more than 1400 clinical trials have been 
approved, with cancer being the target disease in more than 65% of the studies. Other 
applications where gene therapy has been used in clinical trials are cardiovascular diseases, 
inherited monogenic disorders and infectious diseases.  
In order to improve this technology, it is clear that a profound understanding of the 
mechanisms employed by the vectors is necessary to achieve efficient gene delivery and 
expression.  This  introduction  will  then  focus  on  the  biology  of  viruses  and  the 
development of viral based vectors. Particular attention will be given to lentiviruses, which 
were the vectors under research in this project. Adeno-associated viruses (AAV) will also 
be reviewed as they were used in the work presented here. Adenoviruses will be covered 
because  vectors  based  on  this  virus  represent  an  important  tool  for  gene  therapy  (one 
quarter of the total gene therapy trials have used these vectors). 
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1.1 – Retroviruses 
1.1.1 – Biology of Retroviruses 
 
  Retroviruses comprise a large family of viruses that have particular features: their 
genome is a single-stranded RNA molecule that serves as a template for the formation of 
double-stranded DNA, in a process called reverse transcription, and subsequent integration 
into the genome of the host. 
 
1.1.2 – Taxonomy 
 
  In the latest convention, the family Retroviridae is divided into seven genera (Index 
of Viruses - Retroviridae, 2006). Genetic structure and virion morphology are the main 
characteristics  by  which  viruses  are  divided  into  each  group  (Table  1.1).  Due  to  their 
importance  in  gene  therapy,  particular  focus  will  be  given  to  gammaretroviruses  and 
lentiviruses in this introduction. 
 
 
Table 1.1: Genus of the Retroviridae family 
Genus  Species example  Virion morphology  Genome 
Betaretrovirus  Mouse mammary tumour 
virus 
eccentric, spherical core  simple 
Gammaretrovirus  Murine leukaemia virus 
(MLV) 
concentric, spherical core  simple 
Alpharetrovirus  Avian leukosis virus  concentric, spherical core  simple 
Deltaretrovirus  Bovine leukaemia virus  concentric, spherical core  simple 
Lentivirus  Human immunodeficiency 
virus I (HIV 1) 
concentric, cone-shaped 
core 
complex 
Epsilonretrovirus  Walleye dermal sarcoma 
virus 
concentric, spherical core  simple 
Spumavirus  Human foamy virus  central, spherical core  complex 
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1.1.3 – Retroviral pathogenesis 
 
Retroviruses  are  associated  with  a  wide  number  of  diseases,  such  as  cancer, 
neurological disorders and immunodeficiencies. Nowadays, the best known example of a 
disease induced by a retrovirus is acquired immunodeficiency syndrome (AIDS), caused 
by HIV. However, it was much earlier, in the beginning of the 20
th century, that leukaemia 
and sarcoma were demonstrated to be induced in chickens within days of infection by 
transmissible  agents,  later  shown  to  be  the  retroviruses  avian  leucosis  virus  and  Rous 
sarcoma virus, respectively. 
Many retroviruses, including MLV induce tumours. Acutely transforming viruses 
contain oncogenes (v-onc) in their genome, but it has been shown that the origin of v-onc 
genes is in fact, cellular (c-onc) (Stehelin et al., 1976). This was an important find in 
cancer  research  that  lead  to  the  discovery  of  many  cellular  oncogenes.  These  viruses 
acquired at some point c-onc sequences by recombination and upon infection, they deliver 
these genes to the target cells, leading rapidly to cell transformation. However, when the 
oncogene  is  incorporated  into  the  viral  genome,  some  of  the  viruses  are  rendered 
replication defective due to loss of viral sequences. 
Several retroviruses that cause tumours do not contain an oncogene in their genome 
and are replication competent. Transformation arises with the integration of the provirus in 
the host genome. This integration can activate proto-oncogenes, either by transcription 
from the viral promoter (Shen-Ong et al., 1986) or from activation of cellular promoters by 
the viral enhancer (Lazo et al., 1990), leading to cell transformation. The provirus could 
also  be  inserted  within  transcription  units,  resulting  in  coding  sequence  disruption  or 
premature  termination  of  the  transcript.  The  resulting  cellular  protein  can  then  lack 
important  negative  regulatory  domains,  generating  a  constitutively  active  oncoprotein 
(Ceci et al., 1997). Another described mechanism by with the provirus integration can 
induce transformation is the stabilisation of RNA by the disruption of AU-rich elements 
that reduce the half life of mRNA. The mRNA remains in the cytoplasm for a longer 
period of time, leading to an increased protein translation (Selten et al., 1985). 
HIV was first isolated in 1983 (Barre-Sinoussi et al., 1983). When this lentivirus 
infects  a host, an acute immunosupression may develop  and,  as  a result, opportunistic   19 
infections may arise. However, HIV infection can be asymptomatic for many years. During 
this time, there is a gradual decline of CD4
+ T cells and the host becomes more susceptible 
to  opportunistic  infections  such  as  pneumonia  (caused  by  Pneumocystis  carinii 
pneumonia),  Kaposi  sarcoma  (caused  by  Herpes  simplex  virus  8),  Non-Hodgkins 
lymphoma and anogenital cancers (reviewed in Boshoff and Weiss, 2002). 
HIV replicates most efficiently in activated CD4
+ T cells. However, these cells 
have a short life-span of a few days, so latent infection is established in resting/quiescent 
memory CD4
+ T cells and dendritic cells (DCs). These cells do not support replication 
during  latency,  but  are  important  reservoirs  for  the  provirus.  DCs  are  not  infected  as 
efficiently  as  CD4
+ T  cells,  but  they can  capture virions  via c-type lectins  in  the cell 
surface, storing them in intracellular compartments  without degradation of the viruses. 
Upon migration to the lymph node, DCs can then transfer these infectious virions to CD4
+ 
T cells via cell-to-cell contact (McDonald et al., 2003). Afterwards, the viruses can rapidly 
disseminate  to  other  lymphoid  compartments.  The  infected  CD4
+  T  cell  population  is 
destroyed by direct cytopathic effect of the virus and it is now thought that the initial drop 
in viremia is a consequence of the exhaustion of the pool of these cells (Phillips, 1996). 
This population is then replenished by naïve and central memory T cells that had not been 
infected  with  the  virus,  stimulating  a  generalised  state  of  immune  activation.  These 
activated CD4
+ T cells provide a source for HIV replication and it is thought that the loss 
of this ability to regenerate effector memory T cells leads to the eventual drop in overall 
CD4
+ T cells number, increasing the susceptibility for opportunistic infections (reviewed 
in Picker, 2006). 
 
1.1.4 – Genome Structure 
   
The general genome organisation of retroviruses comprises the genes gag, pol and 
env, flanked by the unique 3’ (U3) and repeat (R) sequences downstream and R and unique 
5’ (U5) upstream  (Figure 1.1).  In the provirus DNA, the genes  are flanked by  a long 
terminal  repeat  (LTR),  which  can  be  segmented  into  U3-R-U5.  These  sequences  are 
formed  upon  reverse  transcription,  due  to  the  jumps  of  the  reverse  transcriptase  (RT) 
between templates. U3 contains most of the transcription control elements, including the   20 
promoter and enhancer sequences. The polyadenylation site lies between the R and U5. 
Therefore,  the  promoter  is  only  upstream  of  the  coding  sequences  after  reverse 
transcription (Hughes et al., 1978; Shinnick et al., 1981). 
The gag gene encodes for the structural proteins of the virion, such as matrix (MA), 
capsid (CA) and nucleocapsid (NC).  pol encodes for the viral enzymes protease (PR), 
reverse transcriptase (RT) and integrase (IN). The transmembrane (TM) and surface (SU) 
glycoproteins found in the envelope of the virus are encoded by the env gene. 
Complex  retroviruses  contain  additional  genes.  HIV  1,  for  example,  has  the 
regulatory genes tat and rev and the accessory genes nef, vpu, vpr and vif. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Representation of the genomic organisation of the retroviral genomes  
A: MLV; B: HIV 1. 
 
1.1.5 – Virion structure 
 
  The particle structure (virion) reflects the ability of retroviruses to infect new host 
cells,  providing  a  safe  and  relatively  stable  environment  outside  cells  for  the 
accommodation of their genome. The structural proteins of the retroviruses condense the 
viral genome into a RNA-protein complex that is packaged into protein shells.  
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The particles of the RSV were described first in 1947, but only after a few years 
and with techniques employing electron microscopy, the ultrastructure of retroviruses was 
validated  (Gaylord,  1955).  Mature  particles  measure  between  80-120nm,  have  a  dense 
core, that can be cone-shaped (as for HIV-1) or round-shaped (as for MLV) and an outer 
lipidic membrane. 
The envelope contains the viral glycoproteins TM anchoring SU. These multimers 
can form spikes projecting towards the outside of the particle. Matrix lies just underneath 
the envelope. Further inside, the capsid proteins form a shell, defining the outer layer of 
the virion core. Inside the core are the nucleocapsid-RNA complex and also other proteins 
such as RT and IN. Two RNA copies are packaged in each virion. A model of the HIV 
virion structure can be seen in Figure 1.2. The virions additionally contain proteins derived 
from the host cell (Arthur et al., 1992). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Model of a retrovirus structure: the mature HIV virion 
Env proteins are shown jutting out from the lipid membrane. The cone-shaped core is also 
represented. Not all proteins incorporated in virion particles are shown in this model. Viral 
proteins in this model: surface glycoproteins (SU), transmembrane glycoproteins (TM), 
matrix  (MA),  capsid  (CA),  nucleocapsid  (NC),  retroviral  protease  (PR),  reverse 
transcriptase (RT) and integrase (IN). 
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1.1.6 – Virus Life cycle 
1.1.6.1 – Entry 
 
  The first step in the virus life cycle is the entry of the virion in the target cell. The 
SU protein protrudes from the particle and makes a contact with specific receptors in the 
target cell. The receptors define the target cells and host of each virus. Virions lacking the 
envelope  glycoproteins  are  non-infectious  and  cells  lacking  the  receptor  are  non-
permissive towards the virus. 
  The disease that HIV induces in humans is characterised by the depletion of a 
subset of T-cells. This specificity was correlated with the ability of infection of CD4
+ 
lymphocytes. The primary receptor of HIV-1 was thus identified as CD4, a cell surface 
marker of helper T cells that is also expressed on monocytes, macrophages and dendritic 
cells  (Dalgleish  et  al.,  1984;  Klatzmann  et  al.,  1984).  Direct  evidence  was  shown  by 
Maddon  and  colleagues,  upon  expression  of  this  receptor  in  HeLa  cells,  changing  the 
permissivity of these cells towards HIV-1 (Maddon et al., 1986). Nonetheless, since not all 
human cells expressing the CD4 are infected with HIV-1, this virus requires an additional 
receptor  for  efficient  fusion.  The  chemokine  receptors  CXCR4  (Feng  et  al.,  1996)  or 
CCR5 (Deng et al., 1996; Dragic et al., 1996) were shown to be required as co-receptors to 
mediate membrane fusion.  
After the initial binding between SU and the receptor, fusion is mediated by the TM 
protein,  as  a  result  of  conformational  changes.  Interestingly,  the  glycoprotein  of  the 
Vesicular stomatitis virus (rhabdoviridae family), a commonly used glycoprotein for the 
production of viral vectors, requires the acidic environment of the endosome to activate 
fusion. For that virus, after initial contact with the cell receptor, it is taken into coated pits, 
undergo endocytosis and fusion happens between the virus and the endosome membranes. 
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1.1.6.2 – Uncoating  
 
The  fusion  of  viral  and  cellular  membranes  delivers  the  viral  core  into  the 
cytoplasm, where uncoating and reverse transcription takes place. Disassembling of virus 
capsid appears to be essential for progress of reverse transcription but is one of the least 
known processes of retroviruses. 
Cyclophilin A, a host protein, is thought to be involved in the entry or uncoating 
process of HIV. This protein binds to CA (Luban et al., 1993) and the inhibition of this 
interaction  reduces  virion  infectivity  in  a  step  prior  to  reverse  transcription  but  after 
receptor binding and membrane fusion (Braaten et al., 1996; Franke et al., 1994).  
The  uncoating  of  HIV  is  rapid,  in  contrast  to  MLV  where  the  CA  protein  is 
associated with the reverse transcription complex (RTC) throughout reverse transcription 
(Fassati and Goff, 1999; Fassati and Goff, 2001). Nevertheless, the RTC in both viruses 
contain at least IN and RT and also Vpr, MA and NC for HIV (Bukrinsky et al., 1993; 
Nermut and Fassati, 2003). 
 
1.1.6.3 – Reverse transcription 
 
Reverse transcription is the hallmark of the Retroviridae and is performed by the 
viral enzyme reverse transcriptase (RT). RT possesses RNA- and DNA-dependent DNA 
polymerase activity (Baltimore, 1970; Temin and Mizutani, 1970) and also an ribonuclease 
(RNase H) domain that degrades RNA in RNA:DNA duplexes (Molling et al., 1971). 
Reverse transcription initiates with the annealing of a tRNA primer to the viral 
genomic RNA. All retroviruses encapsidate host tRNA and virions contain a large excess 
of 50-100 free different tRNA molecules. Nevertheless, the use of a specific tRNA for 
primer is different between genera. HIV-1 uses tRNA
Lys3 (Jiang et al., 1993) for reverse 
transcription initiation whereas MLV uses tRNA
Pro (Peters et al., 1977).  
The primer binds to a region called the primer binding site (PBS) and the viral 
enzyme initiates the synthesis of a negative single stranded DNA. Although initiation can 
occur  inside  the  virion  (Trono,  1992),  extension  and  completion  of  the  process  is 
accomplished in the cytoplasm of the host cell.   24 
After initiation, synthesis proceeds to the 5’ end of the viral genome, so the unique 
in  5’  (U5)  and  repeat  (R)  regions  are  encoded  on  this  minus-strand  strong  stop  DNA          
(-sssDNA). Reverse transcriptase degrades the RNA template afterwards with its Rnase H 
activity. The R region is redundant in the viral genome (hence its name), allowing for a 
jump of the -sssDNA from the R in 5’ to the R in 3’ of the viral genome (Mitra et al., 
1979) once the RNA that served as template has been degraded (Tanese et al., 1991). After 
this  strand  transfer,  the  -sssDNA  is  extended  up  to  the  5’  of  the  template  RNA.  RT 
degrades the template RNA while it is forming the -DNA strand except in the polypurine 
tract (PPT). This RNA sequence is then used for initiation of the +DNA strand (Sorge and 
Hughes, 1982; Finston and Champoux, 1984; Smith et al., 1984). Additionally, other RNA 
sequences, such as the central polypurine tract (cPPT) in HIV, are not degraded and are 
also used as primers for +DNA strand synthesis, creating discontinuous DNA products 
(Charneau and Clavel, 1991; Varmus et al., 1978). The +DNA strand is then synthesised 
using  the  -sssDNA  as  a  template,  stopping  at  the  tRNA  primer.  The  tRNA  primer  is 
degraded by the RNase H activity of RT, facilitating an intramolecular second jump. Under 
the current accepted model, the PBS region at the 3’end of the -DNA strand anneals to the 
complementary PBS of the +DNA strand, allowing extension of the -DNA strand using the 
+DNA strand as a template. In this way, the U3, R and U5 regions are duplicated, forming 
the LTR of the viral DNA. The +DNA strand is also extended, using the -DNA strand as a 
template, completing the reverse transcription process. The final product is a blunt-ended 
double stranded DNA that serves as a template for integration (Brown et al., 1989). A 
schematic representation of the process can be seen in Figure 1.3. 
In HIV, the synthesis of the +DNA strand initiated at the PPT displaces the plus 
strand initiated at the cPPT. The displacement creates a discontinuous DNA (DNA flap), 
that appears to be important in steps of the virus life cycle posterior to reverse transcription 
(Charneau et al., 1994). The discontinuous DNA is efficient for integration. Therefore it is 
possible that cellular host proteins complete the DNA synthesis (Miller et al., 1995).   25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Overview of the reverse transcription process 
a) minus strand DNA synthesis initiated from the annealed tRNA primer to the primer 
binding site (PBS) in the RNA genome by the reverse transcriptase (RT);  b) Rnase H 
degradation of the R and U5 sequences in the genomic RNA; c) first strand transfer, with 
annealing of the -sssDNA R sequence to the complementary R in the 3’RNA, -DNA strand 
synthesis with further digestion of RNA template, except for the polypurine tract (PPT); d) 
tRNA removal by Rnase H activity, synthesis of +DNA with the PPT as primer; e) second 
strand transfer through the annealing of the PBS region; f) reverse transcription with strand 
displacement. Grey boxes and letters represent regions of the genomic RNA, white boxes 
represent provirus DNA. 
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1.1.6.4 – Nuclear entry 
 
While the reverse transcription takes place, the RTC migrates to the nucleus, using 
the cellular cytoskeleton. Initial movements of the virus occur in association with the actin 
cytoskeleton,  but  subsequent  translocation to  the nucleus occurs  along the microtubule 
network (Arhel et al., 2006). It is likely that when the RTC reaches the nucleus, reverse 
transcription is finished and RT disassociates from the complex, reducing the size of the 
complex, allowing the translocation through the nuclear pore (Bukrinsky, 2004).  
The  mechanism  of  nuclear  import  of  the  viral  DNA  is  still  unknown. 
Gammaretroviruses, such as MLV require mitosis to access the nucleus and thus, these 
viruses can only infect dividing cells (Roe et al., 1993). However, lentiviruses can infect 
both dividing and non-dividing cells with similar efficiency (Weinberg et al., 1991; Lewis 
et al., 1992). 
In lentiviruses, it is probable that nuclear import requires the use of the nuclear pore 
complex. Nonetheless, a mechanism of disruption of the nuclear membrane by Vpr has 
also been proposed (De Noronha et al., 2001). Nuclear cellular proteins contain a nuclear 
localisation signal (NLS). MA, IN and Vpr are associated with the viral DNA, in the pre-
integration complex (PIC) and are candidates for nuclear import as they have putative 
NLS. Mutations in the putative NLSs have shown reduced nuclear import of viral DNA, 
although replication was not impaired (Yamashita and Emerman, 2005). The DNA flap has 
been also implicated in nuclear import (Zennou et al., 2000). Nevertheless, absence of the 
cPPT and hence the lack of the DNA flap, was shown to only reduce viral infectivity 
(Dvorin et al., 2002). Some experiments have not been replicated by other labs and some 
experiments are still debated, so consensus has not been reached yet about the mechanism. 
Possible models proposed imply that nuclear import involves more than one karyophilic 
protein or a still unknown NLS for binding to cellular nuclear importins and that the DNA 
flap gives the best conformation for nuclear import (Bukrinsky, 2004). Other hypothesis 
rely on the velocity of the uncoating process of the lentiviruses and also the cell cycle of 
the target cell (Yamashita and Emerman, 2006). Additionally, cellular factors have been 
shown to be involved in the nuclear import of HIV-1, including importin 7 (Fassati et al., 
2003)  and  a  3’  CCA  deficient  tRNA  species  that  is  incorporated  into  HIV-1  virions 
(Zaitseva et al., 2006).   27 
1.1.6.5 – Integration 
 
Integration  of  the  provirus  into  the  host  DNA  is  an  important  step  of  the 
retroviruses life cycle. It ensures that the provirus DNA is replicated along with the host 
DNA and transmitted to the progeny as an element of the host chromosomes (Hughes et 
al., 1978; Temin, 1964). 
The  32kDa  viral  integrase  is  the  key  protein  in  integration.  This  protein  is  a 
cleavage product of the gag-pol polyprotein and contains three major domains. The N-
terminal domain contains a zinc binding motif (HHCC) (Johnson et al., 1986). IN can 
indeed bind a zinc ion (Burke et al., 1992) and zinc promotes multimerisation of IN and 
increases  the  enzymatic  activity  (Zheng  et  al.,  1996).  In  the  central  domain  lies  the 
catalytic core, the conserved DD35E motif (Engelman and Craigie, 1992). The C-terminal 
domain has DNA binding properties (Mumm and Grandgenett, 1991). IN binds the viral 
DNA in the attachment sites (att), which are conserved CA dinucleotides situated at the 
end of the LTR (Sherman and Fyfe, 1990).  
Integration occurs in two catalytic steps. In the first, known as 3’-processing, IN 
cleaves and removes a dinucleotide adjacent to the att sites and at the end of the viral DNA 
(Katzman et al., 1989). This reaction occurs in the cytoplasm within the pre-integration 
complex. The second catalytic step, called strand transfer, happens in the nucleus. Here, IN 
mediates a concerted nucleophilic attack by the 3’-hydroxyl residues of the viral DNA on 
phosphodiester bridges located on either side of the major groove in the target DNA and a 
transesterification  reaction  where  the  viral  3’  ends  are  ligated  to  the  5’-O-phosphate 
residues of the target DNA (Bushman and Craigie, 1991). In the final step of integration, 
which is probably mediated by cellular enzymes, the unpaired dinucleotides from the 5′ 
ends of the viral DNA are removed and the single-stranded gaps created between the viral 
5’end  and  target  DNA  are  filled.  Figure  1.4  represents  a  schematic  overview  of  the 
integration process. In lentiviruses, the sites of integration in the target DNA are separated 
by five bases. Therefore, there is a duplication of these bases in the final product, so the 5’ 
and 3’ ends of the integrated DNA are flanked by the same 5 bases (Craigie, 2001). For 
MLV, the repeats flanking the integrated proviruses have 4 bases (Van Beveren et al., 
1980). 
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Figure 1.4: Overview of the integration process 
Viral DNA is represented in black, host DNA in green and viral integrase in purple. In the 
cytoplasm, two dinucleotides on the 3’ of each viral DNA strand are removed by integrase 
(3’processing). In the nucleus, integrase mediates a nucleophilic attack by the hidroxyl 
residues in  the viral  DNA strand on the phosphodiester bridges  of the host DNA  and 
ligation of the two DNA molecules (DNA strand transfer). The removal of the unpaired 
viral dinucleotides on the 5’ viral DNA strand and filling of the single stranded gaps in the 
host genome (DNA repair) is thought to be mediated by host proteins.  
 
 
In addition to the integrated provirus, there are other extrachromosomal viral DNA 
species (Gianni et al., 1975; Varmus et al., 1974). These molecules can either be linear or 
circular. The later can have one LTR (formed by homologous recombination between the 
two LTRs) or two LTRs produced by non-homologous end-joining of the double stranded 
blunt viral DNA produced upon reverse transcription (Ju and Skalka, 1980). Additionally, 
there are other viral DNA circles produced by an intramolecular integration when the viral 
ends of a DNA molecule uses itself as a target (Shoemaker et al., 1980). The formation of 
circular genomes is thought to occur in the nucleus. As a consequence, these molecules 
have been used to quantify nuclear viral DNA. It was thought that these molecules were 
by-products of integration, but recent finding suggested that this non-integrated viral DNA   29 
could support transcription (Brussel and Sonigo, 2004; Engelman et al., 1995; Poon and 
Chen, 2003; Wu and Marsh, 2003). 
The integration site potential of the provirus is very big, spanning virtually the 
whole of the host genome (Withers-Ward et al., 1994). Nonetheless, it appears that each 
virus  has  specific  preferential  sites.  HIV  provirus  has  been  shown  to  integrate 
preferentially  anywhere  within  transcriptional  units,  particularly  in  highly  active  genes 
(Mitchell et al., 2003; Schroder et al., 2002). MLV has a different integration pattern. This 
virus strongly favours CpG islands (whereas HIV does not) and integrates the provirus 
preferentially  near  transcription  start  sites  (either  upstream  or  downstream)  of  actively 
transcribed genes (Wu et al., 2003). The differences in the selection of integration target 
sites may be due to the viral integrase, cellular proteins or regional features in the target 
DNA. 
It  has  been  shown  that  integration  in  nucleosomes  occurs  more  efficiently 
compared with nucleosome-free regions and that preferential targets occur where the major 
grove is exposed. Also, integration is prevented in regions occupied by site-specific DNA-
binding proteins (Pryciak and Varmus, 1992). 
Several  cellular  proteins  are  known  to  bind  the  pre-integration  complex  and 
therefore may regulate the preferential target site for integration. Lee and Craigie have 
shown that there is a cellular protein bound to the PIC that prevents the “suicidal” auto-
integration, called barrier-to-autointegration factor (BAF) (Lee and Craigie, 1994; Lee and 
Craigie, 1998). Also, the lamina-associated polypeptide 2ʱ (LAP2ʱ) interacts with BAF 
and was recently shown to be a component of the MLV PIC. The depletion of LAP2ʱ in 
cells  decreased  MLV  replication,  demonstrating  a  contribution  to  the  nucleoprotein 
organisation of the PIC (Suzuki et al., 2004). However, LAP2ʱ was shown to be required 
for infection of cells by HIV with the wild-type envelope but not with a VSVg envelope 
pseudotype. In the same study, it was also demonstrated that emerin, an integral inner-
nuclear-envelope protein and a binding partner of BAF, is required for efficient integration 
of the HIV provirus in cells but not MLV DNA. When cells are depleted of emerin or 
BAF, HIV episomal DNA circles are accumulated in the nucleus but not integrated in the 
host chromosome. Therefore, HIV and MLV use different inner-nuclear-envelope proteins 
to co-localise with chromatin (Jacque and Stevenson, 2006). Another protein localised in   30 
the  PIC  is  the  high  mobility  group  chromosome  protein  A1  (HMGA1),  a  non-histone 
DNA-binding protein that can modulate transcriptional regulation and chromatin structure 
(Farnet and Bushman, 1997). HMGA1 may not be required for integration, but it has been 
implicated in transcription of the viral genome (Beitzel and Bushman, 2003; Henderson et 
al., 2000). A cellular protein (integrase interactor – INI 1) was found to bind tightly to IN 
and stimulates its DNA-joining activity (Kalpana et al., 1994). Nonetheless, up until now, 
there is no evidence for a possible role of the INI 1 in integration in cells. Lens epithelium 
growth  factor  (LEGF/p75)  was  also  shown  to  associate  tightly  with  the  HIV  IN 
(Cherepanov et al., 2003). A integrase mutant (Q168A) defective for LEGF/p75 binding 
failed to integrate the provirus but not nuclear import of viral DNA, demonstrating the 
importance of this cellular factor in the integration process (Emiliani et al., 2005). The 
analysis of integration sites in LEGF/p75 depleted cells, showed that integration sites are 
less  frequent  in  transcription  units  and  in  LEGF/p75  regulated  genes,  compared  with 
integrants in cells that have normal amounts of this factor  (Ciuffi et al., 2005). These 
results revealed the first cellular protein that influences the integration site selection. 
The viral integrase is also an important factor for site integration selection. This 
was well demonstrated by the Bushman group. A chimeric HIV virus containing a MLV 
integrase caused the hybrid to integrate the viral DNA with a specificity close to the MLV 
virus (Lewinski et al., 2006). Also, an HIV integrase fused to a sequence-specific DNA 
binding  protein  was  found  to  direct  integration  selectively  to  targets  where  the  fused 
protein binds (Bushman, 1994; Bushman and Miller, 1997).  
 
1.1.6.6 – Retroviral transcription and nuclear export 
 
Once integrated in the host cell genome, the provirus behaves like a normal host 
gene, thus relying on the cell machinery for transcription and expression. Therefore, the 
retroviral genome needs to have all the cis-acting elements necessary for interaction with 
the host machinery. These are contained in the viral LTR. 
Viral RNA molecules are transcribed by the host RNA polymerase II. The full 
length  genomic  RNA  transcriptional  start  is  located  at  the  5’  end  of  R  at  the  5’LTR, 
defining the upstream R boundary, and a 3’-end processing event is located at the 3’ end of   31 
R in the 3’LTR, which defines the downstream R boundary. Therefore, the genomic RNA 
organisation is R-U5-gag-pol-env-U3-R. 
The production levels of viral RNA are important. In simple retroviruses, such as 
MLV,  transcription  is  regulated  by  the  host  and  so,  depends  on  the  cell  cycle  and 
differentiation  stage  of  cell.  In  cells  actively  producing  virus,  the  viral  RNA  levels 
increase. As an example, cells infected with RSV may contain viral RNA reaching up to 
10% of all of the cellular mRNA (Lee et al., 1979). However, in complex virus, such as 
HIV, the transcription is also controlled by viral proteins. 
The LTRs provides the cis elements where transcription factors bind to repress or 
augment transcription. In MLV, the U3 region of the LTR can be divided into an enhancer 
and a promoter. The promoter contains the TATA box, necessary for the binding of the 
RNA polymerase II and transcription initiation. The enhancer contains numerous binding 
sites  for  cellular  transcription  factors  and  many  of  them  are  closely  packed  or  even 
overlapping. The nature of these elements contributes for the tissue specific regulation of 
transcription.  The  enhancer,  apart  from  activating  the  LTR  promoter,  is  also  able  to 
activate cellular promoters over large distances, accounting for one of the mechanisms of 
insertional mutagenesis (Bartholomew and Ihle, 1991; Lazo et al., 1990). 
Apart from cellular transcription factors, HIV also encodes a trans-activator protein 
(Tat) that confers tight control over transcription. This additional control may explain the 
ability of the virus to produce latent infection. During the latent stage of lentiviruses, only 
low levels of viral transcripts encoding Tat are found. In the presence of other cellular 
transcription activators, Tat is produced, resulting in high levels of viral expression. This 
may  confer  an  advantage  as  continuous  production  of  high  levels  of  potentially  toxic 
proteins  could  induce  cell  death  before  productive  replication.  Additionally,  low  viral 
protein levels may suppress an effective host immune response. 
The  HIV  LTR  can  be  divided  into  4  functional  domains:  the  trans-activation 
responsive region (TAR), the core promoter, the enhancer region and the regulatory region. 
Several  host  transcription  factor  can  bind  the  LTR.  The  enhancer  contains  two  NFkB 
binding  sites  (Nabel  and  Baltimore,  1987),  important  for  efficient  gene  expression  in 
activated T-cells. In unstimulated T-cells, NFkB p50 homodimers occupy the binding sites 
in  the  enhancer  (Montano  et  al.,  1996).  Histone  deacetylase  1  is  bound  to  p50  and   32 
deacetylates the histones nucleosome 0 and 1, inhibiting the binding of RNA polymerase II 
(Williams et al., 2006). After T-cell stimulation, NFkBp65/p50 translocates to the nucleus 
due to phosphorilation and subsequence degradation of IkB that was restricting p65/p50 
heterodimers to the cytoplasm (Whiteside and Israel, 1997). The heterodimers displace p50 
in the viral enhancer. Additionally, they bind to acetyl transferase p300 that can acetylate 
the  nucleosome  1,  allowing  the  initiation  of  transcription  by  the  RNA  polymerase  II 
(Gerritsen et  al., 1997).  In the absence of Tat, although transcription  can be initiated, 
elongation is inefficient (Kao et al., 1987). However, NFkB p65/p50 can recruit TFIIH and 
p-TEFb that phosphorylates RNA polymerase II stimulating elongation (Barboric et al., 
2001; Kim et al., 2006). Upon Tat production, an increase of the levels of expression can 
be observed (Sodroski et al., 1985). Tat binds to a stable stem loop located in the 5’ of 
nascent viral transcripts (TAR). It recruits the host protein p-TEFb complex, including the 
subunit cyclin-dependent protein kinase 9 (Cdk9). Cdk9 hyperphosphorylates the  RNA 
polymerase II transcription complex, stimulating transcription elongation (Herrmann and 
Rice, 1995). 
The viral RNA molecules are modified with a 5’ cap of m7G5’ppp5’ (Keith and 
Fraenkel-Conrat, 1975) and by polyadenylation at the 3’ end (Lai and Duesberg, 1972). 
The provirus does not control the transcriptional stop, and transcription can carry on into 
flanking host sequences. If the processing of the 3’ viral end of transcripts containing host 
flanking sequences is not correct, those sequences can be translated and also packaged into 
the virion. This is another mechanism of insertional mutagenesis described for retroviruses, 
where a cellular oncogene is expressed at high levels due to insertion of the viral promoter 
in an adjacent site (Hayward et al., 1981; Shen-Ong et al., 1986). 
Apart from the genomic RNA, shorter RNA molecules are also produced (Fan and 
Baltimore,  1973).  These  RNA  molecules  are  the  product  of  RNA  splicing.  In  simple 
retroviruses,  apart  from  the  genomic  RNA,  a  single  spliced  RNA  transcript  is  also 
produced but in complex viruses, multiple spliced transcripts are found (Schwartz et al., 
1990). 
Cellular mRNAs containing introns and unspliced sites are normally retained in the 
nucleus. This poses a problem for retroviruses, as for efficient genomic RNA package and 
translation, the full length RNA need to be exported from the nucleus, especially during   33 
the replication stage of the virus. Simple retroviruses may contain cis-elements, termed 
constitutive export element (CTE) that allow the transport of such RNAs  (Bray et al., 
1994). Complex viruses have evolved a different mechanism for efficient unspliced RNA 
export. HIV encodes the Rev protein that regulates this process. This viral protein binds to 
a complex structure of 5 stem loops (the Rev-responsive element, RRE) in the viral RNA 
(Mann et al., 1994). Rev then recruits the cellular nuclear proteins Eukaryotic initiation 
factor 5A (Ruhl et al., 1993) and importin 1 (Neville et al., 1997). Importin 1 can bind the 
nuclear  export  factor  Ran  guanosine  triphosphatase  (Fornerod  et  al.,  1997).  Once 
assembled it is thought that this complex is competent to be exported from the nucleus into 
the cytoplasm. 
 
1.1.6.7 – Translation of viral proteins 
 
The  RNA  molecules  transcribed  from  the  provirus  resembles  host  mRNA. 
Therefore, translation of the viral proteins uses the host machinery. The ribosomes bind to 
the RNA and scan it towards the 3’ end until finding the initiation codon AUG in the kozak 
consensus sequence (Kozak, 1987). In some retroviruses, this sequence lays in a stable 
secondary structure of the RNA and an internal ribosomal entry site has been described for 
MLV (Berlioz and Darlix, 1995). 
All viral RNA transcripts are template for translation, including the genomic RNA. 
The translation of the full length genomic RNA produces a polyprotein containing the gag 
and pol genes. This gag-pol protein is produced by a bypass of the stop codon of gag. The 
mechanism used by MLV is read-through, where the ribosome recognises the stop codon 
as a sense codon (Yoshinaka et al., 1985). Another mechanism, used for the majority of 
retrovirus,  including  HIV,  is  ribosomal  frameshift,  where  the  ribosome  goes  back  one 
nucleotide  in  this  region  and  can  therefore  proceed  with  protein  synthesis  (Jacks  and 
Varmus, 1985). Using this strategy, only 5% of the total viral protein is gag-pol (Jamjoom 
et al., 1977). 
  After protein synthesis, gag and gag-pol proteins of most retroviruses are modified 
in the amino termini by the addition of a myristyl group to glycine (Henderson et al.,   34 
1983). This post-translational modification has been shown to be required for the binding 
of gag to the cellular membrane (Rein et al., 1986). 
  The envelope proteins are produced from a spliced RNA transcript. The nascent 
polyprotein  is  glycosylated  (Rifkin  and  Compans,  1971).  This  process  occurs  in  the 
endoplasmatic reticulum, as with typical host glycoproteins. Afterwards, the env protein is 
assembled in oligomeric structure and then transported to the golgi compartment, where it 
is cleaved by the cellular protease furin to form the TM and SU proteins  (Bradac and 
Hunter, 1986; Wills et al., 1984; Stein and Engleman, 1990; Hallenberger et al., 1992; 
Einfeld and Hunter, 1988). 
 
1.1.6.8 – Assembly, budding and maturation 
 
After synthesis, gag, gag-pol and env proteins need to come together at the cell 
membrane to assemble and incorporate the genomic RNA to produce infectious virions.  
Typically,  around  2000  molecules  of  gag  are  needed  for  particle  assembly 
(Stromberg et al., 1974) and gag alone is able to form virus-like particles, not containing 
any RNA, env or pol proteins (Gheysen et al., 1989). In MLV and HIV, this process occurs 
at the plasma membrane. The M domain, located in MA, is necessary to direct the gag 
proteins to the membrane (Yuan et al., 1993). Gag proteins must then join with each other 
to form the assembly site. This interaction is made through the I domain located in NC 
(Gheysen et al., 1989). However, for both MLV and HIV, the carboxy-terminal of CA may 
be required for additional interactions (Schwartzberg et al., 1984; Jowett et al., 1992).  
Gag-pol polyprotein is also directed to the assembly site through the signals in gag. 
Interestingly,  it  has  been  shown  that  gag-pol  alone  is  not  capable  of  forming  virions 
(Felsenstein and Goff, 1988). 
The RNA contains a sequence that forms a secondary structure necessary for the 
interaction with gag and incorporation to the virus particle. This sequence is called the 
packaging signal (Ψ) and it interacts with NC. In HIV, it is localised between the major 
donor and acceptor splicing sites. Therefore, only genomic unspliced RNA is packaged 
(Darlix et al., 1990).   35 
  Env  proteins  are  not  required  for  gammaretrovirus  or  lentivirus  budding,  but 
virions without env are not efficiently infectious. In HIV, it is thought that env proteins 
interact with MA in order to actively localise to the assembly site (Egan et al., 1996; Yu et 
al., 1992). 
Vpr is packed in the virion through interaction with the p6 region in gag (Lu et al., 
1993). On the other hand, Nef and Vif are thought to be incorporated non-specifically in 
the virion, although Nef requires myristoylation for efficient incorporation (Bukovsky et 
al., 1997; Camaur and Trono, 1996). 
After all the components have been localised and assembled, buds emerge and the 
virion is then released from the cell. The late domains in gag mediate the process. In HIV, 
the late domain, a PTAP motif in p6 (Gottlinger et al., 1991), interacts with Tsg101, a sub 
unit of the endosomal sorting complex required for transport I (ESCRT I). It is thought that 
this protein interacts then with ESCRT III, a key host protein involved in this process 
(Garrus et al., 2001). Another secondary late domain (YPXnL) is located downstream the 
PTAP sequence has been shown to be also involved in budding. ALIX binds to YPXnL 
and then interacts with ESCRT III (Fisher et al., 2007), promoting budding. Additionally, 
Vpu  is  necessary  for  virion  release  in  some  human  cells,  including  CD4+  T  Cells 
(Terwilliger et al., 1989). These cells encode tetherin, a host protein that causes retention 
of fully formed virions in the cell surface. Vpu colocalises with tetherin, inhibiting this 
effect (Neil et al., 2008).  
After  release  from  the  cell,  the  virions  are  immature  and  not  infectious.  The 
polyproteins are cleaved by protease (PR) to produce the enzymes IN and RT, as well as 
the MA, CA and NC structural proteins. This cleavage is an ordered and sequential process 
(Ledbetter,  1979).  Subsequently,  the  structural  proteins  rearrange  via  a  process  called 
maturation to form the infectious virus particle (Vogt, 1996). 
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1.2 – Retroviral vectors 
 
  Retroviruses insert their genome into the host DNA. This feature is highly desirable 
for gene therapy as the viral DNA introduced in a progenitor cell will be passed on to all 
the progeny enabling stable gene transfer to a tissue. 
  The  two  main  types  of  viral  vectors  were  derived  from  gammaretrovirus  and 
lentivirus. The later have the advantage that they infect non-dividing cells. 
  The basic principle behind vector development is to replace the coding region (gag-
pol-env)  with  the  transgene  of  interest.  The  cis  elements  required  for  the  RNA 
encapsidation, reverse transcription and transcription need to be retained in the transfer 
vector. These include the packaging signal (Ψ), the viral LTR, primer binding site (PBS) 
and the polypurine tract (PPT). Additional proteins necessary for vector production are 
supplemented in trans, in packaging constructs. 
 
1.2.1 – Gammaretroviral vectors 
 
Gammaretroviral  vectors  are  most  commonly  based  on  the  Moloney  murine 
leukaemia virus (MLV). In the simplest transfer vectors, the transgene is placed between 
the packaging signal and the PPT, transcription is regulated by the enhancer and promoter 
in the 5’LTR and the polyadenylation signal is provided in the 3’LTR.  
The splicing signals are elements that overlap with viral genes. The splice donor is 
located upstream of the packaging signal and the splice acceptor is downstream, in the pol 
gene. In the N2 vector, the transgene is placed in the gag position. Therefore, this vector 
does not contain the splice acceptor sequence (Gilboa et al., 1982; Eglitis et al., 1985). 
Other transfer vectors were made where env is replaced by the transgene, thus containing 
the splice donor and acceptor sequences, such as the MFG vector (Danos and Mulligan, 
1988; Dranoff et al., 1993). Increased levels of spliced RNA in target cells explains the 
higher levels of transgene expression from the MFG vector compared with the N2 vector 
(Krall et al., 1996). The MFG vector was therefore chosen as the transfer vector in two   37 
gene  therapy  trials  for  severe  combined  immunodeficiency  (SCID)-X1  disease 
(Cavazzana-Calvo et al., 2000; Gaspar et al., 2004). 
The viral proteins encoded in the viral gag, pol and env genes are provided in trans, 
in retroviral packaging constructs. The first generation of these constructs (pMOV-psi-) 
was accomplished using a retroviral genome missing the packaging signal (Mann et al., 
1983). However, there was a high potential for generating replication competent virus due 
a  recombination  event  between  the  vector  and  the  packaging  construct.  In  a  second 
generation of retroviral packaging constructs, pPAM3, apart from the Ψ signal, all of the 
3’LTR, 352bp on the 5’ of U3 of the 5’LTR and the PPT were also removed (Miller and 
Buttimore, 1986). A further improvement of packaging constructs was made by Danos and 
Mulligan, where the helper functions were split into different constructs. Here, env was 
separated from the gag and pol genes to create the pCRIPenv- (containing the gag and pol 
genes) and the envelope constructs pCRIPAMgag- (expressing the amphotropic envelope) 
and  pCRIPgag-2  (expressing  the  ecotropic  envelope).  With  these  constructs,  further 
recombination events were needed to produce replication competent virus, thus increasing 
the  safety  of  vector  production.  These  constructs  also  allowed  the  development  of 
pseudotyping,  the  generation  of  virion  with  heterologous  env  proteins  (Danos  and 
Mulligan, 1988). 
  
1.2.2 – Lentiviral vectors 
 
The development of lentiviral based transfer vectors followed the gammaretrovirus 
system. In the vector pHR, in addition to the viral LTRs, Ψ signal, PBS and PPT, other 
viral elements were left. These sequences are part of the gag gene which had been shown 
to  augment  packaging  efficiency,  and  the  Rev  response  element  (RRE),  that  is 
encompassed in part of the env gene. In the transfer vector, the Ψ signal and RRE are 
flanked by splice acceptor and donor sequences. The gag gene reading frame was blocked 
by  a  frameshift  mutation.  The  trans-activation  responsive  region  (TAR)  augments  the 
transcription efficiency and RRE allows efficient nuclear export of unspliced RNA in the 
presence of Tat and Rev, respectively. These two viral proteins would only be present in 
the producer cells, supplemented in trans. The lentivirus LTR requires Tat for efficient   38 
expression, so, in this vector design, transcription of the transgene in the target cells had to 
be controlled by an internal promoter (Naldini et al., 1996a; Naldini et al., 1996b). 
  Additional modifications to this transfer vector included the incorporation of the 
central  polypurine tract  (cPPT) to  enable the formation of a  DNA  flap during reverse 
transcription and the post-translational regulatory element of the Woodchuck hepatitis B 
virus (WPRE). This DNA flap has been shown to increase nuclear import of the viral 
DNA, thus increasing the transduction efficiency in both dividing and non-dividing cells 
(Follenzi et al., 2000; Zennou et al., 2000). The WPRE improves transgene expression 
levels, by facilitating the nuclear export of transcripts containing this element (Zufferey et 
al., 1999). 
  The packaging constructs necessary to supplement the viral sequences necessary 
for the production of vectors were designed based on the split retroviral vectors. In the first 
generation pCMVΔR9, expressing the gag and pol genes, the viral LTRs were substituted 
with  the  human  cytomegalovirus  (CMV)  immediate  early  promoter  and  the 
polyadenylation signal from the insulin gene at the 5’ and 3’, respectively. The Ψ signal 
and  adjacent  sequences  were  also  removed,  but  the  splice  donor  site  was  preserved. 
Additionally, the envelope proteins and the accessory protein Vpu were also removed. The 
envelope glycoprotein was supplied in another packaging construct. 
  A  second  generation  packaging  construct  was  made  by  deleting  the  accessory 
genes,  as these proteins  were shown to  be dispensable for efficient  vector production, 
transduction  and  integration  (Zufferey  et  al.,  1997).  These  constructs  would  confer  a 
higher safety as replication competent vectors that may arise during production would lack 
essential viral proteins for HIV-virulence in vivo. 
  In the third generation constructs, the LTR of the transfer vector was replaced by 
constitutively active promoter sequences (either from RSV or MLV) controlling the RNA 
production in producer cells, thus allowing the removal of the tat gene from the packaging 
vector. Furthermore, the rev gene was shown to be necessary for efficient nuclear export of 
the transfer vector, so it was separated from the gag and pol genes and supplemented in a 
separate vector (Dull et al., 1998). 
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1.2.3 – Self-inactivating (SIN) vectors 
 
The U3 region containing most of the enhancer region can be deleted from the 
3’LTR  in  the  transfer  vector,  thus  creating  a  self-inactivating  vector.  Upon  reverse 
transcription, the U3 will be deleted in both LTRs, so expression of the transgene will have 
to be controlled from an internal promoter. 
SIN design is believed to increase the biosafety of these vectors by decreasing the 
probability of generating replication competent vectors in both produced and target cells, 
reducing therefore the risk of mobilisation by wild-type virus in an infected host (Zufferey 
et al., 1998). Most importantly, the deletion of an enhancer reduces the risk of insertional 
mutagenesis. Additionally, it may increase transgene expression by reducing transcription 
interference between the viral LTR and the internal promoter. 
The first SIN retroviral vectors were made in an MLV-based vector (Yu et al., 
1986;  Yee  et  al.,  1987).  The  first  vector  had  a  deletion  of  299bp  in  the  U3  region, 
containing the enhancer and the CAAT box, the second had the additional deletion of the 
TATA box. However, retroviral vectors display weak polyadenylation sites and deletion of 
U3 to generate SIN vectors increased the likelihood of read-through thus augmenting the 
potential for insertional mutagenesis (Furger et al., 2001; Zaiss et al., 2002). Schambach 
and  colleagues  have  described  the  insertion  of  upstream  polyadenylation  elements  to 
improve  3’  processing  to  increase  the  biosafety  of  these  vectors  for  gene  therapy 
(Schambach et al., 2007). 
The first lentiviral SIN vector was described by Zufferey and colleagues (Zufferey 
et al., 1998). In HIV, the upstream polyadenylation element is located between the TATA 
box and the transcriptional initiation site and deletion of a region further upstream had 
minimal effect on 3’ processing (Valsamakis et al., 1991). This characteristic allowed the 
deletion of an extensive part of the U3 region without affecting considerably 3’ processing. 
The lentiviral SIN vector was generated by deletion of 400bp in U3, including the TATA 
box and leaving only 38bp from the 5’end (containing the attachment sites for integrase 
recognition of the viral DNA) and 18bp from the 3’ end of U3 (Zufferey et al., 1998). 
However, even this large deletion did not completely inhibit transcription from the viral   40 
SIN LTR, due to regions containing binding sites for transcriptional activators (SBF1 and 
SP1) located downstream the transcriptional initiation site (Logan et al., 2004). 
  
1.2.4 – Expression cassette 
 
  In the simplest approach for gammaretroviral vectors, the expression of a cDNA, 
encoding the protein of interest, is controlled by the viral LTR. However, in lentivectors 
and SIN vectors, transcription is driven by an internal promoter. This strategy allows a 
more flexible choice of a promoter. 
  The promoter can be constitutively active and derived from virus (such as the LTR 
from the spleen focus-forming virus (SFFV), or the immediate early promoter from the 
cytomegalovirus) or cellular genes (such as the phosphoglycerate kinase or the elongation 
factor  1ʱ).  These  promoters  are  active  in  a  range  of  different  cell  types.  However, 
transcription can be restricted to a given cell type by the use of tissue-specific promoters, 
such  as  the  ʱ1-antitrypsin  promoter  in  liver  (Ciliberto  et  al.,  1985)  or  the  myogenin 
promoter in skeletal muscle (Yee and Rigby, 1993). Alternatively, the incorporation of 
microRNA target sequences in the transcript can also prevent expression in cells where 
those microRNAs are expressed (Brown et al., 2006). The restriction of expression to the 
target cells may avoid an immune response by preventing expression in antigen presenting 
cells. In certain applications, temporal control of transgene expression may be required. 
This can be achieved by the incorporation of an inducible promoter, such as a tetracycline-
responsive promoter (Gossen and Bujard, 1992). 
  Several  strategies  can  be  taken  when  multiple  transgenes  are  required  to  be 
expressed from one vector. Proteins can be expressed using alternative splicing, although 
this strategy presents several drawbacks, such as the ratio of spliced transcripts or the 
generation of alternative splicing with the incorporation of cellular sequences (Cepko et 
al.,  1984;  Korman  et  al.,  1987).  Multiple  promoters  can  be  included,  each  driving 
expression of a different transgene. However, this strategy has the potential problem of 
promoter  suppression,  where  one  of  the  transcripts  is  expressed  more  than  the  other 
(Emerman and Temin, 1984). Another strategy relies on the introduction of an internal 
ribosome entry site (IRES) between transgenes that are being translated from the same   41 
transcript (Adam et al., 1991). Two transgene may also be expressed as a fusion protein 
combining  both  functions  in  a  chimeric  protein  or  separated  during  translation  by  a 
ribosomal skip mechanism or after translation by a protease cleavage site (Germann et al., 
1990; Morrison et al., 1991; Szymczak et al., 2004). 
 
1.2.5 – Pseudotyping 
 
  A process that commonly occurs during viral assembly of viruses in cells infected 
with two or more virus is the formation of phenotypically mixed particles. These particles 
have envelope proteins from both viruses and the tropism of the parental virus is therefore 
altered (reviewed in Zavada, 1982).  
In  the  case  of  HIV,  several  studies  have  demonstrated  that  the  wild-type  virus 
produced in cells infected with xenotropic MLV (Lusso et al., 1990), amphotropic MLV 
(Spector et al., 1990) or herpes simplex virus gives (Zhu et al., 1990) gives rise to viruses 
with an expanded host range, suggesting that heterologous glycoproteins were incorporated 
in the virus envelope. 
A new strategy to alter the tropism of vectors has then emerged with the design of 
packaging constructs where env was split from the gag and pol genes thus allowing the 
expression of different envelope glycoproteins in the producer cell. Using this strategy, the 
tropism of gammaretrovirus vectors based on ecotropic MLV has been broaden to include 
human  cells  by  using  the  MLV  amphotropic  envelope  proteins  (Danos  and  Mulligan, 
1988). 
The most commonly used glycoprotein to pseudotype lentiviral vectors in order to 
expand vector tropism is the glycoprotein from the vesicular stomatitis virus (VSVg). The 
receptor for VSVg, although still undetermined, appears to be ubiquitous in all cell types, 
explaining the broad host range of VSV (Schlegel et al., 1982; Coil and Miller, 2004). 
Furthermore,  VSVg  pseudotyped  vectors  are  highly  stable  and  can  be  efficiently 
concentrated  by  ultracentrifugation,  enabling  the  production  of  serum-free,  high-titre 
vector particles (Burns et al., 1993; Naldini et al., 1996b). However, VSVg is associated 
with cytotoxicity, hindering the creation of packaging cell lines for production of VSVg 
pseudotyped vectors. Nevertheless, progress has been reported using inducible expression   42 
of this envelope protein. Another drawback of this pseudotype is the inactivation by human 
serum complement, preventing its use in vivo (DePolo et al., 2000). Furthermore, it has 
been reported that lentiviral vector preparations pseudotyped with VSVg are contaminated 
with  tubulovesicular  structures  carrying  nucleic  acids  or  proteins  that  may  elicit  an 
undesirable immune response (Pichlmair et al., 2007).  
Heterologous  glycoproteins  have  also  been  used  to  restrict  the  tropism  of  the 
vectors. The neurotropic properties of Lyssavirus, including the rabies and Mokola virus, 
have early been studied. Vectors pseudotyped with those glycoproteins infected neurons 
preferentially (Mochizuki et al., 1998; Desmaris et al., 2001). Retrograde transport has 
been achieved by the use of Rabies glycoprotein (Mazarakis et al., 2001). 
Another  strategy  to  target  specific  cell  types  is  the  engineering  of  envelope 
glycoproteins. Viral envelope proteins have been modified to contain ligands or single 
chain antibodies (Hatziioannou et al., 1999). Using the second approach, by fusing single 
chain  antibodies  to  the  sindbis  glycoprotein,  lentiviral  vectors  have  efficiently  been 
targeted to melanoma cells (Morizono et al., 2005). 
 
1.2.6 – Vector production 
 
Two  strategies  have  been  adopted  to  produce  gammaretroviral  and  lentiviral 
vectors. The production can be accomplished by transient transfection of plasmids coding 
for  the  transfer  vector,  packaging  and  envelope  into  highly  transfectable  cells,  usually 
293T (Naldini et al., 1996b; Soneoka et al., 1995). Stable packaging cell lines have also 
been developed to produce these vectors. For clinical applications, the use of packaging 
cell lines is more appropriate. It allows the production of large and reproducible batches 
enabling control of the quality of the vector. 
Gammaretrovirus and lentivirus present some differences for the development of 
stable cell lines, especially in the complexity of the viral genome. Furthermore, contrary to 
gammaretroviral proteins, the lentiviral protease and Vpr proteins have been reported to be 
cytotoxic  (Kaplan  and  Swanstrom,  1991;  Planelles  et  al.,  1995;  Rogel  et  al.,  1995). 
Therefore, the development of packaging cells for the production of lentiviral vectors has   43 
relied on the use of inducible expression of the viral proteins (Dull et al., 1998; Kafri et al., 
1999; Yu et al., 1996). 
The development of a stable cell line producing lentiviral vectors has been recently 
reported. The STAR cells are derived from 293T or HT1080 human cell lines that were 
transduced an MLV-based vector expressing a codon optimised version of gag and pol 
(lacking RRE) and then co-transduced with Tat and Rev being expressed from separate 
gammaretroviral  vectors.  The  STAR  cells  were  then  stably  transfected  with  plasmids 
expressing either MLV-A, GALV+, or RD114pro glycoproteins to allow for high plasticity 
regarding  vector  pseudotyping.  The  production  of  SIN  and  non-SIN  versions  of 
lentivectors in these cells is similar, with a high titre and stable for up to 3 months (Ikeda et 
al., 2003). 
A  variety  of  gammaretroviral  cell  lines  have  been  developed  and  some  have 
already been used in clinical trials, including the Ψ CRIP cells producing gammaretroviral 
vectors pseudotyped with the MLV amphotropic envelope (Danos and Mulligan, 1988) 
and the PG13 cells that produces gibbon ape leukaemia virus pseudotyped vectors (Miller 
et al., 1991). However, these cell lines were developed from mouse cell lines and vectors 
produced by these cells are rapidly inactivated by human serum (Takeuchi et al., 1994; 
Takeuchi  et  al.,  1996)  and  may  cross-pack  contaminating  endogenous  viral  sequences 
(Patience et al., 1998). Therefore these vectors would not be suitable for in vivo human 
gene therapy. Packaging cell lines derived from human cells have been developed to solve 
these problems (Cosset et al., 1995). 
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1.3 – Adenoviruses 
1.3.1 – Structure and Biology of Adenoviruses 
 
Adenoviruses (Ad) have been associated with mild diseases, such as colds or acute 
respiratory diseases. The virions are non-enveloped, icosahedral structures with long fibres 
extending  from  each  of  the  12  vertices,  with  a  double-stranded  molecule  of  DNA  as 
genome. This complex structure is composed of hexons (forming each of the 20 triangular 
facets of the capsid), penton bases and fibres, and other “minor” components. There are six 
other structural proteins situated in the virion core (Green et al., 1967; Horne et al., 1959; 
Valentine and Pereira, 2003). 
The fibre is composed of a rod and a knob attached to the penton base. The length 
and flexibility of the rod varies among the virus serotypes and the knob function as the 
cellular  attachment  site.  The  major  receptor  for  most  adenoviruses  is  the  Coxsakie 
adenovirus receptor (Coyne and Bergelson, 2005; Philipson and Pettersson, 2004). After 
this initial interaction, the RGD peptide on the penton base binds to cellular ʱvβ3/ʱvβ5 
integrins  (Mathias  et  al.,  1994),  facilitating  virus  internalisation  via  clatherin  coated 
vesicles and into endosomes for further processing (Patterson and Russell, 1983). After 
uncoating  within  the  early  endosome,  the  nucleoprotein  particle  is  released  to  the 
cytoplasm and migrates to the nucleus. The viral terminal protein (TP) remains attached to 
the DNA and drives it to specific sites in the nucleus where viral transcription is initiated 
(Schaack et al., 1990).  
DNA replication of these viruses is a complex process. In Ad2 virus, the 36kb 
DNA contains a long inverted terminal repeat (ITR), where the origin of replication is 
situated. Gene expression can be divided in early and late transcription units, based on the 
kinetics of this process. Six early transcripts (E1A, E1B, E2A, E2B, E3 and E4) encode 
proteins  that  orchestrate  the  virus  expression.  After  infection,  the  first  units  to  be 
transcribed are the E1A and E1B, whose products regulate cellular genes and transactivate 
other  transcription  units.  The  products  from  the  E3  unit  modulate  the  host  immune 
response (Fessler et al., 2004; Flomenberg et al., 1987). E2A generates the DNA-binding 
protein (DBP) and E2B produces the TP and a DNA polymerase. These three proteins,   45 
together with the cellular nuclear factors I, II and III are involved in the replication of the 
virus DNA. After a TP-primed DNA replication initiation, the viral polymerase elongates 
the  nascent  strand.  After  completion,  the  process  is  repeated,  generating  high 
concentrations of viral DNA. The major late promoter is then activated, producing the late 
transcripts that encode the structural proteins. Virion assembly occurs in the nucleus. This 
process is thought to arise from a series of concerted maturation steps involving the viral 
protease and the assembly of scaffolding proteins and precursor structural polypeptides. 
Early experiments suggested that the viral genome is inserted in these preformed capsids 
(Edvardsson  et  al.,  1976;  D'Halluin  et  al.,  1978a;  D'Halluin  et  al.,  1978b)  but  recent 
findings  indicate  that  the  genome  initiates  the  assembly  of  the  capsid  (Zhang  and 
Imperiale,  2000).  Regardless  of  the  mechanism,  it  is  well  accepted  that  selective 
encapsidation of DNA molecules occur by the recognition of cis-acting sequences, located 
close to the left ITR (Grable and Hearing, 1990). Once assembly and DNA encapsidation 
have  been  completed,  the  viral  protease  cleaves  the  structural  proteins,  forming  fully 
mature particles (reviewed in Mangel et al., 2003). Finally, the adenovirus death protein is 
involved in the lyses of the cells and release of the virus progeny (Tollefson et al., 1996). 
 
1.3.2 – Adenoviral vectors 
 
Due to the better understanding of the genome of Ad 2 and 5, and because these 
viruses  never  induced  tumours  in  mice  models,  they  were  used  to  develop  the  first 
generation vectors. The principle was to delete essential sequences of the viral genome in 
order  to  impair  replication  and  to  facilitate  the  accommodation  of  the  transgenes  of 
interest. The E1 genes are required to initiate viral replication and thus, are essential for 
viral replication. Furthermore, it is know that E1 coded proteins are involved in cellular 
transformation. Therefore, the first strategy to produce adenoviral vectors was to delete the 
E1 transcription units. Vector production would require supplementing the E1 genes in 
trans. A cell line was then produced for this purpose. The 293 cell line (Graham et al., 
1977) was transformed with the E1 coding region. Then, a plasmid containing the virus 
ITR, packaging signal and the E1 genes substituted by foreign DNA could be transfected 
in such cells. This technique allowed the production of high concentration of vectors.   46 
This first generation vector permitted the incorporation of 5kb foreign cDNA. Also, 
some vectors were generated with a further deletion on the E3 genes, as these are not 
required for viral replication, increasing the capacity to insert expression cassettes of 8kb. 
Although these vectors showed great potential for gene delivery, problems arose from the 
fact that replicating virus were also produced. The E1 coding region in the complementing 
cell line could recombine with the vector, giving rise to viral DNA with functional E1 
generating replication competent viruses. Other complementing cell lines, such as PER.C6 
(Fallaux et al., 1998), were constructed. In these, the E1 coding region was trimmed to 
minimise  the  overlap  with  the  vector  DNA,  reducing  homologous  recombination. 
However,  experiments  in  animal  models  demonstrated  that,  although  the  vector  could 
efficiently infect cells, expression was transient. This happened due to the activation of the 
host immune responses.  
A new strategy was then generated to minimise the immune response triggered by 
the  vectors.  In  these  so-called  second  generation  vectors,  further  regions  of  the  viral 
genome, such as  E2  and E4, were deleted. Cell  lines  with  the complementary deleted 
sequences were constructed (Schaack et al., 1995; Amalfitano et al., 1996; Amalfitano and 
Chamberlain, 1997), but the vector production in these cells yielded lower titres, compared 
with first generation vectors. The E2 deleted vectors showed longer transgene expression 
in immune competent mice (Hu et al., 1999), but results from the E4 deleted vectors were 
less conclusive (Grave et al., 2000; Armentano et al., 1997). The best strategy then seemed 
to be the complete excision of all transcription units of the adenovirus DNA. These third 
generation  vectors,  also  called  gutless  adenoviral  vectors,  only  have  the  ITRs  and  the 
packaging signal essential for encapsidation of the vector DNA. Therefore, the packaging 
capacity of the vector increased to 36kb. 
In order to produce gutless vectors, several efforts have been made to produce a 
cell line to provide in trans all the necessary viral genes. However, due to the complexity 
of  the  Ad  genome  and  its  regulation,  such  task  has  not  yet  been  reported.  The  most 
common strategy relies on the infection of the producer cell with a helper Ad. However, 
separation  of  the  produced  vectors  from  the  helper  virus  had  to  be  addressed.  The 
strategies reported so far, rely on the reduction of the packaging efficiency of the helper 
genome  compared  to  the  gutless  vector.  This  has  been  accomplished  by  mutating  the   47 
helper virus packaging signal, a different genome size (smaller or bigger genomes than the 
optimal do not pack efficiently) or by specific removal of the packaging signal during 
vector production using a recombinase such as Cre, Flp or the unidirectional recombinase 
ʦC31.  Nevertheless,  contaminating  helper  virus  still  remains  in  the  final  preparation, 
although at low levels (approximately 0.2%). 
The  immunogenicity  and  transient  expression  of  adenoviral  vectors  may  be  a 
hurdle for the application to the treatment of inherited genetic disorders. However, these 
same characteristics provide an excellent tool for vaccination and cancer treatment. In fact, 
the first gene therapy product is an E1-deleted adenoviral vector (Gencidine
TM, SiBiono 
GeneTech), that is now commercially available in China (Garber, 2006). The E1B-55k Ad 
protein inactivates the p53 protein (Dobner et al., 1996) and thus, vectors lacking this gene 
can only replicate in cells that lack p53 function  (Bischoff et al., 1996). Since a high 
percentage  of  tumour  cells  have  mutations  in  the  p53  gene,  the  oncolytic  vectors 
selectively replicate in these cells, lysing tumour cells but not normal cells (Chang et al., 
1995; Heise et al., 1997). 
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1.4 – Adeno-Associated Viruses (AAV) 
1.4.1 – Structure and Biology of AAV 
 
  The AAV virus was first discovered as a contaminant of Adenoviruses preparations 
(Atchison et al., 1965). Although most humans have been infected, this virus has not been 
associated with any disease. 
This is one of the smallest viruses known, with an icosahedral capsid of 20nm in 
diameter and a small linear single-stranded DNA genome of 4.7kb. The genome is very 
compact, with only two coding regions flanked by ITRs (reviewed in Berns, 1990). The 
rep gene encodes four regulatory proteins. These proteins are produced through the use of 
two promoters (p5 and p19). Splicing of the transcript originated from the p5 promoter 
gives rise to the Rep78 and Rep68 proteins that are important in all stages of the virus life 
cycle. The p19 promoter transcript can be spliced to produce the smaller proteins Rep52 
and Rep40 that are involved in the accumulation of the genome during replication. The cap 
gene is transcribed from one promoter (p40), but alternative splicing gives rise to two 
transcripts. The larger produces the VP1 capsid protein and the smaller encodes the VP2 
and VP3 structural proteins through the use of a noncanonical start codon. These three 
proteins  assemble  to  form  the  capsid  (Hermonat  et  al.,  1984;  Tratschin  et  al.,  1984; 
Chejanovsky and Carter, 1989). 
  AAV2 particles use the ubiquitous heparan sulphate proteoglycans as docking sites, 
explaining  the  broad  tropism  of  these  viruses  (Summerford  and  Samulski,  1998). 
Internalisation  is  aided  by  the  co-receptors  ʱvβ5  integrin  (Summerford  et  al.,  1999), 
fibroblast co-receptor type 1 (Qing et al., 1999) and the hepatocyte growth factor receptor 
c-met (Kashiwakura et al., 2005). 
  There are two stages in the AAV life cycle, depending if the cell is superinfected 
with a helper virus, such as Adenoviruses or Herpes Simplex viruses. When AAV infects 
human  cells  alone,  expression  is  auto-repressed  and  latency  is  established  by  the 
integration of the virus genome in the chromosome 19, in the AAVS1 site (Kotin et al., 
1990). This site-specific integration is unique among viruses and therefore, very attractive 
in  the  gene  therapy  context.  The  process  is  not  completely  understood,  but  the  virus   49 
elements necessary for site-specific integration have been elucidated. These include one of 
the Rep 68 or Rep78 proteins in trans and the ITRs or the integration efficiency element in 
the p5 promoter in cis (Surosky et al., 1997; Philpott et al., 2002). In the host genome, 
there are multiple Rep binding elements but only the AAVS1 site has the required Rep 
specific nicking site (known by terminal resolution site) at the proper distance (Weitzman 
et al., 1994). 
  When the cell is infected with a helper virus, the AAV starts a productive cycle. 
Rep expression is repressed by the binding of the host factor YY1 to a sequence in the p5 
promoter.  When  the  cell  is  infected  with  Adenovirus,  the  E1A  protein  binds  to  YY1 
relieving  the  Rep  expression  inhibition  (Shi  et  al.,  1991).  Rep78  and  Rep68  are  then 
produced and act as a transactivator of the p19 and p40 promoters to produce the smaller 
Rep  proteins  and  cap  proteins.  Also,  they  excise  the  integrated  provirus  and  start 
replication. The ITR of the genome can fold on itself due to base complementarity and 
form  a  characteristic  T-shaped  hairpin  structure.  This  secondary  structure  provides  the 
initiation primer for DNA replication (Hauswirth and Berns, 1977). Upon completion of 
DNA polymerisation of the leading strand, the double-stranded molecule, closed at one 
end, is resolved by site-specific nicking at the terminal resolution site on the ITR of the 
parental strand (Snyder et al., 1990). Then, the ITR is copied using the free 3’hydroxyl 
group in the parental strand. Finally, the palindromic linear duplex termini can renaturate 
into terminal hairpins, the strands separate and the process can be re-initiated. Concatemers 
can also be formed when the nicking does not occur, but resolution of these structures may 
still occur afterwards (Straus et al., 1976).  
The other adenovirus proteins necessary for AAV replication are the E1B 55K and 
E4orf6 proteins, that have been shown to facilitate the export of the mRNA transcripts to 
the cytoplasm (Samulski and Shenk, 1988; Huang and Hearing, 1989) and also the E2A 
protein and the VA RNAs which are required for translation of the capsid mRNA (Janik et 
al., 1989). Finally, the genome packaged into assembled capsids and released from the 
cells by lyses induced by the helper virus. 
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1.4.2 – AAV vectors 
 
  When  Samulski  and  colleagues  cloned  the  whole  AAV  genome  into  a  transfer 
plasmid, transfected it in cells and infected them with Adenoviruses, they could rescue 
infective AAV virions (Samulski et al., 1982). This observation provided the basis for 
AAV vector development. The only cis sequences necessary for encapsidation of the AAV 
genome are the ITRs. Therefore, the AAV vectors can be striped out of the cap and rep 
genes. Nevertheless, these genes need to be supplemented in trans for replication of the 
vector genome and production of the viral capsid. Also, AAV is a virus whose replication 
is dependent on the infection of a helper virus. Therefore, in order to produce a vector 
based on AAV, it was necessary to supplement in trans the necessary virus helper proteins 
to accomplish effective production. 
  Initially, producer cells were transfected with the AAV vector plasmid, containing 
the expression cassette of interest flaked by the ITRs, and a plasmid coding for the cap and 
rep  genes  (Samulski  et  al.,  1989).  These  cells  would  then  be  infected  with  helper 
adenovirus  to  produce  AAV  vectors.  Nevertheless,  it  was  necessary  to  subsequently 
remove the Adenovirus from the preparation. The elimination of Adenovirus relied on the 
difference  in  physical  properties  of  the  virions,  such  as  thermostability  and  density. 
Typically, the Adenovirus could be eliminated by heat inactivation or the AAV vectors 
could be rescued after separation in a caesium chloride density ultracentrifugation. Later, 
the discovery that AAV had a receptor for heparan sulphate proteoglycan permitted the 
development of a purification strategy based on affinity chromatography (Zolotukhin et al., 
1999). 
  The  finding  of  which  helper  proteins  were  involved  in  the  AAV  replication 
permitted  the  construction  of  a  plasmid  expressing  all  of  the  necessary  proteins  and 
enabled the production of AAV vectors without the need for Adenovirus infection (Xiao et 
al., 1998).  
  The efficiency of these vectors is hindered by the slow process of second strand 
synthesis necessary for transgene expression. AAV vectors can package plus and minus 
single-stranded DNA genomes. Therefore, when multiple vectors infect one cells, the plus 
and  minus  DNA  strands  can  anneal  by  base  pairing.  Although  the  probability  of   51 
occurrence of this mechanism increases with vector dose, host recombination factor may 
play  an  important  role  in  promoting  strand  annealing  so,  it  is  difficult  to  predict  the 
efficiency in certain cell types. However, this step can be optimised by the use of self 
complementary  vectors  (reviewed  in  McCarty,  2008).  These  vectors  carry  an  inverted 
repeat genome that can fold into a double-stranded DNA molecule, without the need of 
DNA synthesis or strand annealing, thus increasing the efficiency of the vector expression. 
However, in order to package such genomes, the expression cassette can only contain a 
maximum of 2.2Kb, which limits the application of these vector to the expression of small 
proteins, but there are still several applications for these vectors, such as haemophilia B 
(Nathwani et al., 2006). 
  The  common  AAV  vector  has  been  derived  from  the  AAV-2  serotype.  Gene 
transfer from these vectors can be hampered by neutralising anti-AAV-2 antibodies, which 
are highly prevalent in human population. However, this drawback can be circumvented by 
the use of different serotypes (reviewed in Wu et al., 2006). The development of new AAV 
vectors  based  on  different  serotypes  can  help  to  evade  the  humoral  immune  response 
towards AAV-2 and also enhance the infection in target cells. The AAV-2 vector genome 
can be cross-packaged into the capsids of other serotypes and, it has been shown that these 
“pseudotyped” AAV vectors display different tissue tropism. Therefore, this technique can 
be exploited in order to broaden the targets for AAV vectors or to develop tissue-targeted 
vectors while escaping the anti-AAV-2 immune response. 
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1.5 – Vectors in gene therapy 
   
In  order  to  ameliorate  a  genetic  disease,  the  defective  gene  can  be  repaired  or 
substituted  or  a  corrected  gene  can  be  introduced  in  the  target  cell.  This  can  be 
accomplished ex-vivo  or directly in  patients  and there are different  methods  to  deliver 
nucleic acids to target cells. 
Physical  delivery  of  naked  DNA  has  been  achieved  by  microinjection, 
electroporation, ultrasound, hydrodynamic pressure and particle bombardment. Although 
the concept of direct delivery of the DNA without disruption of the cells or incorporation 
of any other foreign molecules would be ideal, this technology has been hindered by the 
low transfer of DNA and the fact that these techniques are invasive in vivo (Reviewed in 
Wells, 2004).  
Chemical approaches have been developed to enhance DNA transfer by mimicking 
viral  properties.  Normally,  these  non-viral  vectors  consist  in  a  carrier  molecule  (lipid, 
peptide or polymer-based) complexed with DNA. Although success has been achieved in 
animal models, the transfer of this technology into a clinical setting remains elusive due to 
factors controlling stability and pharmacokinetics of these vectors and because the results 
obtained may not be similar in humans (reviewed in Niidome and Huang, 2002). 
Viruses have evolved to efficiently transfer their genome to the host cell and many 
have then been exploited to  develop  vectors for gene therapy. Viral  based vectors are 
currently the most effective means of gene delivery. In fact, they represent ~70% of the 
vectors used in clinical trials. The vectors used to achieve gene delivery have been a wide 
range,  with  adenovirus  and  retrovirus  comprising  the  majority  used  in  clinical  trials 
(Journal of Gene Medicine, clinical trials database). 
Each viral vector system is characterised by a set of properties, some of which 
inherited from the parental virus. Hence, given the diversity of disease targets, it is clear 
that no single vector is suitable for all applications. The choice of vector depends largely 
on the cell type to be targeted and duration of expression required, but other properties 
such as low cytotoxicity and low immune response are highly desirable to ensure safety in 
a clinical setting. Table 1.2 summarises the properties of vectors.   53 
 
Table 1.2: Vectors used in gene therapy 
Vector  Packaging 
capacity 
Host range  Features 
AAV  ~4 Kb  Dividing and non-
dividing cells 
Slow expression onset,  
long term expression 
Adenovirus  Up to 30 Kb  Broad (low in neurons)  Transient expression, 
strong immunogenicity 
Alphaviruses  <7.5 Kb  Broad (neuron and glial 
cell-specific strains) 
Transient high expression, 
low immunogenicity 
Herpes 
simplex virus 
40 Kb 
150Kb in 
amplicons 
Broad, (strong for 
neurons) 
Latent infection, long-
term expression, low 
toxicity 
Lentivirus  8-10 Kb  Dividing and non-
dividing cells 
Genome integration, 
long-term expression, 
inefficient production 
Retrovirus  8 Kb  Restricted to dividing 
cells 
Genome integration, 
long-term expression 
 
 
1.5.1 – Retroviral vectors in gene therapy: Success with consequences 
 
Retroviral vectors can integrate their genome into the host genome. This particular 
characteristic  makes  them  useful  for  target  diseases  that  require  prolonged  transgene 
expression in dividing cells. Indeed, the first successful clinical trials used these vectors for 
the treatment of immunodeficiencies. 
X-linked severe combined immunodeficiency (SCID-X1) results from mutations in 
the gene encoding the common cytokine receptor gamma-chain (γc). The failure of γc 
signalling results in a classical phenotype characterised by the absence of T and natural 
killer (NK) cells, whilst B cells are present but poorly-functional (White et al., 2000). 
Unless  patients  are  treated  with  haematopoietic  stem  cells  (HSC),  they  succumb  to 
infections during the first years of life. The aim of two clinical trials using gene therapy for 
the  treatment  of  this  disease  was  the  immune  reconstitution  with  autologous  HSCs 
manipulated to express γc. So, HSCs were isolated from patient and transduced ex vivo 
with  a  gammaretroviral  vector  expressing  γc.  The  cells  were  then  infused  back  into 
patients and reconstitution of the immune system was monitored over time. The reports 
from the two clinical trials conducted in France and United Kingdom demonstrated clearly   54 
that the cure of this disease had been achieved by the use of gene therapy (Cavazzana-
Calvo et al., 2000; Gaspar et al., 2004). Since then, similar encouraging results have been 
published for the gene therapy clinical trials to treat adenosine deaminase deficient - SCID 
and chronic granulomatous disease (CGD) (Aiuti et al., 2002; Gaspar et al., 2006; Ott et 
al., 2006). 
After the positive news, the scientific community soon became apprehensive due to 
the development of a lymphoproliferative disorder that arose in two patients following 
gene  therapy  treatment.  Analysis  of  the  T-cell  clones  revealed  a  retroviral  vector 
integration in the vicinity of the LIM domain only-2 (LMO2) proto-oncogene promoter, 
leading to aberrant translation of the protein. Although there is already a strong advantage 
for  the  genetically  modified  cells  to  proliferate,  the  activation  of  the  LMO2  gene 
expression probably boosted this ability of the clones to the point of malignancy (Hacein-
Bey-Abina et al., 2003a; Hacein-Bey-Abina et al., 2003b). 
The leukaemias in the French SCID-X1 gene therapy trial represent the first reports 
of gene therapy vector-induced insertional mutagenesis in humans. These news prompted 
the scientific community to endeavour all necessary efforts to understand how viral vectors 
can cause insertional mutagenesis. Several in vivo and in vitro assays have been developed 
to investigate and quantify this process. A protocol has been adapted from the observation 
that primary bone marrow cells can be immortalised by infection with gammaretroviruses 
(Du et al., 2005). This in vitro method is able to quantify insertional mutagenesis that leads 
to transformation by comparison with background. It has been possible to establish that the 
transformation frequency detected with a SIN retroviral vector is lower compared with a 
non-SIN counterpart and that the cellular promoter EF1a used as internal promoter in a 
SIN retroviral vector does not give rise to detectable transformed cells (Zychlinski et al., 
2008; Modlich  et  al., 2006). Another recent  report  using a different  assay to quantify 
insertional mutagenesis also demonstrates that SIN vectors are safer compared with the 
non-SIN  design.  In  this  study,  the  rise  of  clones  that  can  grow  independently  of 
interleukin-3 in BAF3 derived cells, that normally need this factor for growth, gives an 
estimate  of  the  frequency  of  insertional  mutagenesis.  Retroviral  and  lentiviral-based 
vectors were compared in this study and it was found that the transformation frequency is 
similar, but by a different mechanism. Lentiviral vectors transform cells by activating the   55 
growth hormone receptor (ghr) transcription whereas gammaretroviral vectors upregulate 
expression of cytokine IL-3. It was also shown that the SIN lentivector design prevents  
activation of the ghr gene (Bokhoven et al., 2009). 
One  assay  using  mice  models  have  also  been  used  to  compare  insertional 
mutagenesis induced by retroviral and lentiviral-based vectors. In this study, bone marrow 
cells from the tumour prone Cdkn2a
-/- mouse were transduced with a SIN lentivector and a 
non-SIN retroviral vector, transplanted to lethally irradiated mice and tumourigenesis was 
monitored over time. The results demonstrate that SIN-lentiviral vectors have a reduced 
potential for insertional mutagenesis (Montini et al., 2006).   56 
1.6 – Project aims 
 
Lentiviral vectors are very promising tools for gene delivery due to their relatively 
large packaging capacity and ability to infect a range of different cell types. The vector is 
integrated into the host genome promoting stable transgene expression in dividing cells. 
However,  integration  can  also  be  problematic  due  to  a  variation  in  gene  expression 
between  cells,  possible  gene  silencing  and  most  importantly,  insertional  mutagenesis 
which can lead to undesirable effects such as malignant transformation. Expression of a 
transgene in non-dividing cells does not require integration. Also, transient expression may 
have  useful  applications.  The  aim  of  this  project  is  therefore  to  study  non-integrating 
lentiviral vectors. 
In order to produce NILVs, integration has to be blocked specifically. IN cannot be 
deleted because it is involved in reverse transcription (Zhu et al., 2004) and possibly in 
nuclear entry (Gallay et al., 1996). Nevertheless, several groups have demonstrated that 
mutations  in  IN  or  in  the  cis-acting  sequences  interacting  with  IN  (att  sites)  blocks 
integration. Here, a combination of selected mutations has been introduced in the lentiviral 
transfer vector and in the packaging construct. 
The resulting vectors will then be suitable for gene therapy in post-mitotic tissues. 
NILVs have previously been studied in retina and brain. Hence, in order to extend the 
NILVs application, expression from these vectors has been studied in muscle. Expression 
has been compared with the integrating counterpart and with other episomal vectors. 
Another possible application of NILVs is the delivery of a protein to a target cell 
(pseudo-transduction).  A  new  vector,  based  on  NILVs,  has  been  developed  with  this 
objective. In this vector, a foreign protein has been incorporated within the virion during 
vector production and delivery to the target cells was studied.   57 
 
 
 
 
 
 
 
Chapter Two 
Material and Methods 
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2 – Material and Methods 
2.1 – Materials 
All  tissue  culture  reagents  were  supplied  by  Gibco  BRL  (Invitrogen)  and  all 
general chemicals were supplied by Sigma, unless otherwise stated. Solutions and buffers 
stated in the text are listed in table 2.1. Primers (Invitrogen) and probes (MWG) used are 
listed in table 2.2. 
 
2.1.1 - Reagents and Enzymes 
 
1kb Plus DNA Ladder            Invitrogen 
AEC substrate             Vector Laboratories 
Agar                Merck 
Agarose               Invitrogen 
Alexa Fluor 488 Phalloidin          Invitrogen 
Ampicillin              Stratagene 
Calf intestinal alkaline phosphatase        New England Biolabs 
DNA polymerase I large (Klenow) fragment     Promega 
ECL western blotting substrate        Pierce 
Formaldehyde (methanol free) 16% Ultrapure    Polysciences, Inc 
HALT protease inhibitor cocktail        Thermo Scientific 
Histoclear solution             R.A. Lamb 
HiTrap Heparin column          Sigma 
Iodixanol              Accurate Chemical 
Kodak BioMax film             Kodak 
Lipofectamine 2000            Invitrogen 
Lysis buffer              Roche 
MOPS Buffer             Invitrogen 
NuPAGE NOVEX Bis-Tris gels        Invitrogen 
PfuTurbo DNA polymerase, buffer        Stratagene   59 
Platinum qPCR SuperMix-UDG with ROX      Invitrogen 
Proteinase K, PCR-grade          Roche 
Rapid-HybTM Buffer           GE Healthcare 
Rediprime II Random Prime Labelling System     GE Healthcare 
Redivue [ʱ-32P] dCTP           GE Healthcare 
Restriction Endonucleases          New England Biolabs 
SDS PAGE running buffer          Invitrogen 
T4 DNA Ligase            New England Biolabs 
Taq DNA polymerase, dNTPs, buffer      Promega 
Vectashield hard set mounting medium containing Dapi  Vector Laboratories 
 
2.1.2 - Antibodies 
 
Matched-pair of antibodies set for hFIX ELISA    Affinity Biologicals Inc. 
Monoclonal anti-eGFP (AB1218-100)      Abcam 
Biotin-conjugated polyclonal anti-eGFP (AB6658-100)  Abcam 
Rabbit anti-GFP rabbit serum (A6455)      Invitrogen 
Biotin-conjugated goat anti-rabbit antibody (BA-1000)  Vector Laboratories 
 
2.1.3 - Kits 
 
Plasmid miniprep/maxiprep/megaprep kit      Qiagen 
QIAquick gel extraction kit          Qiagen 
QIAquick PCR purification kit        Qiagen 
Quick change II XL site-directed mutagenesis kit    Stratagene 
HIV-1 p24 Antigen ELISA          Beckman Coulter 
Biorad protein assay kit          Biorad 
Vectastain ABC kit            Vector Laboratories 
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2.1.4 - Centrifuges 
 
Microcentrifuge            Heraeus Biofuge Fresco 
Tabletop centrifuge            Sorvall Legend RT 
Superspeed centrifuge           Sorvall Evolution RC 
Ultracentrifuge            Sorvall Discovery SE 
Ultra centrifuge            Beckman Coulter 60 Ti 
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Table 2.1: Buffers and solutions 
Buffers 
1x Phosphate-buffered 
saline (PBS) 
1.9mM NaH2PO4, 8.1mM Na2HPO4 and 154mM NaCl, 
pH 7.4  
1x Hanks balanced salt 
solution (HBSS) 
5.4mM KCl, 0.3mM Na2HPO4·7H2O, 0.4mM KH2PO4,   
4.2mM NaHCO3, 1.3mM CaCl2, 0.5mM MgCl2·6H2O, 
0.6mM MgSO4·7H2O, 137mM NaCl and 5.6mM D-glucose,  
pH 7.4 
1x TAE buffer  40mM Tris (pH 7.8), 20mM sodium acetate and 1mM EDTA 
6x DNA loading buffer  10mM Tris pH 7.5, 50mM EDTA, 10% Ficol 400 and 0.05% 
bromophenol blue 
Nuclei lysis buffer  10mM Tris-HCl, 400mM NaCl, and 2mM Na2EDTA, pH 8 
Proteinase K buffer  2mM Na2EDTA and 1% SDS 
ELISA coating buffer  1.59g/L of Na2CO3 and 2.93g/L of NaHCO3, pH 9.6 
ELISA wash buffer  PBS with 0.05% (v/v) Tween 20 
ELISA blocking buffer  3% of BSA in PBS with 0.05% (v/v) Tween 20 
ELISA sample diluent  23.8g/L HEPES, 5.84g/L NaCl, 3.72g/L Na2EDTA, 10% 
bovine serum albumin with 0.1% Tween-20, pH 7.2 
Citrate-phosphate buffer  5.2g/L citric acid and 13.8g/L Na2HPO4 
OPD substrate solution  5mg of o-Phenylenediamine.2HCl added to 12mL of citrate-
phosphate buffer containing 0.03% H2O2 
Sodium-citrate buffer  2.94 g/L sodium citrate, pH 6 
Bacterial media and solutions 
LB (Luria-Bertani) agar  1% bacto typtone, 0.5% bacto yeast, 0.5% NaCl (pH 7.0) 
with 15g/L bactoagar 
LB (Luria-Bertani) broth  1% bacto typtone, 0.5% bacto yeast and 0.5% NaCl (pH 7.0) 
SOC medium   2% tryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM KCl, 
10mM MgCl2, 10mM MgSO4 and 20mM glucose 
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Table 2.2: Primers and probes 
Primers for PCR 
eGFP Forward 1  5’ – ATGGTGAGCAAGGGCGAGGAGCTG – 3’ 
eGFP Reverse 2  5’ – TGCTGGTAGTGGTCGGCGAGCTGC – 3’ 
eGFP Forward 3  5’ – CCTGGTCGAGCTGGACGGCC – 3’ 
eGFP Reverse 4  5’ – CCGTCCTCGATGTTGTGGCG – 3’ 
eGFP BspEI Forward  5’ – ATCCGGTCTCCGGAATGGTGAGCAAGG – 3’ 
eGFP BspEI Reverse  5’ – CCTTGCTCACCATTCCGGAGACCGGAT – 3’ 
Primers for mutagenesis 
D64V Forward  5’ – CCAGGAATATGGCAGCTAGTTTG 
TACACATTTAGAAGG – 3’ 
D64V Reverse  5’ – CCTTCTAAATGTGTACAAAC 
TAGCTGCCATATTCCTGG – 3’ 
N120L Forward  5’ – GTACATACAGACAATGGCA 
GCCTTTTCACCAGTACTACAGTTAAGG – 3’ 
N120L Reverse  5’ – CCTTAACTGTAGTACTGGTG 
AAAAGGCTGCCATTGTCTGTATGTAC – 3’ 
W235E Forward  5’ – GGACAGCAGAGATCCAGTT 
GAGAAAGGACCAG CAAAGC – 3’ 
W235E Reverse  5’ – GCTTTGCTGGTCCTTTCTCAACTGG   
ATCTCTGCTGTCC – 3’ 
Q1248A Forward  5’ – GGCATTCCCTACAATCCCCAA 
AGTGCAGGAGTAATAGAATCTATG – 3’ 
Q148A Reverse  5’ – CATAGATTCTATTACTCCTGCA 
CTTTGGGGATTGTAGGGAATGCC – 3’ 
K264R Forward  5’ – GTAGTGCCAAGAAGAA 
GAGCAAAGATCATCAGGG – 3’ 
K264R Reverse  5’ – CCCTGATGATCTTTG 
CTCTTCTTCTTGGCACTAC – 3’ 
K264,266,273R Forward  5’ – CCAAGAAGAAGAGCAAGGATC 
ATCAGGGATTATGGAAGACAGATGGCAGG – 3’ 
K264,266,273R Reverse  5’ – CCTGCCATCTGTCTTCCATAAT 
CCCTGATGATCCTTGCTCTTCTTCTTGG – 3’ 
att 3’LTR forward  5’ – GCCACTTTTTAAAAGAAAA 
GGGGGGACCAGAAGGGCTAATTC – 3’   63 
att 3’LTR reverse  5’ – GAATTAGCCCTTCTGGTCCC 
CCCTTTTCTTTTAAAAAGTGGC – 3’ 
att 5’LTR forward  5’ – GGAAAATCTCTAGTGGTGGC 
GCCCGAACAGGGACTTGAAAGCG – 3’ 
att 5’LTR reverse  5’ – CGCTTTCAAGTCCCTGTTCGGG 
CGCCACCACTAGAGATTTTCC – 3’ 
P2mut Forward  5’ – GGCTGAAGCAATGAGCT 
CCGGAACAAATCCAGCTACC – 3’ 
P2mut Reverse  5’ – GGTAGCTGGATTTGTTCC 
GGAGCTCATTGCTTCAGCC – 3’ 
P2ins1 Forward  5’ – GCAATGAGCCAAGTAACAAATGGC 
AATTCCGGACCAGCTACCATAATGATA C – 3’ 
P2ins1 Reverse  5’ – GTATCATTATGGTAGCTGG 
TCCGGAATTGCCATTTGTTACTTGGCTCATTGC – 3’ 
P2ins2 Forward  5’ – GCAATGAGCCAAGTAACAAA 
TATGATACAGAAAGGCAATTCCGGACCAGCTACC – 3’ 
P2ins2 Reverse  5’ – GGTAGCTGGTCCGGAATTGCCTT 
TCTGTATCATATTTGTTACTTGGCTCATTGC – 3’ 
P2ins3 Forward  5’ – GCAATGAGCCAAGTAACAAATC 
CAGCTACCATAATGATACAGAAAGGCAATTCCGG – 3’ 
P2ins3 Reverse  5’ – CCGGAATTGCCTTTCTGTATCAT 
TATGGTAGCTGGATTTGTTACTTGGCTCATTGC – 3’ 
Primers and probes for qPCR 
Total viral DNA 
(Late RT) forward  5’ – TGTGTGCCCGTCTGTTGTGT – 3’ 
Total viral DNA 
(Late RT) Reverse  5’ – GAGTCCTGCGTCGAGAGAGC – 3’ 
Total viral DNA 
(Late RT) Probe  (FAM) 5’ – CGCCCGAACAGGGACTTGAA – 3’ (TAMRA) 
Total viral DNA 
(WPRE) forward  5’ – TGGATTCTGCGCGGGA – 3’ 
Total viral DNA 
(WPRE) Reverse  5’ – GAAGGAAGGTCCGCTGGATT – 3’ 
Total viral DNA 
(WPRE) Probe  (FAM) 5' – CTTCTGCTACGTCCCTTCGGCCCT – 3’   64 
2LTR circles forward  5’ – AACTAGAGATCCCTCAGACCCTTTT – 3’ 
2LTR circles reverse  5’ – CTTGTCTTCGTTGGGAGTGAATT – 3’ 
2LTR circles probe  (FAM) 5’ – CTAGAGATTTTCCACACTGAC – 3’ 
Titin forward  5’ – AAAACGAGCAGTGACGTGAGC – 3’ 
Titin reverse  5’ – TTCAGTCATGCTGCTAGCGC – 3’ 
Titin probe  (FAM) 5’ – TGCACGGAAGCG 
TCTCGTCTCAGTC – 3’ (TAMRA) 
Primers for sequencing 
att seq LA 1R  5’ – TTCAGCAAGCCGAGTCCTGCG – 3’ 
att seq LA 2F  5’ – TCGAGGCAATTCGAGCTCGG – 3’ 
att seq LA 3R  5’ – CCTTATGTATCATACACATACG – 3’ 
int seq LA 0F  5’ – GCTGTGATAAATGTCAGC – 3’ 
int seq LA 1R  5’ – CCTCTGTCGAGTAACGCC –  3’ 
int seq LA 2R  5’ – ATTGTGGATGAATACTGCC – 3’ 
int seq LA 3F  5’ – GACAGGTAAGAGATCAGGC – 3’ 
P2 seq LA 1F  5’ – GGATGACAGAAACCTTGTTGG – 3’ 
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2.2 – Molecular Biology Techniques 
2.2.1 – Growth and maintenance of E.coli 
 
Escherichia coli (E.coli) were grown in liquid LB media at 37ºC with agitation at 
250rpm or streaked out on solid LB plates containing 1.5% bacto agar. E.coli transformed 
with plasmids were grown on the same media supplemented with ampicillin (50µg/ml). 
For long-term storage, bacterial cultures were stored in 20% volume for volume 
(v/v) of glycerol in LB media at -80°C. 
 
2.2.2 – Production and transformation of electro-competent E.coli 
 
1L of LB media without antibiotics was inoculated 1:1000 from a fresh overnight 
culture of E.coli DH5ʱ. The culture was grown at 37°C with agitation until the optical 
density  at  600nm  (OD600)  reached  between  0.6-0.8.  The  cells  were  harvested  by 
centrifugation  at  4500rpm  in  a  superspeed  centrifuge  for  ten  minutes,  the  supernatant 
discarded and the cell pellet resuspended in 1L of cold sterile 10% glycerol. The spin was 
repeated, the supernatant discarded and the cell pellet was resuspended in 250mL of cold 
sterile 10% glycerol. The cells were centrifuged again, after which the supernatant was 
carefully discarded and the cells resuspended in the 10mL of 10% glycerol. The cells were 
transferred  to  a  smaller  centrifuge  tube  and  spun  at  7000rpm  for  ten  minutes.  The 
supernatant was removed and the cell pellet resuspended in 2mL cold sterile 10% glycerol, 
100µL of cells were transferred to microfuge tubes and snap-frozen in a dry ice-ethanol 
bath. The electro-competent cells were subsequently stored at -80°C. 
  To introduce DNA in electro-competent E.coli, cells were thawed slowly on ice 
and mixed with 1-10ng of desalted DNA. The cell/DNA mixture was then pipetted into 
pre-chilled disposable micro-electroporation cuvettes (0.2cm) and electroporated at 2.5kV, 
200 , 25µF using a Bio-Rad Gene Pulser. 1mL of room temperature SOC media was 
added to the cuvette and the media/bacterial mixture was transferred to a 5mL tube. The 
cells recovered at 37°C, with agitation at 250rpm for one hour. The cells were pelleted by 
centrifugation at 2000rpm for five minutes and the supernatant discarded. The cells were   66 
then  resuspended  in  100μL  and  spread  on  LB  agar  plates  containing  the  appropriate 
antibiotics. The plates were incubated overnight at 37°C. 
 
2.2.3 – Production and transformation of chemical-competent E.coli 
 
100mL  LB  media  without  antibiotics  was  inoculated  with  1:1000  from  a  fresh 
overnight culture of E.coli DH5ʱ. This was grown in a shaking incubator at 37 ºC until the 
OD600 was 0.6. The culture was cooled on ice for five minutes, then the bacteria were 
pelleted and re-suspended in 50mL ice-cold TFB-I buffer. After  five minutes incubation 
on  ice,  bacteria  were  pelleted  again,  re-suspended  in  5mL  ice-cold  TFB-II  buffer  and 
incubated on ice for fifteen minutes. 100μL aliquots were prepared and stored at -80°C. 
To transform chemical-competent cells, bacteria were slowly thawed on ice and 
DNA added to each aliquot. This mixture was left on ice for thirty minutes. Bacteria were 
heat shocked for forty five seconds at 42°C and immediately put back on ice for two 
minutes. 1mL of SOC medium was added and cells recovered in a shaking incubator at 
37°C for  one hour. The cells were pelleted and the supernatant discarded. Bacteria were 
then  resuspended  in  100μL  of  LB  media,  spread  on  LB  agar  plates  containing  the 
appropriate antibiotics and incubated overnight at 37ºC. 
 
2.2.4 – Plasmid DNA preparation 
 
Small-scale  plasmid  DNA  was  extracted  from  a  5mL  bacteria  culture  grown 
overnight at 37ºC using the min-prep kit from Quiagen as per manufacturer’s instructions. 
Large-scale plasmid DNA was obtained from 100mL or 500mL bacteria cultures using a 
Quiagen maxi-prep or mega-prep kit, respectively, following the manufacter’s instructions. 
The plasmid DNA concentration was calculated by measuring the absorbance of 
light with a wavelength of 260nm using a NanoDrop ND-1000 spectrophotometer with a 
0.2mm  path  length,  at  this  wavelength  50µg/mL  of  double-stranded  DNA  has  an 
absorbance of 1.   67 
2.2.5 – Cloning 
2.2.5.1 – Restriction enzyme digestion 
 
Plasmid DNA (typically 1-2µg) was  digested in  a final  volume of 10µL of 1x 
buffer (supplied by the manufacturer) and bovine serum albumin (0.1mg/ml). The amount 
of enzyme used varied depending of the concentration of the enzyme stock and the amount 
of DNA, but never exceeded 10% (v/v) of the total reaction volume. The endonuclease 
reaction was carried out at the manufacturer’s recommended temperature for 1-3 hours and 
DNA digestion was verified by agarose gel electrophoresis. Double or triple digestions 
were performed either in compatible buffers or sequentially, after clean-up of DNA by 
ethanol  precipitation  using  the  Qiaquick  PCR  purification  kit  and  following  the 
manufacturer’s protocol. 
 
2.2.5.2 – Polymerase Chain Reaction (PCR) 
 
PCR reactions were performed in a total volume of 50µL containing template DNA 
(10ng), forward  and reverse primers listed in  table 2.2 (0.5µM  each),  dNTPs  (each  at 
200µM), MgCl2 (1.5mM), buffer (1x) and Taq DNA polymerase (1U). Typically cycling 
conditions were as follows: 30 cycles of 94 C for 1min, 60 C for 1min, 72 C for 1min. 
 
2.2.5.3 – Isolation of DNA fragments 
 
DNA fragments were resolved by electrophoresis through 0.8-2% agarose gels in 
1x TAE buffer. To prepare the gels, agarose was dissolved in 1x TAE buffer by boiling in 
a microwave. After cooling, ethidium bromide was added (to obtain a final concentration 
of  0.5 g/ml)  for  visualisation  of  DNA.  DNA  samples  were  mixed  with  DNA  loading 
buffer before loading onto agarose gels. A 1 kb plus DNA ladder was included in each gel 
to enable size determination of DNA fragments. Gels were electrophoresed using a voltage 
of 50-100V (up to 150mA) and the separated DNA fragments subsequently visualised by 
exposure to ultra-violet light using an UVIdoc gel documentation system.   68 
Following electrophoresis, DNA fragments were excised from agarose gels using a 
clean scalpel blade under ultra-violet light. The DNA was then extracted from the agarose 
using a QIAquick gel extraction kit as per the manufacturer’s instructions. 
 
2.2.5.4 – Ligation of DNA fragments 
 
When the digested vector DNA ends had compatible termini with the insert DNA, 
the digested plasmid vector DNA was  treated  with  calf  intestinal  alkaline phosphatase 
(CIP) to  dephosphorylate the DNA ends  prior to  ligation. Dephosphorylation  reactions 
were  performed  directly  in  restriction  endonuclease  buffers,  immediately  following 
digestion by adding 10 units of CIP enzyme to the reaction mixture and incubating at 37°C 
in a water bath for one extra hour.  
Ligation of DNA fragments were performed using vector to insert ratios of 1:1 or 
1:4 (v/v) in a final volume of 10µL of 1x T4 DNA Ligase buffer containing 1 unit of T4 
DNA  Ligase.  The  vector  DNA  concentration  used  was  typically  20-50ng  of  DNA. 
Ligation reactions were incubated overnight at room temperature or 16°C. The ligation 
reactions were either immediately transformed into E.coli or stored at -20°C for later use. 
 
2.2.6 – Genomic DNA Isolation 
 
DNA was extracted from samples using the salting out method (Miller et al., 1988). 
Cells were pelleted by centrifugation at 1500rpm for five minutes. The supernatant was 
discarded and it was added 3mL of nuclei lysis buffer, 0.5mL of proteinase K buffer, 
0.2mL of SDS (10%) and proteinase  K (1mg). The mixture was digested overnight at 
37ºC. 1mL of saturated NaCl (6M) was added and the tubes were shaken vigorously for at 
least fifteen seconds. The tubes were centrifuged at 4500rpm for fifteen minutes and the 
supernatant transferred to a clean tube. Two volumes of absolute ethanol were added and 
the tubes were inverted several  times until  the DNA precipitated. The DNA was  then 
removed, passed through ethanol (70%), transferred to a clean eppendorf and resuspended 
in 100μL of H2O. The final concentration of DNA was accessed by quantification the 
absorbance at 260nm using a NanoDrop ND-1000 spectrophotometer.   69 
2.2.7 – Total RNA Isolation 
 
1-10x10
6 cells were well resuspended in 1mL of TRI reagent and incubated at room 
temperature for ten minutes. 0.2mL of chloroform was added to each sample after which, 
the tubes were shaken vigorously and then left resting at room temperature for fifteen 
minutes. The tubes were then centrifuged at  12000rpm  for  fifteen minutes. The upper 
aqueous phase was transferred to a new tube and 0.5mL of isopropanol was added to each 
sample to precipitate the RNA. The samples were incubated for one hour at –20ºC and then 
the RNA was pelleted by centrifugation at 12000rpm for ten minutes. The supernatant was 
discarded and the RNA was washed with 1mL of ethanol. The ethanol was removed by 
centrifugation (12000rpm, ten minutes) and the RNA resuspended in H2O. The RNA was 
quantified  by  measuring  the  absorbance  at  260nm  using  a  NanoDrop  ND-1000 
spectrophotometer, at this wavelength 40µg/mL of RNA has an absorbance of 1. 
 
2.2.8 – Site directed mutagenesis 
 
Mutagenesis of plasmid DNA was performed using the Quickchange II XL site-
directed mutagenesis kit from stratagene. The primer design was performed according to 
the manufacturer directions. Table 2.2 shows the primers used for each reaction. The PCR 
reaction was performed in a total volume of 50µL, containing a total of 100ng of template 
DNA, buffer (1x), 125ng of primer forward, 125ng of primer reverse, 1µL of dNTP mix, 
3µL of quick solution reagent and 2.5U of Pfu Turbo DNA polymerase. All reactions 
followed the thermal cycling parameters: 1min at 95ºC followed by 16 cycles of 30s at 
95ºC, 1min at 55ºC and 11min at 68ºC. After the PCR reaction, the parental DNA was 
digested with Dpn I enzyme for three hours. The resulting DNA was then transformed in 
chemical competent bacteria. DNA was extracted from single clones and sequenced to 
confirm correct mutagenesis. 
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2.3 – Tissue Culture Techniques 
2.3.1 – Cell lines propagation 
 
The following cell lines were used: 293T, C2C12 and HT1080. 293T cells are a 
highly transfectable cell line derived from the 293 human embryonic kidney cell line that 
express the SV40 large T antigen. The C2C12 cell line is a mouse myoblast cell line, 
which can be terminally differentiated into muscle fibres by serum starvation (Yaffe and 
Saxel, 1977). HT1080 is a human cell line derived from a fibrosarcoma (Rasheed et al., 
1974) that maintains a close kariotypic similarity to the initial kariotype over cell passages 
(Chen et al., 1983). 
All  cell lines were maintained in  Dulbecco’s  modified eagle medium (DMEM) 
containing  GlutaMAX  supplemented  with  foetal  calf  serum  (10%  v/v),  penicillin 
(100UI/mL) and streptomycin (100μM/mL). Cells were grown in 37ºC incubators in a 5% 
CO2 atmosphere. Cells were passaged when confluency reached 90-95%, the monolayers 
were first washed with Dulbecco’s phosphate buffered saline (PBS) and then incubated for 
2-5 minutes at 37°C with trypsin/EDTA, the cells were subsequently diluted 1:3 up to 1:10 
in fresh complete culture media and transferred to new tissue culture flasks. 
C2C12 cells were differentiated using DMEM supplemented with 2% horse serum, 
penicillin (100UI/mL) and streptomycin (100μM/mL) to maintain the cells. 
 
2.3.2 – Cell lines storage 
 
Cells  from  a  90%  confluent  monolayer  in  a  175cm
2  tissue  culture  flask  were 
pelleted  by  centrifugation  at  1200rpm  in  a  tabletop  centrifuge  for  five  minutes, 
resuspended in 10mL freezing medium (90% FCS, 10% dimethylsulfoxide) and transferred 
to a cryovial. Cells were frozen slowly overnight to -80°C in an isopropanol freezing box 
and then transferred to liquid nitrogen. 
To revive frozen cells,  aliquots were thawed rapidly in  a 37°C water  bath  and 
transferred to 4mL growth medium. The cells were pelleted at 1200rpm in a centrifuge to 
remove the dimethylsulfoxide and then resuspended in 5mL culture media and transferred 
to a 80cm
2 tissue culture flask.   71 
2.3.3 – Lentiviral vector production 
 
Viral vectors were produced by transient transfection. 10
7 293T cells were seeded 
in 175cm
2 tissue culture flasks one day before transfection. The transfection media was 
prepared by mixing 50μg of vector plasmid, 37.5μg of packaging plasmid and 17.5μg of 
envelope  plasmid  in  5mL  of  Optimem  and  5mL  of  Optimem  containing  2nM  of 
Polyethylenimine (PEI). This transfection media was incubated twenty minutes at room 
temperature prior to addition onto cells. Cells were washed with PBS and the transfection 
media was added to the cells. Cells were incubated for three hours at 37ºC and 5% CO2. 
The transfection media was removed and fresh culture media was added to the cells. On 
the following day, the media was removed and 30mL of fresh culture media was added to 
each flask. Two and three days after transfection, the media was collected and cell debris 
were removed by filtration through a 0.22µm filter. The media was then centrifuged at 
150000g in an ultracentrifuge. The supernatant was removed and 150μL of Optimem was 
added to each tube and the tubes were incubated on ice for twenty minutes. The pellet was 
resuspended and 20μL aliquots were prepared and rapidly frozen at –80ºC. 
 
2.3.4 – Adeno-Associated vector production 
 
Viral vectors were produced by transient transfection. 10
7 293T cells were seeded 
in ten 20cm tissue culture plates one day prior to transfection. The transfection media was 
prepared by mixing 50mL of Optimem containing 300μg of vector plasmid and 1400μg of 
packaging plasmid (pDG) with 50mL of Optimem containing 2nM of PEI. This mixture 
was then incubated twenty minutes at room temperature. Cells were washed with PBS and 
10mL of transfection media was added to each plate. Cells were incubated for four hours at 
37ºC  and 5% CO2. The transfection media was  removed  and fresh  culture media was 
added  to  the  cells.  Cells  were  harvested  two  days  after.  Cells  were  then  pelleted  and 
resuspended in 15mL of 50mM Tris (pH 8.5) containing 150mM NaCl. Cells were then 
lysed by three freeze-thaw cycles. Benzonase was then added to the mixture at a final 
concentration of 50U-mL and incubated at 37ºC for one hour. 
An iodixanol gradient was used to purify the vectors. The iodixanol gradient was 
prepared in  35mL ultracentrifuge tubes, overlaying (from bottom  to  top) 5mL of 60%   72 
iodixanol, 5mL of 40% iodixanol, 6mL of 25% iodixanol and 9mL of 15% iodixanol. The 
cell lysate was then transferred to this tube and the tube sealed with rotor cap accessory. 
The tubes were then centrifuged at 350000g for two hours. The vectors were then removed 
from the clear 40% layer by making an air hole on the top of the tube and removing the 
layer with a needle. The vectors were further purified using a HiTrap heparin column. 
Aliquots were then prepared and frozen at –80ºC. 
 
 
2.3.5 – Vector transduction in vitro 
 
  Cells were seeded one day before transduction. Typically, 10
5cells/well in 24 well 
plates or 5x10
5cells/well in 6 well plates were used. The vectors were diluted to obtain the 
desired final vector concentration in half the typical culture volume used to grow cells and 
added to the cells. One day after infection, the media was removed and fresh culture media 
added to the cells when cells were grown more time. 
 
 
2.3.6 – Vector infection in vivo 
 
  This procedure was performed by Dr Simon Waddington. 1-day old neonatal mice 
were  placed  on  ice  slush  until  they  no  longer  moved  when  touched.  For  intravenous 
injection, the heads were illuminated and 40µL of concentrated lentiviral vectors injected 
into the superficial temporal vein (a prominent vessel located on either side of the head, 
visible just below the eye) using a 33G Hamilton needle. For intramuscular injections, the 
hind legs were illuminated and 5μL of concentrated lentiviral vectors injected in the tibialis 
anterior muscle using a 33G Hamilton needle. Following the procedure, the mice were 
allowed to return to normal temperature on a warming mat before being returned to their 
mothers. 
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2.3.7 – Integration efficiency 
 
The level of integration of the different vectors was quantified by infecting 1x10
6 
HT1080 cell with vectors expressing neomycin phosphotransferase (Neo). Three days after 
infection,  the  medium  was  replaced  with  medium  containing  1mg/mL  of  G418 
(Invivogen).  Cells  were  grown  for  three  weeks  and  colonies  from  single  clones  were 
counted. 
 
2.4 – Analyses of in vitro and in vivo samples 
2.4.1 – Flow cytometry 
 
To calculate the titre of a vector batch expressing a fluorescent marker, 10
5 cells 
per well, in a 24 well plate, were infected with serial dilutions of the vector, in a final 
volume of 300µL. The cells were harvested two days after transduction, washed with PBS 
and pelleted in a FACS tube by centrifugation at 1500rpm for five minutes. The samples 
were then resuspended in 200µL of PBS and 200µL of PFA (2%) was added to each 
sample. Cells were then stored in the dark and analysed by flow cytometry within two 
days.  The  titre  of  the  vector  was  then  calculated  by  multiplying  the  percentage  of 
fluorescent cells (less the percentage of positive cells in an untransduced well) by 10
5 and 
divided by the volume of vector used in that well. Only wells that had between 5 and 40% 
of fluorescent positive cells were used to quantify the titre. 
To quantify the percentage or the intensity of fluorescent positive cells, cells were 
infected with a viral vector or transfected with a plasmid. Samples were harvested at a 
given time after transduction and an average of 2-5x10
5 cells were then used for flow 
cytometry. The cells were pelleted by centrifugation (1500rpm for five minutes), washed 
with PBS and resuspended in 200µL of PBS. 200µL of PFA (2%) was then added to each 
sample. The samples were then analysed by flow cytometry. 
All  samples  were  analysed  using  a  CyAn  ADP  flow  cytometry  analyser  and 
Summit version 4.1 software (DakoCytomation).  
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2.4.2 – Titration of p24 in lentiviral preparations 
 
The quantity of p24 antigen in lentiviral supernatants was measured using a Coulter 
HIV-1 p24 antigen assay as per the manufacturer’s instructions. Supernatants were diluted 
1:1 x 10
6, 1:5 x 10
6 and 1:1 x 10
7 and added to p24 antibody-coated wells together with 
diluted  calibration  standards.  Samples  were  lysed,  washed  and  then  incubated  with 
biotinylated anti-HIV-1. The samples were washed again and subsequently incubated with 
streptavidin-HRPO  followed  by  the  addition  of  tetramethybenzidine  and  Coulter  stop 
reagent  (4N  H2SO4).  The  absorbance  of  each  plate  was  then  read  at  450nm  and  the 
quantity  of  p24  reagent  calculated  from  a  standard  curve  generated  from  the  diluted 
calibration standards. 
 
2.4.3 – Quantitative real-time PCR 
 
Quantitative real-time PCR (qPCR) was used to determine the total cell number in 
a sample, the copy number of total viral DNA or 2LTR viral circles in transduced cells or 
the number of plasmids in transfected cells. Total DNA was isolated as described in 2.2.6. 
Between 10 and 100ng of DNA were then used as a template for each PCR. Reactions 
were performed in triplicate in a final volume of 25µL containing forward and reverse 
primers at 0.9µM (table 2.2), a fluorescently-labelled probe at 0.2µM and a pre-mixed 
mastermix (Platinum qPCR SuperMix-UDG with ROX) diluted to 1x with sterile distilled 
water.  Standard  curves  of  diluted  plasmids  harbouring  the  target  DNA  were  used  for 
quantification. Reactions were performed using an ABI Prism 7000 Sequence Detection 
System (Applied Biosystems) using the default cycling parameters – 1 cycle of 50°C for 
2min, 1 cycle of 95°C for 10min followed by 40 cycles of 95°C for 15s and 60°C for 1min. 
 
2.4.4 – Enzyme-linked immunosorbent assay (ELISA) 
2.4.4.1 – Factor IX (FIX) ELISA 
 
Approximately 90µL of peripheral blood was collected from the tail vein of mice 
and mixed immediately with 10µL of sodium citrate buffer (0.1M). Samples were then   75 
centrifuged at 13000rpm in a micro-centrifuge for ten minutes and the serum transferred to 
fresh eppendorfs and stored at -20ºC. 
Maxisorp  96-well  NUNC-Immuno  ELISA  plates  (NUNC)  were  coated  with 
100µL/well with FIX capture antibody diluted 1:100 in coating buffer, wrapped in cling 
film and stored overnight at 4°C. The coated plates were washed three times with 100µL of 
ELISA wash buffer and blocked for one hour at room temperature in ELISA blocking 
buffer.  The plates were washed a further three times and 100µL of diluted samples in 
ELISA sample diluent  added in triplicate along with 100µL of diluted human plasma. 
Plates were incubated at room temperature for ninety minutes and washed three times. 
100µL/well of FIX detection antibody diluted 1:100 in ELISA sample diluent was added to 
each well and plates were incubated at room temperature for ninety minutes in the dark. 
The  plates  were  subsequently  washed  three  times  and  100µL/well  of  OPD  substrate 
solution was added. The plates were incubated for eight minutes at room temperature in the 
dark, at which time the reaction was stopped by adding 50µL stop solution (2N H2SO4). 
The absorbance of each well was then read at 490nm using a FLUOstar Optima plate 
reader. Standard curves of diluted human plasma were used to quantify the percentage of 
hFIX contained in each sample.   
 
2.4.4.2 – Enhanced green fluorescent protein (eGFP) ELISA 
 
Samples were prepared from muscle or cultured cells. Protein was extracted in lysis 
buffer using a homogenizer. Total protein was assayed using the Biorad protein assay kit 
with bovine serum albumin as a standard and following the manufacturer’s instructions. 
The  eGFP  was  quantified  in  triplicate  against  a  recombinant  eGFP  standard  using  the 
monoclonal antibody ab1218-100 (1:10000) as primary antibody, and the biotin labelled 
secondary antibody ab5688 (1:5000). Streptavidine-peroxidase was used to develop the 
ELISA, and the absorbance was read at 450nm using a FLUOstar Optima plate reader. 
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2.4.5 – Immunohistochemistry 
 
Samples  from  the  tibialis  anterior  muscle  were  fixed  in  paraformaldehyde  and 
sections  (5µm)  were  cut  from  paraffin-embedded  tissue  blocks.  Slides  were  placed  in 
histoclear solution and then hydrated in graded ethanol solutions. Antigen retrieval was 
performed using sodium citrate buffer and heating. Endogenous peroxidase was blocked 
by incubation with 0.3% H2O2 in phosphate-buffered saline for ten minutes. Slides were 
incubated  with  2%  normal  mouse  serum,  then  with  avidin  and  biotin.  Slides  were 
incubated overnight with rabbit anti-GFP serum, and then with biotinylated goat anti-rabbit 
secondary antibody for forty minutes. After being thoroughly washed in PBS, the slides 
were  incubated  with  Vectastain  ABC  kit  in  accordance  with  the  manufacturer's 
instructions. AEC substrate was used for detecting peroxidase activity, in accordance with 
the manufacturer's instructions. Hematoxylin was used for counterstaining and slides were 
then mounted in aquamount. Images were obtained on a Leica DMLS upright microscope 
using  a  40  objective  with  a  Canon  Coolpix  4500  digital  camera,  and  processed  with 
Adobe Photoshop software. 
 
2.4.6 – Western Blot 
 
Cells were washed in PBS and pelleted in 1.5mL eppendorf tubes by centrifugation 
at 1500rpm for five minutes in a table-top centrifuge. Protein was harvested from cell 
pellets  by  resuspension  in  100µL  lysis buffer supplemented with  1µL  HALT Protease 
inhibitor cocktail and incubation on ice for ten minutes with occasional shaking. Viral 
lysates were prepared by resuspending 25µL of concentrated virus in lysis buffer with 1µL 
HALT Protease inhibitor cocktail and incubating on ice for ten minutes. The lysates were 
spun at 13000rpm in a microcentrifuge at 4°C for fifteen minutes and the supernatants 
containing  the  nuclear  and  cytoplasmic  protein  transferred  to  fresh  eppendorfs.  The 
samples  were  diluted  1:1  with  loading  buffer  (100mM  Tris-HCl,  4%  SDS,  0.2% 
bromophenol blue, 20% glycerol and 10% β-mercaptoethanol) and heated to 95°C for five 
minutes. Samples were then stored at -20ºC until run in a polyacrylamide gel.    77 
Protein samples were loaded onto 4-12% Bis-Tris Novex pre-cast gels along with a 
pre-stained  protein  standard.  Proteins  were  separated  by  polyacrylamide  gel 
electrophoresis at 200V for fifty minutes in an XCell SureLock Mini-Cell (Invitrogen) in 
1x  NuPAGE  MOPS  SDS  running  buffer.  The  separated  proteins  were  subsequently 
immunoblotted onto PVDF membrane using the XCell II blot module (Invitrogen) at 30V 
for one hour. The PVDF membrane was washed with methanol for thirty seconds, rinsed in 
distilled water and then washed in 1x NuPAGE transfer buffer prior to immunoblotting.  
Following  immunoblotting,  PVDF  membranes  were  incubated  overnight  with 
blocking  buffer  (PBS,  0.1%  (v/v)  Tween  20,  5%  (w/v)  milk  powder)  to  prevent  non-
specific antibody staining. Membranes  were subsequently washed five times in PBS-T 
(PBS, 0.1% (v/v) Tween 20) and incubated with primary antibody in 3mL blocking buffer 
for two hours at room temperature with agitation. The membranes were washed a further 
five times in PBS-T and then incubated with an HRP-conjugated secondary antibody in 
3mL  blocking  buffer  for  forty  five  minutes  at  room  temperature  with  agitation.  The 
membranes were washed for a final five times after which 1mL of ECL western blotting 
substrate  was  added  directly  to  the  membrane  and  incubated  for  one  minute  at  room 
temperature.  Protein  bands  were  visualised  using  an  UVIchemi  (UVItec) 
chemiluminescence documentation system and UVIsoft (UVItec) software. 
 
2.4.7 – Southern Blot 
 
Genomic DNA was digested overnight at 37°C with a selected restriction enzyme. 
DNA fragments were then separated by overnight gel electrophoresis on a 0.6% agarose 
gel at 20V. The gel was sequentially submerged in  0.25M HCl for ten minutes, 0.5M 
NaOH with 1.5M NaCl for thirty minutes and 1M Tris-HCl + 1.5 M NaCl (pH 7.4) for 
thirty  minutes.  Each  of  these  incubations  was  done  on  a  revolving  platform  at  room 
temperature and the gel was rinsed with distilled water in between incubations with the 
different solutions. DNA fragments were blotted overnight by neutral transfer, using 20X 
SSC,  onto  a  positively  charged  nylon  membrane  (HybondTM–XL,  Amersham 
Bioscience).  The  membrane  was  then  washed  in  2X  SSC.  The  membrane  was  pre-
hybridised  in  15mL  Rapid-HybTM  Buffer  supplemented  with  10μg/mL  Salmon  Testis   78 
DNA (Sigma) overnight at 65°C. DNA was probed with a 32P labelled GFP probe (PCR 
product generated using primers GFP Forward 1 and GFP Reverse 2). The probe was made 
using the Rediprime II Random Prime Labelling System. Each probe was labelled with 
50μCi (1.85MBq) of Redivue [ʱ-32P] dCTP. Unincorporated nucleotides were removed 
using the QIAquick Nucleotide Removal kit (Qiagen). Prior to addition to the hybridisation 
buffer, the probe was denatured by heating it to 100ºC for five minutes. The membrane 
was hybridised in the presence of the probe overnight at 65°C. The following day, the 
membrane was washed sequentially in 2% SSC + 0.1% SDS, 1% SSC + 0.1% SDS, 0.5% 
SSC + 0.1% SDS and 0.25% SSC + 0.1% SDS. Each wash was performed at 65°C for 
twenty minutes. The membranes were then exposed to Kodak BioMax film. 
 
2.4.8 – Confocal microscopy 
 
  One  day  prior  before  infection,  10
4  cells  were  plated  on  poly-L-Lysine  coated 
slides. Cells were then transduced with serial dilutions of vectors and incubated at 37ºC 
and 5% CO2, for eighteen hours. Samples were then prepared for confocal microscopy. 
Cells  were  fixed  in  4%  PFA  for  thirty  minutes  at  room  temperature.  Cells  were  then 
permeabilised  with  0.5% Triton  X for five minutes and stained with  Alexa Fluor 488 
Phaloidin for five minutes. Samples were always washed with PBS between each step. A 
cover  slip  was  then  placed  on  top  of  the  cells  and  sealed  with  Vectashield  hard  set 
mounting  medium  containing  Dapi.  Samples  were  then  visualized  in  a  confocal 
microscope  TCS  SP2  (Leica)  and  data  collected  was  analysed  with  Leica  confocal 
software. 
 
2.4.9 – Statistical Analysis 
 
Data  from  the  integration  efficiency  quantification  assays  and  eGFP  ELISA 
measurements  were  analysed  using  a  Kuskal–Wallis  test  for  statistical  significance            
(P < 0.05), and particular groups were compared using a Mann–Whitney test. 
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Chapter Three 
Development of Non-integrating Lentiviral Vectors 
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3 – Development of Non-Integrating Lentiviral Vectors 
3.1 – Introduction 
 
Vectors based on lentiviruses are able to deliver DNA into a broad range of cell 
types,  both  dividing  and  non-dividing.  Furthermore,  their  characteristic  of  genome 
integration into the host genome makes them particularly useful when prolonged transgene 
expression is required in dividing cells. However, an integration event nearby an oncogene 
or a tumour suppressor gene may cause malignant transformation. The lymphoproliferative 
condition that arose in two patients in a successful clinical trial demonstrates the risk of 
insertional mutagenesis that may be caused by integrating vectors(Hacein-Bey-Abina et 
al., 2003a; Hacein-Bey-Abina et al., 2003b). 
Integration may not be necessary in non-dividing cells. Also, transient transgene 
expression  can  have  useful  applications  (Nightingale  et  al.,  2006).  Upon  reverse 
transcription, viral DNA enters the nucleus in order to be integrated into the host genome. 
Nevertheless, circular DNA molecules are also created as by-products of integration. These 
molecules can have one  LTR  (formed by homologous  recombination between the two 
LTRs) or two LTRs produced by non-homologous end-joining of the double stranded blunt 
viral DNA produced upon reverse transcription (Butler et al., 2002). The formation of 
circular genomes is thought to occur in the nucleus. As a consequence, these molecules 
have been used to quantify nuclear viral DNA. It was believed that these molecules were 
by-products of integration, but recent findings suggest that this non-integrated viral DNA 
could support transcription (Wu and Marsh, 2003; Brussel and Sonigo, 2004; Poon and 
Chen, 2003). Indeed, two reports have shown stable transgene expression in post-mitotic 
tissues  in  vivo,  from  non-integrating  lentiviral  vectors  (NILVs)(Philippe  et  al.,  2006; 
Yanez-Munoz et al., 2006). 
There has been some controversy about these recent finding since first generation 
NILVs showed little transgene expression (Blomer et al., 1997; Naldini et al., 1996b). 
Bayer et al have recently published a study showing that the deletion of a large sequence 
within  the  unique  in  3’  (U3)  region  of  the  virus  (self  inactivating  (SIN)  vectors)  is 
responsible for the different expression profiles of these NILVs, compared with NILVs   81 
containing  the  whole  U3  region.  The  removal  of  that  sequence  in  SIN  vectors  allows 
efficient expression from episomal lentiviral vectors (Bayer et al., 2008). 
In order to produce NILV that express the transgene of interest, integration has to 
be blocked specifically. Integrase (IN) cannot be deleted because it is involved in reverse 
transcription  (Zhu  et  al.,  2004)  and  possibly  in  nuclear  entry  (Gallay  et  al.,  1996). 
Nevertheless, several groups have demonstrated that mutations in IN or in the cis-acting 
sequences interacting with IN (att sites) block integration. 
The  catalytic  core  of  IN  contains  a  motif  (DD35E)  that  is  conserved  among 
retroviral integrases and transposable elements (Johnson et al., 1986) and is absolutely 
necessary for integration. Mutation of any of the residues impairs integration (Leavitt et 
al., 1996). Other mutations in residues can block specifically one of the catalytic steps of 
the integration reaction. For example, the Q148 residue is implicated in IN binding to viral 
DNA  and  3’processing  (Esposito  and  Craigie,  1998;  Gerton  et  al.,  1998).  Lysines  at 
position  264,  266  and  273  are  involved  indirectly  in  strand  transfer:  Cereseto  and 
colleagues demonstrated that these residues are acetylated in the target cells and that this 
modification is required for strand transfer (Cereseto et al., 2005). A mutation in residue 
N120,  which  is  near  the  catalytic  site,  but  implicated  in  DNA  binding,  also  blocks 
integration (Leavitt et al., 1996; Lu et al., 2005). Tryptophan at position 235 is also related 
with  DNA  binding  and  mutation  of  this  amino  acid  blocks  integration  (Leavitt  et  al., 
1996). The conserved dinucleotides CA (att sites) in the viral genome are essential for 
integration, as they are the recognition sequence for integrase binding to the genomic viral 
DNA. Mutations in either U3 or U5 att sites reduce integration 60 and 30%, respectively. 
Most  importantly,  a  synergistic  effect  is  observed  when  the  viral  genome  has  both 
mutations, where integration represents 1% of the wt genome (Masuda et al., 1998). 
The aim of this work was the development and assessment of NILVs. Mutations 
that target  different  mechanisms  of integration  were studied and combined in  a single 
vector. This may contribute towards improving the safety of using NILVs in gene therapy. 
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3.2 – Production of non-integrating lentiviral vectors 
 
In order to produce non-integrating vectors, two approaches can be taken: mutation 
of the viral IN or mutation in the vector genome in the attachment sites (att), where IN 
binds.  Figure  3.1  shows  where  point  mutations  were  introduced.  The  mutations  were 
generated by site-directed mutagenesis and confirmed by sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Schematic illustration of the mutations created in the integrase and in the viral 
genome.  
A - Integrase domains representation. Bold represents conserved amino acids (Zn finger 
(HHCC) and catalytic core (DD(35)E), italic and underlined residues represents mutations 
done in the enzyme. B - Viral genomic RNA representation. Mutations produced in the 
attachment sites (conserved dinucleotides) are shown in italic and underlined 
 
 
 
To confirm that the introduction of the mutations did not affect vector production, 
viral particles were assessed by quantification of the p24 protein, using an ELISA kit. As 
shown in Table 3.1, the vector stocks had similar order of magnitude of viral p24 protein 
for all of the mutant and the integrating vectors, implying that the mutations did not affect 
vector production.  
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Infectivity was measured by assessing the concentration of transducing units. 293T 
cells were infected with several dilutions of the viral vectors expressing eGFP from the p5 
promoter.  This  is  a  promoter  derived  from  adeno-associated  virus.  Two  days  after 
infection, cells were harvested and the number of eGFP expressing cells was accessed by 
flow cytometry. Table 3.1 shows that high titre was achieved for all of the vector mutants. 
 
 
Table 3.1: Quantification of viral particles and infectivity 
 
Vectors  Viral particles 
(pg (p24)/mL) 
(a) 
Infectivity 
(TU/mL) 
(b) 
Integrating vector  1.95E+07  3.51E+08 
D64V  4.39E+07  5.12E+08 
N120L  4.11E+07  7.61E+08 
W235E  1.43E+07  1.84E+08 
Q148A  4.82E+07  4.63E+08 
K264R  6.03E+07  2.92E+08 
K264,266,273R  3.28E+07  9.56E+07 
∆att  2.53E+07  1.25E+09 
(a)  –  Viral  particles  were  quantified  by  measuring  the  concentration  of  p24  in  serial 
dilutions of each vector using a p24 ELISA kit. An average of at least 3 different vector 
productions is shown. 
(b) – To assess infectivity of vector preparations, 293T cells were infected with serial 
dilutions of vectors expressing eGFP. On the second day post infection, cells were scored 
for eGFP by flow cytometry, using untransduced cells as negative control. Titres were then 
calculated (#infected cells x % transduced cells / volume). The values shown are the mean 
of at least three experiments. 
 
 
3.3 – Assessment of integration from NILVs in vitro 
 
To evaluate the vector expression over time, 293T cells were infected with the 
same MOI (0.3 – to ensure low vector copy numbers at start) and eGFP expressing cells 
were then accessed by flow cytometry at several time points.   
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Figure 3.2: Transgene expression profile over time of cells infected with mutant vectors.  
293T cells were infected with the same MOI (0.3) with vectors expressing eGFP from the 
p5 promoter. The percentage of transgene expressing cells was then monitored by flow 
cytometry analysis over time. For easy comparison, wt and D64V vectors were plotted in 
all graphs. A - cells infected with N120L, W235E and ∆att vectors; B - cells infected with 
Q148A, K264R and K264,266,273R mutant vectors. 
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Cells  infected  with  the  D64V  integrase  mutant  vector  express  the  transgene 
transiently  (Figure  3.2).  The  kinetics  of  transgene  expression  for  N120L  and  W235E 
mutants is similar (Figure 3.2 A). For the three mutants, the percentage of eGFP expressing 
cells decreases over time, being indistinguishable from the negative control on the 14
th day 
post  infection.    The  kinetics  of  expression  from  the  mutants  Q148A,  K264R  and 
K264,266,273R  differ  from  the  D64V  vector  (Figure  3.2  B).  Although  the  cells  lose 
expression over time, the percentage of GFP positive cells reaches a plateau. Expression 
was 1.5, 2 and 5 fold lower than expression from the integrating vector for the mutants 
K264R, Q148A and K264,266,273R, respectively. 
 
Therefore, it was demonstrated that these vectors are able to efficiently transduce 
cells. However, expression is lost over time indicating that integration of the vector into 
the host cell genome is blocked. 
 
 
3.4 – Mutant vector expression characterisation 
 
In  order  to  verify  the  levels  of  transgene  expression,  the  mean  intensity  of 
fluorescence  was  measured  in  cells  infected  with  the  same  MOI  (0.3).  This  value  is 
correlated with  transgene expression. Table 3.2 shows that the mutations  had minimal 
impact  on  the  level  of  transgene  expression,  as  MFI  is  no  more  than  2  fold  lower, 
compared with the integrating vector. 
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Table 3.2: Expression levels (MFI) of eGFP positive cells infected with vectors 
 
Vectors  MFI 
(a) 
Integrating vector  1.00 
D64V  0.50 
N120L  0.51 
W235E  0.52 
Q148A  0.87 
K264R  0.97 
K264,266,273R  0.86 
∆att  0.96 
(a)  –  293T  cells  were  infected  with  the  vectors  at  MOI  0.3.  At  the  second  day  post 
infection, cells were harvested and expression levels were scored by flow cytometry. The 
mean  intensity  fluorescence  (MFI)  obtained  was  standardised  using  the  MFI  of  the 
negative control and then compared with the value obtained for the integrating vector. 
 
 
 
 
  The  accumulation  of  viral  DNA  in  cells  was  also  studied.  After  reverse 
transcription, the linear viral DNA enters the nucleus where it becomes integrated into the 
host  genome.  However,  through  non-homologous  end  joining,  viral  DNA  circles 
containing  2LTR  are  formed.  Viral  DNA  circles  containing  1LTR  are  also  created, 
probably  due  to  homologous  recombination  between  the  viral  LTRs.  Therefore,  to 
investigate the kinetics of these processes, 293T cells were infected with the integrating 
vector  and  the  mutant  vector  D64V.  Total  DNA  was  harvested  from  infected  cells  at 
several time points and a Southern Blot was performed to detect the viral DNA forms. 
When the viral DNA is digested with EcoR I (an enzyme that cuts the DNA between the 
viral LTRs), and the DNA probed with the transgene, it is possible to distinguish the 3 
viral DNA forms. Figure 3.3 shows a schematic representation of this process. 
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Figure 3.3: Southern Blot of DNA harvested from cells infected with integrating and non-
integrating vectors. 
293T cells were infected with the integrating vector (int +) and the non-integrating vector 
D64V (int -). The DNA was extracted at several time points, digested with EcoR I and 
probed for the transgene (eGFP). A – Schematic representation of the viral DNA forms 
detected with the southern blot. B – Southern blot of 7μg of total genomic DNA probed for 
eGFP and β-actin. 
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Figure 3.3 shows that viral DNA can be clearly detected as early as 8h, for both 
integrating and non-integrating vectors, although a faint band can also be identified at 3h 
for both vectors. In cells infected with the integrating vector, the concentration of the viral 
linear DNA form increases from the 8h to the 19h time point, but it decreases slightly 
afterwards. A similar pattern is also seen for the D64V vector, nonetheless, the decrease of 
the concentration of the linear form is more pronounced for this vector. Due to the similar 
size,  it  is  not  possible  to  clearly  distinguish  between  1LTR  and  2LTR  circles,  so  the 
corresponding bands will be regarded as one, corresponding to the total viral DNA circles. 
The viral DNA circles were detected 8h post infection in cells infected with both vectors, 
the concentration increased in the 19h time point and then it remains constant at the 30h 
time point. It is important to mention that 30h after infection, the relative concentration of 
DNA circles is higher in cells infected with the D64V vector than with the integrating 
vector. 
   
The  viral  DNA  forms  were  then  investigated  in  more  detail.  293T  cells  were 
infected with the vectors and DNA was harvested two days after infection. Total viral 
DNA and 2LTR circles were then measured by qPCR. The results (Figure 3.4) show that 
total viral DNA levels were similar for all vectors tested (p>0.05 at a significance level of 
95%,  tested  by  one-way  ANOVA).  The  mean  of  2LTR  circles  levels  was  also  not 
statistically  different  (tested  by  one-way  ANOVA,  at  a  significance  level  of  95%), 
although a pattern can be detected. NILVs have higher levels of 2LTR circles, on average, 
than the integrating vector. One exception is the 2LTR DNA circles from the mutants 
K264R and K264,266,273R, which appear to have levels comparable to the integrating 
vector. 
 
 
 
 
 
   89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Viral DNA quantification in infected cells with lentiviral vectors. 
293T  cells  were  infect  at  the  same  MOI  (0.3)  with  vectors.  On  the  second  day  after 
infection, total DNA was harvested from cells. qPCR was performed to the samples, in 
parallel  with  a  standard  derived  from  serial  dilutions  of  plasmid  DNA  containing  the 
sequence amplified by the primers. A – Quantification of total viral DNA (amplifying a 
region  between  U5  and  the  packaging  signal)  B  –  Quantification  of  2LTR  circles 
(amplifying the sequence between U5 on the 5’LTR and U3 on the 3’LTR). The values 
obtained were then normalised so the integrating vector (wt) would have the value 1. Bars 
represent the obtained mean and error bars the standard error of the mean. 
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3.5 – Quantification of background integration 
 
The  study  of  transgene  expression  over  time  in  cells  infected  with  NILVs 
demonstrated that these vectors are not being integrated into the host genome. Next, to 
quantify the background level of integration of the mutants, HT1080 cells were infected 
with vectors expressing the protein neomycin phosphotransferase that confers resistance to 
an antibiotic. Cells expressing the transgene survive when cultured in medium containing 
G418, but cells that do not produce this protein will die. Therefore, only cells that have an 
integrated viral DNA and express the transgene will survive under these conditions over 
time. G418 resistant cell colonies were quantified 3 weeks after infection. This provides a 
defined  level  of  background  integration  that  can  be  compared  with  the  integration 
efficiency of the integrating vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Quantification of background integration of mutant vectors.  
HT1080  cells  were  infected  with  serial  dilutions  of  vectors  expressing  neomycin 
phosphotransferase.  Cells  were  incubated  in  medium  supplemented  with  G418  and 
colonies  counted  3  weeks  after  infection.  The  number  of  colonies  obtained  from  cells 
infected with NILVs was compared with the ones infected with the integrating counterpart. 
Bars represent the average of at least two different experiments. Error bars represent the 
standard error of the mean. 
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As shown in Figure 3.5, the D64V mutant integrates 10
3 fold less efficiently than 
the  integrating  vector.  Similar  levels  were  found  for  the  mutants  N120L  and  W235E. 
Integration levels for K264R, Q148A and K264,266,273R mutants were 3, 13 and 14 times 
lower than the integrating vector, respectively. The ∆att mutation gives a background level 
of integration of 100 fold compared with the wild type genome vector.  
 
 
 
 
3.6 – Multiple mutant vectors 
 
 
  The vectors harbouring the single mutations D64V, N120L and W235E showed the 
lowest integration efficiency. Therefore, the next step was to incorporate the mutations in 
the same integrase and combine the mutant integrase with the mutant att sites in the vector. 
The mutations were introduced by direct site mutagenesis and confirmed by sequencing 
the  DNA.  The  production,  infectivity  and  level  of  expression  were  then  accessed.  As 
described previously, the production was evaluated by measuring the concentration level 
of  p24,  the  infectivity  by  measuring  the  concentration  of  infectious  particles  and  the 
expression level by accessing the MFI of infected cells. 
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Table 3.3: Quantification of viral particles, infectivity and expression levels (MFI) of 
multiple mutant vectors 
 
Vectors  Viral particles 
(pg (p24)/mL) 
(a) 
Infectivity 
(TU/mL) 
(b) 
MFI 
(c) 
D64V + N120L  3.22E+07  2.30E+08  0.49 
D64V + W235E  1.20E+07  2.05E+08  0.49 
D64V + N120L + W235E  1.91E+07  9.03E+08  0.69 
D64V + ∆att  4.53E+06  1.82E+08  0.97 
D64V + N120L + W235E + ∆att  2.73E+07  9.35E+07  0.69 
All values represent the average of at least three different vector productions. 
(a) – Particles were quantified by measuring the p24 protein levels using an ELISA kit. 
(b) – 293T cells were infected with serial dilutions of vectors expressing eGFP controlled 
by the p5 promoter. Two days after infection, cells were harvested and eGFP positive cells 
were  quantified  by  flow  cytometry,  using  untransduced  cells  as  a  negative  control. 
Infectious titre was then calculated. 
(c) – eGFP production was assessed two days after infecting 293T cells with lentiviral 
vectors (using MOI 0.3). In order to measure expression, the mean intensity fluorescence 
(MFI) was scored by flow cytometry. The MFI obtained was normalised with the negative 
control and then compared with the value obtained for the integrating vector. 
 
 
Table 3.3 shows that, as for single mutants, all multiple mutants had similar levels 
of p24 and infectivity, compared with the integrating vector. The expression from these 
NILVs was 2 fold lower than the integrating counterpart. 
 
  The lack of integration was confirmed by studying the expression of cells infected 
with  these multiple mutant  vectors  over time.  Figure 3.6 demonstrates that 293T cells 
express the transgene transiently and that, similarly to the D64V mutant, expression is not 
detected after day 14 after infection.  
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Figure 3.6: Transgene expression profile over time of cells infected with multiple mutant 
vectors.  
293T cells were infected with the same MOI (0.3) with vectors expressing eGFP from the 
p5 promoter. Green positive cells were monitored by flow cytometry over time. For the 
ease of comparison, integrating (wt) and D64V vectors were plotted in both graphs. A - 
cells infected with D64V + N120L (DN), D64V + W235E (DW) and D64V + N120L + 
W235E (DNW); B - cells infected with combination of mutant integrases and mutant viral 
genomes: D64V + ∆att and D64V + N120L + W235E + ∆att (DNW + ∆att). 
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  The background integration was then measured by the antibiotic resistance assay 
described previously in section 3.5. For the ease of comparison, the results of the levels of 
integration of the mutant D64V IN mutant and the ∆att vector mutant are also shown in 
figure 3.7. Interestingly, the combination of mutations D64V+N120L and D64V+W235E 
in IN did not diminish further the level of background, compared with the mutations alone. 
The triple mutant D64V+N120L+W235E (DNW) background was 1.4 fold lower than the 
D64V mutation alone, but not statistically significant. This implies that these mutations do 
not have a synergistic or additive effect on background integration. The ∆att mutation 
gives a background level of integration of 100 fold compared with the wt genome vector. 
In combination with the D64V IN mutant, the level is similar to the one of the D64V 
mutant alone (10
3 fold). In combination with the DNW mutant, the level was lowered 
further, being 3x10
3 fold less integrated than the integrating vector but not statistically 
different from the D64V vector (tested by one-way ANOVA, with a significance level of 
95%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Quantification of background integration of multiple mutant vectors.  
HT1080  cells  were  infected  with  serial  dilutions  of  vectors  expressing  neomycin 
phosphotransferase.  Cells  were  incubated  in  medium  supplemented  with  G418  and 
colonies  counted  3  weeks  after  infection.  The  number  of  colonies  obtained  for  cells 
infected with NILVs was compared with the integrating counterpart. Bars represent the 
average of at least 2 different experiments and error bars the standard error of the mean. 
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3.7 – Discussion 
 
Non-integrating lentiviral vectors (NILVs) use the advantages of lentiviral based 
vectors without the potential problem of insertional mutagenesis. As these vectors do not 
integrate into the host chromosomes and lack a replication signal, the viral DNA will be 
diluted out during cell division. Therefore, NILVs will be particularly useful, for example, 
in post mitotic tissue gene therapy.  
NILVs  were  designed  by  mutating  integrase,  the  key  viral  enzyme  in  the 
integration process and the cis-acting sequences (att sites) in the vector DNA where IN 
binds. It was demonstrated that the generated mutants could be produced at similar levels 
as the integrating vector and that infectivity is also similar (Table 2), implying that the 
mutations introduced did not affect vector production (assembly and budding). As shown 
in  Figure  3.2,  expression  diminishes  over  time  for  all  mutant  vectors  generated.  This 
implies that viral DNA is degraded or diluted out with cell division indicating that these 
vectors fail to integrate the viral DNA into the host chromosomes. 
The viral DNA accumulation in cells infected with integrating and non-integrating 
vectors was then studied. For the integrating and non-integrating vectors under analysis, 
the  viral  DNA  can  be  detected  in  infected  cells  as  soon  as  3h  after  infection.  The 
concentration of the linear form of the viral DNA increases until 19h but then decreases in 
the last time point. Most importantly, this effect is more pronounced in the D64V mutant 
vector.  Regarding  the  viral  DNA  circles,  it  is  possible  to  detect  these  forms  8h  after 
infection. The concentration increases afterwards, in the 19h time point and is maintained 
in the last time point. Also, the relative concentration of DNA circles is higher for the 
D64V mutant compared with the integrating counterpart vector. These results imply that 
reverse transcription occurs early after infection and possibly the viral DNA detected at the 
3h time point is still in the cell cytoplasm. LTR circles are an indication of nuclear viral 
DNA, as recombination only occurs in the nucleus, so it is possible to infer that nuclear 
entry  has  happened  between  3  and  8h  after  infection.  The  decrease  of  linear  DNA 
concentration from 19h to 30h can be explained by assuming that this is the substrate for 
integration and viral DNA circles formation. Viral DNA forms were quantified 48h after 
infection by qPCR, and the results show that the total viral DNA concentration of NILVs is   96 
similar  to  the  integrating  counterpart  vector,  implying  that  reverse  transcription  is  not 
impaired.  Also,  the  concentration  of  viral  2LTR  circles  was  even  higher  for  NILVs, 
indicating that nuclear entry is also not blocked. For the NILVs, integration is impaired, so 
the linear viral DNA may be converted to DNA circles at a rate higher than the integrating 
vector, explaining the higher concentration of circle forms for the NILVs. 
The  integration  background  was  then  quantified.  Single  mutations  in  residues 
D64V, N120 and W235 of Integrase affected integration, lowering it to 10
3 fold less than 
the integrating vector. Similarly, Leavitt and colleagues show that a vector harbouring the 
N120L mutation in IN integrates 10
-3 and that vectors containing the mutations D64V and 
W235E integrate at 10
4 fold lower than the integrating vector (Leavitt et al., 1996). The 
mutations  K264R,  Q148A  and  K264,266,273R  were  less  effective.  Integration  was 
lowered 3, 13 and 14 fold, respectively when compared with the integrating counterpart. 
This is correlated with the plateau of eGFP expression seen in 293T transduced with these 
mutants (Figure 3.2). The mutation of the att sites diminishes integration by 100 fold. This 
result is similar to the one obtain by Masuda and colleagues (Masuda et al., 1998).  
NILVs were then further developed to incorporate double and triple mutations in 
integrase  and  combined with  the att sites  mutant  vector. Results  show that integration 
could not be reduced much further. Although the quadruple mutant DNW + ∆att integrated 
at a 3x10
3 rate less than the integrating counterpart vector, this value was not statistically 
significant.  Nightingale  and  colleagues  recently  publish  similar  results,  combining  the 
D64V mutation and the ∆att mutations (Nightingale et al., 2006). These results suggest 
that the combination of mutations is neither additive nor synergetic.  
Linear double stranded DNA can be integrated non-specifically in the host genome. 
When there is a double strand break in the host genome, the DNA is repaired either by 
homologous recombination or non-homologous end joining. The last pathway involves the 
ligation of two double stranded DNA molecules, not requiring any homology between 
them  (reviewed  in  van  Gent  et  al.,  2001).  Using  this  mechanism,  the  cells  may  then 
integrate the viral linear DNA produced upon reverse transcription or viral DNA circles 
that were broken at double stranded break points in the genome. Therefore, it is important 
to consider that the cells used in this assay may not be the best model because they are   97 
very  recombinogenic  –  HT1080  have  a  random  integration  rate  of  4x10
-4  (Yanez  and 
Porter, 2002). Possibly, primary cells would be more suitable models for this experiment.  
The  occurrence  of  mutations  during  or  before  vector  production  in  packaging 
constructs that  encodes  an integration deficient  enzyme may  result in  vectors  carrying 
active INs.  Hence, it is important to emphasise that the triple mutant packaging plasmid 
(DNW) lowers the risk of reversion back to an integrating phenotype. Furthermore, the 
mutation of the att sites within the viral genome reduces the risk of rescue or integration of 
the vector if a patient treated with NILVs is infected with a wild type HIV. Therefore, the 
multiple mutations in these NILVs represent a safer vector for the use in gene therapy.   98 
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4 – Application of Non-Integrating Lentiviral Vectors 
4.1 – Introduction 
 
  In  the  previous  chapter,  it  was  shown  that  non-integrating  lentiviral  vectors 
(NILVs) are produced in a similar manner to their integrating counterpart. It was also 
demonstrated that NILVs are infective and the transgene is efficiently expressed in the 
target  cells.  However,  the  viral  DNA  of  the  developed  NILVs  does  not  contain  a 
replication origin. Therefore, expression decays when these vectors are used to transduce 
dividing cells, since the viral DNA does not integrate into the host genome, as depicted in 
Figures 3.2 and 3.6. The application of these vectors will then be studied in this chapter. 
   
Transient  expression  of  a  transgene  can  have  several  applications,  such  as  the 
introduction of a signal to stimulate cell proliferation or to provide a differentiation signal. 
Another  application  of  the  developed  NILVs  would  be  suicide  gene  therapy.  The 
application of these NILVs in gene therapy of monogenic diseases may require prolonged 
expression of the transgene. This can only be achieved in non-dividing cells that do not 
degrade the viral episomal DNA. 
It was previously shown that NILVs are able to sustain expression in non-dividing 
tissues, such as brain and retina for long periods of time. Prolonged transgene expression 
was seen in cortical primary neurons infected with NILVs in vitro and in brain after a 
stereotactical injection. The well established model of retinal dystrophies Rpe65
rd12/rd12 was 
also used to show that NILVs are able to efficiently transduce retinal cells and rescue 
Rpe65 deficiency (Philippe et al., 2006; Yanez-Munoz et al., 2006). The aim of the work 
presented in this chapter is to extend this research to study the application of NILVs in 
muscle. Muscle cells do not divide unless there is a lesion and thus, they provide a good 
target for stable expression from NILVs. 
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4.2 – Test of NILVs in non-dividing cells 
 
C2C12 cells are a good model to study muscle cells in vitro. These cells are easily 
differentiated into non-dividing fibres by serum starvation. The kinetic of expression from 
NILVs was studied in dividing and non-dividing C2C12 cells. Dividing and differentiated 
cells were infected with similar concentrations of vectors expressing eGFP from the p5 
promoter.  The  GFP  positive  cell  percentage  was  then  quantified  over  time  by  flow 
cytometry.  
 
 
As shown in Figure 4.1, all the vectors tested are able to infect muscle cells. The 
expression in dividing C2C12 cells with NILVs has similar kinetics as in 293T cells: for all 
vectors  studied,  expression  is  transient  and  not  detected  after  12  days.  In  contrast, 
transgene expression is stably maintained in non-dividing cells for up to 12 days. In the 
differentiated C2C12 cells, the percentage of transgene expressing cells was higher at the 
second time point, five days after infection than at the first time point. This may indicate 
that  expression  in  these  cells  is  delayed  compared  to  293T  cells,  where  the  highest 
percentage  of  transgene  expressing  cells  was  detected  two  days  after  transduction.    A 
decrease of the percentage of eGFP positive cells is then seen at the last time point for 
most of the vectors, including the integrating vector. This may be attributed to cell death 
due to cytotoxicity of the transgene. 
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Figure 4.1: Expression profile in dividing and non-dividing muscle cells over time. 
Dividing and non-dividing C2C12 cells were infected with similar MOI (10) with vectors 
expressing eGFP from the p5 promoter. At different time points, transgene expression was 
assessed by flow cytometry. Graphs on the left hand side represent dividing cells and on 
the right,  differentiated  cells.  A - Cells  infected with  vectors  harbouring  IN mutations 
N120L, W235E, Q148A, K264R and K264,266,273R; B - Cells infected with combination 
of IN mutations D64V + N120L and D64V + W235E; C - Cells infected with integrating 
vector, the catalytic mutant D64V, the viral genome mutant ∆att and the combination of 
D64V + ∆att. 
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4.3 – Viral DNA forms in non-dividing cells 
 
It was demonstrated that NILVs are able to infect muscle cells and the transgene 
was detected for the whole life span of the cells. For prolonged transgene expression, the 
viral episomal DNA has to be maintained in the cell. Consequently, it is important to study 
the kinetic of viral circles in non-dividing cells. Viral DNA forms in non-dividing cells 
were then assessed at three different time points (3, 6 and 12 days post infection) by qPCR.  
 
Figure  4.2  shows  that  total  viral  DNA  concentration  was  similar  for  all  of  the 
vectors tested. Importantly, viral DNA was not degraded over time, as the levels were 
maintained  to  the  last  time  point  (12  days  post  infection).  2LTR  circles  were  also 
quantified. It was found that 2LTR circle levels for NILVs were higher compared with the 
integrating vector. Also, 2LTR circles accumulated in cells infected by NILVs. At the 12
th 
day post infection, the mutant vectors ∆att, D64V and D64V + ∆att accumulated 4, 5 and 7 
fold more 2LTR circles than the integrating vector. 
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Figure 4.2: Viral DNA quantification in non dividing cells.  
C2C12 cells  were infected at  the same MOI  (10) with  vectors and growth arrested in 
medium  containing  2%  horse  serum.  This  induces  differentiation  of  these  cells  into 
myotubes. On the 3
rd, 6
th and 12
th day after infection, total DNA was harvested from cells. 
Total viral DNA (A) and 2LTR circles (B) were quantified by qPCR using serial dilutions 
of plasmid DNA containing the sequence amplified by the primers as  a standard. The 
values obtained were then compared to the integrating vector (wt). 
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4.4 – Expression of NILVs in vivo in muscle 
 
  It was demonstrated that NILVs are able to infect muscle cells in vitro and that 
expression in differentiated cells is stable, without loss or degradation of the viral DNA. 
The vectors were then tested in vivo. The model chosen were neonatal mice, as these mice 
do not develop an immune response against injected antigens. The expression required in 
vivo will be higher than in vitro so, it was chosen to use the strong viral-derived SFFV 
promoter,  instead  of  the  p5  promoter,  which  is  a  weaker  promoter.  To  allow  an  easy 
detection of protein expression from the vectors, eGFP was used as a transgene. 
 
The  transfer  vector  was  constructed  by  cloning  the  SFFV  promoter  in  the  p5 
promoter place. Lentiviral vectors were then produced. The infectious titre was measured 
in vitro in 293T cells and vector particles were assessed by quantifying the p24 protein 
concentration in vector preparations. MF1 neonatal mice were then injected with 5μL of 
each vector intramuscularly in the tibialis anterior muscle. The mice were sacrificed at 
several time points and eGFP positive tissue was visualised in a steromicroscope. Samples 
from the green muscle area were then taken for further analysis. 
   
All mice injected with integrating and non-integrating vectors were eGFP positive 
(Figure 4.3). Most importantly, the transgene was detected in all the samples at all time 
points,  even  8  months  after  injecting  the  vectors.  This  results  indicates  stable  and 
prolonged transgene expression form both integrating and NILVs. 
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Figure 4.3: Transgene expression from muscle in vivo. 
MF1 neonatal mice were injected intramuscularly with 5μL of vectors (integrating vector 
(wt), D64V, ∆att, D64V + ∆att and D64V + N120L + W235E +∆att) expressing eGFP 
from the SFFV promoter. Vector titres (TU/mL) were: wt – 1.4x10
9, D64V – 9.9x10
9, ∆att 
– 6.4x10
9, D64V + ∆att – 3.8x10
9 and D64V + N120L + W235E + ∆att – 5.3x10
9. Mice 
were sacrificed one, three and eight months after injection and transgene expression was 
visualised in whole legs under a fluorescence microscope. Pictures were taken using the 
same parameters (gain = 1, exposure time = 0.5s, amplification = 1x). One representative 
picture out of four replicates is shown. scale bars = 4mm. 
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In order to confirm that muscle cells were indeed expressing the transgene, tissue 
samples taken from mice sacrificed one month after injection were sectioned and eGFP 
was  visualised in  cells  by immunohistochemical  staining. Figure  4.4 demonstrates that 
muscle fibres were eGFP positive for all mice injected with integrating and non-integrating 
vectors.  
It is also important to quantify the levels of expression. Protein was extracted from 
samples taken from the green part of the muscle and eGFP was then quantified by ELISA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Identification of eGFP expressing muscle cells in vivo by 
immunohistochemistry. 
Vectors were injected intramuscularly in one day old MF1 mice using 5μL of each vector 
per mouse. Vector titres (TU/mL) were: wt – 1.4x10
9, D64V – 9.9x10
9, ∆att – 6.4x10
9, 
D64V + ∆att – 3.8x10
9 and D64V + N120L + W235E + ∆att – 5.3x10
9. Tibialis anterior 
muscle sections were taken one month after injection. Intracellular eGFP was stained with 
3-amino-9-ethylcarbazole (red), scale bar = 100μm. One representative photograph of at 
least five replicates is shown. 
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Figure 4.5: Quantification of eGFP protein from in vivo samples. 
Vectors (5μL) were injected intramuscularly in neonatal MF1 mice. Vector titres (TU/mL) 
were: wt – 1.4x10
9, D64V – 9.9x10
9, ∆att – 6.4x10
9, D64V + ∆att – 3.8x10
9 and D64V + 
N120L + W235E + ∆att (DNW ∆att) – 5.3x10
9. One and three months after injection, 
samples from the eGFP positive muscle were collected. Total protein was extracted by 
grinding 20mg of tissue in lysis buffer. Total protein was quantified using a Bradford 
based assay. eGFP was quantified by ELISA in parallel with a commercial eGFP standard. 
eGFP concentration (pg(eGFP)/mg(total  protein) was then divided by the injected transducing 
units (TU). Each point represents the average obtained for one mouse. A – one month 
samples;  B –  three months  samples.  Statistical analysis was  performed using one way 
ANOVA to detect statistical differences between means and a Tukey test in order to detect 
which group of vectors was statistically different. 
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High levels of transgene expression were detected (0.01- 0.1% of total protein) at 
both 1 and 3 months post injection in all samples. At the first time point, the expression 
from  the integrating vector was  5 fold higher than in  the mutants,  but  levels  between 
mutants were not statistically different (p>0.05, tested by one-way ANOVA). At 3 months 
post injection, all vectors expressed similar levels of eGFP (p>0.05, tested by one-way 
ANOVA). It is also important to mention that from 1 to 3 months post injection, a 10 fold 
reduction of the eGFP concentration for both integrating and non-integrating vectors was 
seen.  Also,  the  concentration  of  eGFP  in  mice injected  with  NILVs  is  more  scattered 
compared with samples from mice injected with the integrating counterpart. 
  The viral 2LTR circle concentration was also studied for both time points. Total 
DNA was harvested from samples and quantified by qPCR. From Figure 4.6 it can be seen 
that it was possible to detect 2LTR circles in all samples. It also shows that the levels are 
higher  for  NILVs  compared  with  the  integrating  vector,  although  not  statistically 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Quantification of viral 2LTR circles in in vivo samples. 
Total DNA was extracted from mice muscle samples one and three months after injection. 
2LTR circles were quantified by qPCR along plasmid standards. The values obtained were 
then compared with the integrating vector (wt). Bars represent the average obtain and error 
bars the standard error of the mean. 
 
0,01
0,1
1
10
100
Neg CTR WT D64V   att D64V   att DNW   att
Vectors
2
L
T
R
 
D
N
A
 
c
i
r
c
l
e
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(
F
o
l
d
 
c
o
m
p
a
r
i
s
o
n
 
w
i
t
h
 
w
t
)
1month
3month
 
 
      
 
 
 
 
 
 
  Δ                                                   Δ                               Δ   109 
4.5 – Discussion 
 
NILVs  are  able  to  efficiently  transduce  retina  and  brain,  mediating  prolonged 
transgene expression (Philippe et al., 2006; Yanez-Munoz et al., 2006). This work was 
extended by studying the infection of muscle cells by NILVs. C2C12 muscle cells were 
used as a model in vitro. It was demonstrated that NILV are able to transduce these cells 
(Figure  4.1).  In  dividing  C2C12  cells,  eGFP  expression  diminishes  over  time  with 
comparable kinetics to  transduced 293T  cells.  In contrast,  when cells  were  allowed to 
differentiate, hence stopping cell division, transgene expression was maintained through 
the course of the experiment (Figure 4.1). 
Viral  DNA  was  quantified  at  several  time  points  in  non-dividing  C2C12  cells 
(Figure  4.2).  For  all  the  mutants  tested,  values  of  total  viral  DNA  were  similar. 
Interestingly, 2LTR levels in NILV were higher and increasing over time, compared with 
the integrating vector, even at the later time point (12 days). Saenz and colleagues show 
similar results in growth arrested cells infected with catalytic IN mutants, where episomal 
DNA is maintained (Saenz et al., 2004). Taken together, these results imply that episomal 
DNA  is  not  degraded  in  non-dividing  cells,  and  that  they  are  templates  for  gene 
expression.  Also,  the  results  suggest  that  linear  viral  DNA  that  does  not  integrate 
undergoes circularisation. It should be noticed that the ratio between 1LTR and 2LTR 
circles is 9:1 (Butler et al., 2001). Therefore, the quantification of 2LTR circles may be an 
underestimate of the total episomal viral circles. 
Selected vectors were then injected intramuscularly in neonatal mice. One, three 
and  eight  months  after  injection,  mice  were  sacrificed  and  transgene  production  was 
detected by microscopy. All mice injected with lentiviral vectors were eGFP positive at all 
time points. Upon quantification, it was shown that eGFP was expressed at high levels one 
and three months after injection. At the first time point, the integrating vector expressed 
more transgene than injected NILVs. This is correlated with the MFI measured in 293T 
cells  in  vitro.  Most  importantly,  expression  from  D64V,  ∆att,  D64V  +  ∆att  and  the 
quadruple  mutant  D64V  +  N120L  +  W235E  +  ∆att  were  similar.  At  three  months, 
expression decreased for all vectors. This could be due to promoter silencing, cytotoxicity 
of the transgene or a host immune response. It has been proposed that the SFFV promoter   110 
may be silenced in mice bone marrow cells 3 months after infection (Zhang et al., 2007a), 
which is in accordance with the results obtained in muscle cells. Therefore, this promoter 
may  not  be  the  best  choice  for  prolonged  transgene  expression  from  muscle  tissues. 
Interestingly,  the  reduction  for  the  integrating  vector  was  higher  (8  fold)  than  for  the 
NILVs (3 fold on average). It can be hypothesised that expression and possibly promoter 
silencing of integrated viral DNA is not similar for all the viral DNA forms. Also, it is 
possible  that  the  higher  level  of  transgene  produced  may  induce  an  immune  response 
against the cells with integrated vectors. 
  This work demonstrates that NILVs are able to infect muscle cells and that viral 
DNA is not degraded, allowing expression to be maintained for very long periods of time 
in non-dividing cells, both in vitro and in vivo (up to 8 months). NILVs may therefore be 
used for gene therapy of muscle diseases or when it is necessary to express a transgene 
from muscle cells. 
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5 –Correction of a Disease Model with Non-Integrating 
Lentiviral Vectors 
5.1 – Introduction 
 
In the previous chapters, it was demonstrated that the developed non-integrating 
lentiviral  vectors  (NILVs)  are  able  to  sustain  transgene  expression  from  non-dividing 
muscle cells, both in vitro and in vivo. The vectors are then suitable to be used in a gene 
therapy context, by assessing disease correction of an animal disease model. 
There are muscle disease models that would be useful to study the application of 
NILVs in gene therapy, such as Duchenne muscular dystrophy. This is a well studied x-
linked recessive genetic disorder. It is characterised by the lack of functional dystrophin in 
muscle cells, leading to progressive weakness, loss of skeletal muscle and cardiomyopathy. 
It was demonstrated that expression of microdystrophin in the mdx mice disease model 
prevents the development of the skeletal muscle pathology (Gregorevic et al., 2006). Also, 
a lentiviral vector was used to deliver a truncated form of dystrophin. The minidystrophin 
gene was expressed for up to 6 months but the levels of expression were relatively low (Li 
et al., 2005). NILVs seem to have a lower expression level compared with the integrating 
vector indicating that this model may not be adequate to the application of NILVs. 
It is known that muscle can be genetically modified in order to produce proteins 
(Arruda et al., 2001; Herzog et al., 1997; Song et al., 1998). There is a concern that a 
protein  not  usually  produced  by  muscle  fibres  will  not  be  active  due  to  a  lack  of  or 
incorrect posttranslational modifications. However, Arruda and colleagues have shown that 
these modifications in Factor IX (FIX) produced by myotubes or in liver (natural producer) 
are similar and specific activity is not affected. In order to use the muscle potential as a 
producer of plasma proteins, other disease models where non-integrating vectors can be 
used are haemophilia B and ʱ1-antitrypsin (AAT) deficiency.  Both enzymes are produced 
naturally in liver cells and then secreted into plasma.  
AAT’s function is to protect lung alveolar tissues from destruction by neutrophil 
elastase (Primhak and Tanner, 2001). In patients with this monogenetic deficiency, AAT is   113 
not  found  at  normal  levels  in  the  blood.  Although  gene  delivery  into  the  liver  is  the 
obvious  rationale,  it  has  been  demonstrated  that  secretion  of  the  transgene  by  muscle 
transduced by adeno-associated virus can yield therapeutic levels of protein (Lu et al., 
2006). Nevertheless, direct delivery into the lung constitutes a more promising approach 
because the expression levels required for a therapeutic benefit may be lower (Stecenko 
and Brigham, 2003).  
Haemophilia B is a bleeding disorder resulting from the mutation of the FIX gene. 
This protein is required for the generation of a fibrin clot and the clinical severity of the 
disease correlates well with the circulating levels of FIX. Low plasma concentrations of 1-
5% of normal levels are sufficient for disease amelioration (Ljung, 1998). It has been 
previously  shown  that  intramuscular  injections  in  immunodeficient  mice  with  adeno-
associated vectors (AAV) expressing FIX generate 5-7% of normal FIX levels in plasma 
(Herzog et al., 1997). This work was extended to study the expression levels achieved by 
the vectors in a canine model. In dogs, the levels of normal FIX levels reached 1.4% 
(Herzog  et  al., 1999). These vectors were then used in  a clinical  trial. Although gene 
transfer was demonstrated in the trial, expression of FIX was low (Manno et al., 2003). 
Also, in another clinical trial targeting liver using similar vectors, expression was transient 
due to an immune response against the AAV capsid (Manno et al., 2006; Mingozzi et al., 
2007). Therefore, it will be necessary to use vectors less immunogenic than the AAV 
vectors, such as lentiviral vectors. 
The correction of haemophilia B in a disease model may be an ideal candidate to 
test the use of the developed NILVs in gene therapy: the vectors have low immunogenicity 
and the levels of expressed protein necessary to reach disease correction are relatively low. 
 
5.2 – Production of vectors expressing FIX 
 
  It was demonstrated that NILVs are able to infect muscle cells with high levels of 
expression and that the transgene is detected for up to 8 months. The NILVs will then be 
suitable to deliver a vector for expression of FIX from muscle cells. 
  The transgene used in the previous experiments shown in chapter 3 and 4 was 
eGFP, which allows the rapid  detection and quantification in  expressing cells  by flow   114 
cytometry. However, for the application of the vectors to the haemophilia B model, the 
vector was modified by replacing eGFP with the human FIX gene, being expressed from 
the SFFV promoter. The human FIX was cloned into the vector with and without the att 
site  mutation  and  sequenced.  To  insure  that  the  vector  expressed  FIX  and  that  the 
transgene was detectable, the integrating vector was produced and tested in vitro in 293T 
and dividing and differentiated C2C12 cells. These cells were infected with the vector and 
three  days  after  infection  the  supernatant  was  removed.  The  FIX  concentration  in  the 
supernatant was then measured by ELISA. 
 
Figure 5.1: Expression of hFIX in vitro. 
293T cells were infected with 4.5ng(RT) of an integrating lentiviral vector expressing hFIX. 
Dividing and differentiated C2C12 cells were infected with 45ng(RT) of the same vector. 3 
days after infection, the supernatant was collected and hFIX was quantified by ELISA. 
   
 
Figure 5.1 shows that the transgene can be detected in both cell lines. This indicates 
that the vector is efficiently expressed, secreted and able to be quantified by ELISA. Also, 
this data shows that muscle cells are able to express and secrete the transgene.  
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5.3 –Vector expression of hFIX in vivo 
 
  There has not been any report of expression of FIX by muscle cells infected with 
lentivectors in vivo. Hence, it was decided to perform a pilot experiment in vivo where 
immunocompetent  MF1  mice  would  be  injected  intramuscularly  with  the  integrating 
vector  expressing  hFIX  from  the  SFFV  promoter.  Neonatal  mice  were  injected  in  the 
tibialis anterior muscle of one leg with 5μL of concentrated vector (35.1ng(RT)/μL). At 
several time points, a blood sample was taken from mice and plasma hFIX was quantified 
by ELISA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: hFIX expression in vivo. 
Neonatal MF1 mice were injected in the tibialis anterior muscle with 5μL of the integrating 
vector expressing hFIX from the SFFV promoter (1x10
8pg(p24)/mL). Blood samples were 
taken from mice at several time points, and hFIX was quantified in plasma by ELISA. Bars 
represent the mean and error bars the standard error of the mean obtained in three animals. 
 
  As shown in Figure 5.2, hFIX was detected in the plasma of all injected mice. The 
concentration of the transgene in the plasma was 1-2% of normal human values one month 
after  injection.  At  the  second  time  point,  the  levels  of  FIX  decreased,  yet  were  still 
detectable in all mice. After the fourth month after injections, the levels of FIX raised, with 
the achievement of 7.3% of normal levels of hFIX in the plasma in one mouse.  
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  Knowing that it was possible to detect hFIX in the plasma of mice injected with 
lentiviral vectors, the integrating and the non-integrating vectors expressing hFIX were 
then compared in vivo. MF1 mice were injected with 5μL of concentrated vectors of the 
integrating  (35.2ng(RT)/µL),  D64V  (28.2ng(RT)/µL)  and  the  DNW  Δatt  (38ng(RT)/µL) 
vectors.  Blood  samples  of  injected  mice  were  taken  at  several  time  points  and  the 
concentration of hFIX in the plasma was accessed by ELISA. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Comparison of hFIX expression from integrating and non-integrating lentiviral 
vectors in vivo. 
Neonatal MF1 mice were injected with 5μL of concentrated vectors in the tibialis anterior 
muscle (titres were: integrating vector (wt) – 35.2ng(RT)/µL, D64V – 28.2ng(RT)/µL and 
D64V + N120L + W235E + ∆att (DNW ∆att) – 38ng(RT)/µL. Plasma hFIX was assessed by 
ELISA in blood samples taken at several time points. Points in the graph represent the 
average obtained for three animals and error bars the standard error of the mean. 
   
Human FIX was identified in all mice injected with the integrating vector, but no 
plasma hFIX was detected in samples from mice injected with the NILV (Figure 5.3). The 
average hFIX concentration levels in mice injected with the integrating vector were similar 
to  the  previous  experiment  (Figure  5.2).  An  average  of  1.2%  of  normal  levels  were 
detected one month after injection, a lower level obtained at the three months time point, 
and the highest levels reached at the last time point. 
  The  integrating  and  non-integrating  vectors  were  also  tested  using  the  mouse 
disease model of haemophilia B. Since it was known that the levels of circulating hFIX 
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were not very high, it was decided to increase the vector dose injected into these animals. 
Haemophiliac  mice  were  injected  with  a  total  of  15μL  of  concentrated  vectors  in  the 
tibialis anterior muscle in both legs. The particle concentration of the injected integrating 
and  the  non-integrating  vector  were  different,  being  61.8ng(RT)/μL)  and  25.6ng(RT)/μL, 
respectively. It was decided not to dilute the integrating vector to match the NILV titre in 
order to maximise the concentration of transgene in the plasma. Blood samples from the 
injected mice were then taken at several time points, and the concentration of hFIX was 
measured by ELISA. 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Expression of hFIX in haemophiliac mice 
Haemophilia B mice were injected with 15μL of integrating and non-integrating lentiviral 
vectors  in  the  tibialis  anterior  muscle  of  both  legs.  Titres  were  61.8ng(RT)/μL  and 
25.6ng(RT)/μL  for  the  integrating  (wt)  and  non-integrating  (DNW  ∆att)  vectors, 
respectively Blood samples were taken at several time points and hFIX was then quantified 
in plasma by ELISA. Points in the graph represent the average obtained for three animals 
and error bars the standard error of the mean. 
 
  The  levels  of  hFIX  found  in  mice  injected  with  the  integrating  vector  were 
approximately 7% one month after injection (Figure 5.4), but the concentration of FIX in 
these mice diminished in the fourth month after injection, as it happened in normal mice 
(Figure 5.3). It is important to note that these levels are sufficient to ameliorate the disease. 
In mice injected with the NILV DNW Δatt, no FIX was detected four weeks after injection 
and only 0.5% in one mouse was detected in the fourth month. This reflects the difference 
0
2
4
6
8
10
0 4 8 12 16
Time (wks)
[
F
I
X
]
 
(
%
)
WT
DNW Δatt  118 
of vector particles delivered in each injection, but it also confirms that expression of hFIX 
from the vectors tested needs to be improved in order to achieve disease amelioration. 
5.4 – Optimisation of hFIX expression from muscle cells 
 
In  order  to  improve  expression  from  the  developed  vectors,  it  is  possible  to 
optimise  the  codon  sequence  of  the  transgene.  There  has  been  a  report  of  a  codon 
optimised version of the hFIX transgene that potentially increases expression (Nathwani et 
al., 2006). The hFIX coding sequence in this report was modified by using a subset of 
codons
 most frequently found in highly expressed eukaryotic genes ("codon
 optimisation"), 
and then adjusted to reduce the potential for
 inappropriate splicing and CpG methylation to 
augment transgene
 expression. 
FIX produced in muscle cells accumulates in the extracellular space. Possibly, this 
is due to an interaction with collagen IV which is regarded as a natural binding for FIX 
(Wolberg et al., 1997), trapping the protein in the extracellular space. Schuettrumpf and 
colleagues demonstrated that the plasma concentration of a mutated form of FIX with low 
affinity  for  collagen  IV  (FIX  K5A/V10K)  expressed  from  an  AAV  vector  injected 
intramuscularly in mice is 2-5 fold higher than the wt FIX. It was also published in the 
same report that the mutation R338A increases the specific activity of the FIX protein 
(Schuettrumpf et al., 2005). Therefore, it was decided to use the codon optimised version 
of the hFIX (hFIXco) containing the two mutations that would increase the circulating 
levels of the expressed protein. The mutations K5A and V10K were introduced in the 
FIXco transgene by site directed mutagenesis obtaining the hFIXcoKV transgene.  The 
mutations were confirmed by sequencing the plasmid. The hFIX transgene in the vector 
was then replaced by hFIXco and hFIXcoKV, and vectors were produced. The vectors 
were then tested in vitro. 293T cells and dividing and non-dividing C2C12 cells were 
infected with an integrating vector expressing FIXco or FIXcoKV. The levels of FIX in the 
supernatant were then measured two days after infection by ELISA.   119 
 
Figure 5.5: Comparison of expression of different codon optimised hFIX versions in vitro. 
Integrating vectors were produced carrying the hFIX codon optimised cDNA with and 
without the mutations K5A and V10K (FIXcoKV and FIXco, respectively). 293T cells 
were  then  infected  with  4.5  and  3.8  ng(RT)  with  the  vectors  FIXco  and  FIXcoKV, 
respectively. Dividing and differentiated C2C12 cells were also infected but with 10 fold 
more vectors than 293T cells. The concentration of hFIX was assessed in the supernatant 3 
days after infection by ELISA 
 
hFIXco was expressed in all cell lines tested (Figure 5.5), but it was not clear if the 
mutated form of FIXco is expressed in higher concentrations. These vectors were then 
tested in vivo. MF1 neonatal mice were injected with 33μL of vectors in several muscle 
groups (tibialis anterior and intercostal muscles), maximising the amount of vector able to 
be injected in such mice. The concentration of injected vectors was again different, since it 
was decided not to dilute the vector stocks. The concentration of injected integrating vector 
expressing FIXco and FIXcoKV were 77.5ng(RT)/μL and 34.8ng(RT)/μL, respectively and 
the concentration of the DNW Δatt vector injected expressing FIXco and FIXcoKV were 
55.8ng(RT)/μL and 66.1ng(RT)/μL, respectively. Plasma hFIX was subsequently quantified 
by ELISA in blood samples taken from the mice at several time points. 
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Figure 5.6: Comparison of expression of different hFIX transgenes in vivo. 
Integrating (wt) and non-integrating (DNW Δatt) lentiviral vectors expressing the codon 
optimised  version  of  hFIX  (FIXco)  and  the  codon  optimised  hFIX  harbouring  the 
mutations K5A and V10K (FIXcoKV) were injected in neonatal MF1 mice. A total of 
33μL of each vector was injected intramuscularly in each mouse. The titres (ng(RT)/mL) of 
the vectors injected were: FIXco (wt) – 77.5, FIXco (DNW Δat) – 55.8, FIXcoKV (wt) – 
34.8 and FIXcoKV (DNW Δat) – 66.1. Blood samples were then taken at several time 
points and the hFIX plasma concentration was quantified by ELISA. The data collected is 
shown in two configurations. The concentration of plasma hFIX found in each mouse is 
represented in A. Bars in B represent the average FIX concentration obtained for each mice 
group taking into account the concentration of injected particles and error bars the standard 
error of the mean. 
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The quantity of injected viral  particles  for each vector was  different,  so  it was 
decided to show two representations of the data collected from this experiment. Figure 5.6 
B  takes  into  account  the  different  titre  of  the  injected  vectors  and  permits  a  direct 
comparison of expression from the vectors. Figure 5.6 A allows the estimation of disease 
amelioration by showing the percentage of normal FIX circulation reached by the vectors 
in the blood of the animals. It is clear that the codon optimised version of hFIX harbouring 
the two mutations K5A and V10K increases the circulating FIX levels compared with the 
transgene  without  mutations  (Figure  5.6  B).  The  levels  of  plasma  hFIX  obtained  by 
injecting the mutated improved form of FIX were two fold higher, on average, than in mice 
injected with the version not mutated of FIX, both in the case of integrating and non-
integrating vectors. FIXcoKV is therefore the best transgene to reach the maximum levels 
of hFIX in the plasma of mice. 
The levels of expressed and secreted FIX in mice achieved by the injection of 
integrating vectors expressing hFIXco and hFIXcoKV were 8.5% and 8.6%, respectively, 
the highest value obtained in all experiments. These values are clearly higher than the 
threshold value for disease amelioration. The levels of hFIX obtained in mice injected with 
the non-integrating DNW Δatt vector were lower, being 0.3% for the vector expressing 
hFIXco and 0.5% for the vector expressing hFIXcoKV.  
 
 
5.5 – Discussion 
 
Data presented in the previous chapter demonstrated that NILVs are able to infect 
muscle cells, both in vitro and in vivo, with sustained transgene expression for up to 8 
months in vivo. This research was then extended by testing the developed NILVs in gene 
therapy. 
There  are  several  models  were  NILVs  can  be  tested  for  disease  correction  of 
genetic diseases. The chosen model – correction of haemophilia B by expression of FIX 
from muscle – possessed several characteristics where NILVs would be ideal candidates to 
be the vector of choice for the treatment of this disease. The vector only needs to achieve 
expression and secretion of FIX up to 1% of normal levels in plasma to ameliorate the   122 
disease (Ljung, 1998). The published approaches to achieve disease correction rely on the 
use of AAV vectors to deliver the transgene to muscle or liver cells. It was reported that 
when this vector was delivered to the liver, there was an immune response against the 
vector  in  humans  (Manno  et  al.,  2006;  Mingozzi  et  al.,  2007).  When  the  vector  was 
delivered to muscle, the expression of the transgene was low and transient (Manno et al., 
2003). Up until this moment, there has not been any report of the use of lentivirus based 
vectors  to  deliver  the  transgene  to  muscle  cells,  so  the  investigation  of  the  use  of 
lentivectors for this purpose would be very interesting. 
The vectors that were used in the previous experiments had eGFP as a transgene, so 
it was necessary to change this transgene into the clinically relevant hFIX transgene. The 
vectors were then produced and tested in vitro. It was demonstrated that the integrating 
lentiviral  vector  expressing  hFIX  from  the  SFFV  promoter  was  able  to  deliver  the 
transgene to 293T and C2C12 muscle cells and that the cells were able to secrete the 
transgene to the supernatant (Figure 5.1). Most importantly, the produced hFIX was readily 
detectable and quantifiable by ELISA. 
Next, it was necessary to perform pilot experiments in vivo, as there was no report 
of the use of these vectors to deliver the hFIX transgene to muscle cells  in vivo. The 
integrating lentivector was injected in MF1 neonatal mice, and hFIX was monitored over 
time. Data from this experiment showed that hFIX was detected in blood, at 1-2% of 
normal FIX levels. Although these levels were low, the concentration of plasma FIX was 
higher than the therapeutic threshold. 
In  a  second  experiment,  also  performed  in  immunocompetent  MF1  mice, 
expression from muscle cells by the integrating lentivector, the D64V and the DNW Δatt 
mutants were compared. Unfortunately, expression from the NILVs was not detected at 
any time point after injection. It is possible that the NILVs tested were able to deliver the 
DNA to muscle cells and that expression of the transgene was present, although at such 
low concentration levels that were not detected due to the sensitivity of the ELISA assay. 
Nevertheless,  disease  amelioration  levels  were  again  achieved  by  the  injection  of 
integrating lentiviral vectors, as the concentration of FIX in plasma was higher than the 1% 
of normal levels threshold.   123 
The integrating and non-integrating vectors were also tested in the animal disease 
model of haemophilia B. In this experiment, the vector dose injected was increased in 
order to achieve a higher level of plasma FIX. The FIX expressed from the NILV was not 
detected one month after injection, but it was detected in one mouse four months after 
injection, although at the low concentration of 0.5% of normal levels.  In addition, the 
concentration of plasma FIX achieved by the integrating vector was higher than in the 
previous experiments. In these mice, 7% of normal levels of hFIX in the plasma were 
quantified in the blood samples, reflecting the higher concentration of particles injected in 
these mice. 
It was therefore demonstrated that integrating lentiviral based vectors were able to 
achieve the target FIX concentration for disease amelioration, both in immunocompetent 
MF1 and haemophilic mice. Nevertheless, it was apparent that expression and secretion of 
FIX had to be improved to achieve detectable levels in plasma by NILVs. In order to 
augment the concentration of hFIX in blood, the hFIX sequence was codon optimised to 
increase expression. Secretion to plasma was improved by mutating residues to disrupt 
interaction of this protein with collagen IV without compromising enzymatic activity, as 
reported previously (Schuettrumpf et al., 2005). 
Integrating vectors expressing the codon optimised version of FIX with and without 
the mutations K5A and V10K were produced and tested in vitro. It was demonstrated that 
both  293T  and  C2C12  muscle  cells  were  able  to  produce  and  secrete  this  transgene, 
although it was not clear whether the optimisation of FIX would increase expression or 
secretion by the cells. 
Next, the improved vectors were tested in vivo. Comparing the values obtained 
with the vector expressing the codon optimised and the normal version of hFIX, it was not 
clear if the codon optimisation increases the expression levels of the transgene in muscle 
cells.  For  the  integrating  vector,  the  average  value  reached  by  the  vector  expressing 
hFIXco was 8.5%, at the one month time point, when 2556ng(RT) were injected in MF1 
mice. For the integrating vector expressing hFIX, the levels reached in MF1 mice at the 
same time point were 1.2% when 176ng(RT) were injected and 7.1% when 920ng(RT) were 
injected in haemophiliac mice. The haemophiliac mice used were of BL6 background, so a 
direct comparison with the MF1 mice is not correct, because there can be differences of   124 
expression not due to the vector but due to the biological phenotype of the animals. Also, 
the amount of injected vector particles in the MF1 mice was very different. Hence, it is 
possible that the comparison  is  not  appropriate since the dependence  between injected 
particles and the percentage of hFIX obtained may not be linear. If there was a correlation, 
and the codon optimisation improved expression from muscle cells, it would be expected 
to obtain more than 17.5% with the higher amount of vector injected. However, this was 
not the case, as only half of that concentration was obtained. 
For the DNW Δatt vector, the comparison is even more difficult as hFIX was not 
detected at the one month time point in mice injected with the vector expressing the normal 
hFIX.  But  when  mice  were  injected  with  the  vector  expressing  the  codon  optimised 
version, at the same time point, the levels of hFIX in the plasma were 0.3%. It may be 
possible that it is necessary to reach a certain threshold to be able to quantify secreted FIX 
in the plasma, and that it was not possible to reach it by injecting only 140ng(RT) of the 
vector. 
Comparing the vectors expressing the mutated and non-mutated forms of hFIX, it 
was shown that there was a 2 fold increase of expression when the mutated form was used 
as a transgene. These results confirm the previous data published, where AAV vectors 
were  used  to  deliver  the  wild  type  and  mutated  forms  of  hFIX  to  muscle  cells 
(Schuettrumpf et al., 2005). It was therefore proven that the best transgene to achieve the 
highest concentration of hFIX in plasma by production of the protein by muscle cells is the 
FIX transgene mutated to inhibit interaction with collagen IV. Haemophilia B patients may 
therefore be treated with muscular injections of integrating lentiviral vectors expressing 
this transgene. However, in order to increase the levels of hFIX in plasma and reach the 
therapeutic threshold, it may be necessary to increase the volume of injected vectors or 
even repeat injections at several time points.  
Despite the efforts taken to improve expression from the NILVs, it was concluded 
that there was a problem with expression from these vectors. It is therefore important to 
study  the  reasons  for  it,  in  order  to  improve  expression.  Nevertheless,  it  should  be 
emphasised that the integrating lentiviral vector is able to sustain expression of hFIX in 
mice at a higher level than the therapeutic threshold, indicating disease amelioration of 
haemophilia B.   125 
 
 
 
 
 
 
 
Chapter Six 
Comparison of Expression from  
Episomal and Integrated vectors 
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6 – Comparison of Expression from Episomal and Integrated 
Vectors 
6.1 – Introduction 
 
  Gene therapy is a powerful technique that involves the use of vectors to deliver a 
transgene  of  interest  into  cells.  Vectors  for  gene  therapy  have  been  developed  and 
improved throughout the last years. Some vectors have been engineered based on viruses 
in order to use their natural capabilities to deliver genetic material into cells. All developed 
vectors  have  advantages  and  disadvantages.  The  choice  of  vector  has  to  be  careful  to 
achieve the appropriate goal. It relies on several different aspects such as vector packaging 
capacity, efficiency of transduction of the target cell, immunological reaction to the vector, 
infection of dividing or non-dividing cells, integration of the genetic material into the cell 
chromosomes for prolonged transgene expression when cells are dividing, among others 
characteristics. 
  Vectors based on adenoviruses have the advantages of a large packaging capacity 
and infection of non-dividing cells, but elicit a major immune response. Adeno-associated 
viral vectors (AAV) also infect non-dividing cells, but have a small packaging capacity 
(4.9kb) and do not integrate the vector DNA into the cell chromosomes. Retroviruses and 
lentiviruses have a relatively large packaging capacity (9kb) and integrate the viral genome 
into the host DNA. Also, lentiviral vectors have the ability to infect non-dividing cells, 
contrary to retrovirus vectors. Clinical trials have demonstrated the efficiency of retroviral 
vectors, but uncovered also a potential drawback of these vectors. In the X-linked severe 
combined immunodeficiency trials, several patients developed leukaemia due to insertional 
mutagenesis of the vector (Hacein-Bey-Abina et al., 2003b). 
  Here, NILVs were developed in order to exploit the capacity of lentiviral vectors of 
efficiently infecting non-diving cells while reducing the risk of insertional mutagenesis. 
This study has demonstrated that NILVs are able to transduce non-dividing cells in vitro 
and in vivo with prolonged transgene expression. Most importantly, it has been shown that 
the episomal viral forms are stable and not degraded in cells (chapter 4). However, the   127 
level of expression from NILVs was lower compared to the integrating vector. A secreted 
transgene being expressed from muscle cells transduced with NILVs was found in the 
blood  stream  at  a  10  fold  lower  concentration  compared  with  cells  infected  with  the 
integrating counterpart (Figure 5.6). 
It is therefore important to study the reason for this discrepancy in order to optimise 
expression levels. In this chapter, it will be studied in which step of expression NILVs are 
impaired, by comparison to the integrating counterpart. It is also important to compare the 
performance of these NILVs with other episomal vectors. Here, the first comparative study 
of expression from integrating and non-integrating lentiviral vectors with an AAV vector 
and also with plasmid transfection will be presented.  
 
6.2 – Comparison of expression from integrated and non-integrated 
lentiviral vectors 
 
It was previously shown in chapter 4, that NILVs are able to sustain expression in 
muscle  cells  for  up  to  8  months  in  vivo.  When  eGFP  was  quantified  in  muscle  from 
injected mice, it was found that expression from NILVs was statistically not different to 
integrating  vectors,  three  months  after  injection.  eGFP  is  a  very  stable  protein  that  is 
accumulated in the cytoplasm of cells. When NILVs were tested in the haemophilia model, 
expressing  a secreted protein, it was  found that NILVs expressed 10  fold  less protein 
compared with their integrating counterpart. FIX is secreted and has a short half-life in 
circulation. These characteristics show that the comparison of expression from integrating 
and  non-integrating  lentivectors  in  the  haemophilia  model  does  not  have  the  bias  of 
analysing a random area of injected muscle to assess intracellular protein production and 
the accumulation of a stable protein intracellularly.  
From the previous experiments, there was a difference of expression when different 
promoters were used, so it was necessary to determine if lower expression from NILVs 
was promoter independent. Since expression from NILVs occurs from episomal DNA, the 
SFFV promoter was compared with the p5 promoter. p5 is a promoter derived from adeno-
associated  virus  (AAV),  which  is  a  natural  episomal  virus.  Expression  from  the   128 
ubiquitously  acting  chromatin  opening  element  (UCOE)  was  also  compared,  as  this 
enhancerless  promoter  is  involved  in  chromatin  assembly  and  re-configuration.  This 
promoter is derived from the human HNRPA2B1-CBX3 locus and it has been shown that 
linked to CMV it prevents silencing and increases median levels of expression (Zhang et 
al., 2007a; Williams et al., 2005). The 293T cell line was chosen as target cells to perform 
this study because they are a permissive cell line, where the promoters chosen do not have 
a  particular  advantage.  293T  cells  were  infected  with  integrating  and  non-integrating 
vectors expressing eGFP from the different promoters. Two days after infection, the cells 
were  harvested  and  assessed  for  eGFP  production  by  flow  cytometry  analysis.  The 
transgene production was estimated by the mean intensity fluorescence (MFI) of infected 
cells, in populations where only 30% of the cells were expressing, to insure that cells were 
not infected with more than one vector copy, on average. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Comparison of expression from different promoters in integrating and non-
integrating lentiviral vectors in vitro. 
Integrating  and  non-integrating  lentiviral  vectors  expressing  eGFP  driven  by  different 
promoters were produced and used to infect 293T cells, at MOI 0.3. Three days after 
infection, cells were harvested and the eGFP produced was quantified by measuring the 
mean  intensity  fluorescence  (MFI)  by  flow  cytometry.  Bars  represent  an  average  of  3 
experiments and error bars the standard error of the mean. 
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It was found that regardless of the promoter used, NILVs always expressed less 
transgene than the integrating vector (Figure 6.1). Nevertheless, expression from NILVs 
was only 1.7 fold lower when p5 promoter was used, compared with expression from the 
integrating counterpart. The drop of expression is higher when the SFFV promoter was 
employed in the vectors, being 3.4 fold, on average, in this case. It is interesting to note 
that expression from the UCOE promoter in the context of NILVs is similar to the p5 
promoter, as the expression from these promoters is only 2 fold less compared with the 
integrating promoter. 
   
 
In order to study the reason for lower expression 293T cells were infected with 
integrating and non-integrating lentivectors expressing eGFP from the SFFV promoter, the 
promoter with highest difference in expression between the integrated and non-integrated 
vectors. The experiment was designed in order to deliver similar quantities of DNA from 
the vectors into cells.  Two days  after infection, cells  were harvested.  Total  DNA was 
extracted from cells by salting out. Total RNA was extracted using TRI reagent and cDNA 
was prepared by reverse transcription using random primers. The vector DNA and RNA 
concentration  was  then  assessed  by  qPCR  with  primers  designed  against  the  WPRE 
sequence. The production of protein was accessed by measuring the MFI of eGFP positive 
cells by flow cytometry. 
 
  For the ease of comparison, the integrating vector DNA and RNA concentration 
was assumed to be 1 and the other vectors were compared to this value. In Figure 6.2 it is 
shown  that  when  similar  viral  DNA  concentration  of  integrating  and  non-integrating 
lentivectors are delivered into cells, there is a lower amount of transgene produced from 
NILVs. Furthermore, it can be seen that the vector RNA concentration in NILV infected 
cells was lower compared with the integrating counterpart. It is therefore demonstrated that 
the episomal lentivectors are less transcriptionally active than the integrating vectors. 
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Figure 6.2: Analysis of DNA, RNA and Protein in cells infected with lentiviral vectors.  
293T cells were infected with integrating (wt) and non-integrating (DNW and DNW Δatt) 
lentiviral vectors expressing eGFP from the SFFV promoter at MOI 0.3. Two days after 
infection, cells were harvested. DNA and RNA were extracted and quantified by qPCR. 
eGFP was quantified by flow cytometry. The values obtained were then compared with the 
integrating vector. 
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6.3 – Comparison of expression from episomal and integrated viral 
vectors 
 
It was proven that NILVs express less transgene than their integrating counterparts 
and the reason for it is a lower transcription activity from NILVs. Therefore, it is important 
to extend this research and compare expression of NILVs with other episomal vectors.  
AAV is a promising vector for gene therapy. It has been used in clinical trials to 
deliver FIX to the liver and muscle of patients with haemophilia B. Unfortunately, the 
expression was transient in liver delivery due to an immunological reaction and expression 
levels were low when delivered to muscle. Nevertheless, there is scope to improve this 
vector and use it in genetic diseases, where the transgene can be accommodated into the 
low capacity of this vector. This viral vector delivers a single stranded DNA (ssDNA) copy 
to  the  cell.  After  second-strand  synthesis,  circles  and  concatemers  are  formed  and 
maintained  in  non-dividing  cells  as  episomal  DNA.  This  vector  was  then  chosen  to 
compare expression between integrated and episomal vectors. 
The AAV and lentivector systems are very different, and a direct comparison is 
difficult. Both systems have particular need of sequences in the vector to be incorporated 
into the virus particles. Also, while the lentiviral based vector is incorporated in the virion 
as RNA, the AAV vector genome is a single stranded DNA (ssDNA). Furthermore, these 
vectors infect cells with different efficiencies, so a permissive cell line to both vectors has 
to be used to allow a comparison. 293T cells are a permissive cell line for both AAV and 
lentivectors. C2C12 cells are a good model to study infection of muscle cells in vitro. So 
these cell lines were chosen to perform this study. 
In order to compare the expression performance from lentivirus and AAV based 
vectors,  the  promoter  and  transgene  have  to  be  the  same.  Retroviruses  manage  to 
efficiently export unspliced RNA into the cell cytoplasm. This is achieved by cis-acting 
elements, such as the woodchuck hepatitis virus post-transcriptional regulatory element 
(WPRE). The WPRE element is commonly used in lentiviral vectors, to achieve higher 
titres.  This  element  may  also  influence  RNA  stability  in  infected  cells.  Therefore,  the 
SFFV-eGFP-WPRE sequence used in the lentivectors was cloned into an AAV vector.    132 
An experiment was designed where differences in infection were not taken into 
account.  Instead, it only relied on the delivery of a similar quantity of DNA containing the 
same expression cassette into the cells. With these characteristics, the protein production 
would only vary from intrinsic differences of the DNA or viral proteins carried in the 
vector and, with a similar expression cassette, a difference would derive from the particular 
cis-acting sequences used specifically in each vector. 
All  vectors  were  first  titred  in  293T  cells  to  quantify  the  concentration  of 
transducing units (TU) present in each vector preparation. 293T and dividing C2C12 cells 
were then infected with different concentrations of the vectors. Two days after infection, 
DNA was  harvested and the viral  vector copy  number was  quantified by qPCR.  The 
protein  production  was  assessed  at  the  same  time  point  analysing  the  MFI  by  flow 
cytometry. In order to standardise between different experiments, the MFI of the eGFP 
positive cells obtained for each sample was normalised against the MFI value obtained for 
unstransduced cells in the same experiment. 
The expression from the AAV vectors can be delayed due to the second-strand 
synthesis,  which  is  a  slow  process.  Therefore,  differentiated  C2C12  cells  were  also 
infected with the vectors and vector copy number and expression analysed 12 days after 
infection. 
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Figure 6.3: Expression from different integrating and episomal viral vectors in vitro 
Cell  lines  were  infected  with  different  concentrations  of  integrating  (Int  +)  and  non-
integrating (NILV) lentiviral vectors and with AAV vectors (AAV). All vectors expressed 
eGFP from the SFFV promoter. Transgene production was assessed by measuring the MFI 
by flow cytometry. The value obtained for each sample was normalised against the MFI of 
untransduced cells analysed at the same time. For 293T (A) and dividing C2C12 cells (B), 
cells were harvested 2 days after infection. For differentiated C2C12 cells (C), the analysis 
was performed 12 days after infection. 
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Figure  6.3  shows  that,  in  all  cell  lines  tested,  the  increase  of  concentration  of 
vectors used during infection increases the MFI obtained in eGFP expressing cells. Also, in 
293T cells, in order to obtain a value of MFI in cells transduced with the AAV vector 
similar to the integrating lentivector, it is necessary to infect cells with at least 100 fold 
more transducing units per cell. In dividing and differentiated C2C12 cells, the level of 
MFI obtained in cells infected with the AAV vector never reached the one obtained for the 
integrating vector. The data also indicates that there is eGFP accumulation in C2C12 cells 
over time, as the MFI levels in differentiated cells (analysed 12 days after infection) are 
higher compared with the values obtained 2 days after infection in dividing C2C12 cells.  
Transgene expression was then compared in samples where 20-40% of the cells 
were eGFP positive. To achieve such percentage in dividing and differentiated C2C12 
cells,  the  concentration  of  integrating  and  non-integrating  lentiviral  vectors  used  was 
10TU/cell and 2TU/cell for the AAV vector. 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Expression comparison between integrated and episomal viral vectors 
293T cells were infected with integrating (Int +) and non-integrating (NILV) lentiviral 
vectors  and  AAV  vectors  (AAV)  at  a  concentration  of  0.3TU/cell.  Dividing  and 
differentiated C2C12 cells were infected with 10TU/cell of Integrating and NILVs and 
with 2TU/cell of an AAV vector. All vectors expressed eGFP from the SFFV promoter. 
Expression  was  analysed  2  days  after  infection  for  dividing  cells  and  12  days  after 
infection for the differentiated cells by measuring the MFI by flow cytometry. The values 
obtained were standardised with the MFI of a negative control (untransduced cells) and 
then divided by the average value of cells infected with the integrating lentiviral vector. 
Bars represent the mean of MFI obtained for at least three replicates of three independent 
experiments. Error bars represent the standard error of the mean.   135 
Figure  6.4  demonstrates  that  the  amount  of  eGFP  produced  by  the  integrating 
vector is higher than the one produced by the episomal vectors. Both NILV and AAV 
vectors transgene expression levels were similar and only 20-25% of the value obtained 
with the integrating lentiviral vector. This result was similar in all the cell lines tested. 
 
The relation between the DNA delivered and the protein produced was also studied. 
The number of vector copies obtained by qPCR was normalised against the concentration 
of extracted DNA (that was standardised to obtain the number of cells in each sample) and 
plotted against the corresponding MFI values.  
Figure 6.5 shows that, in all the cells tested, the increment of DNA delivered to the 
cell increases the amount of transgene being produced. For the 293T cells, when similar 
concentrations of vector DNA were delivered to the cells, the concentration of protein 
produced  from  the  integrating  lentiviral  vector  was  always  higher  compared  with  the 
episomal vectors. Both episomal AAV and non-integrating lentiviral vectors had a similar 
expression pattern, which was 3-5 fold lower than the integrating vector. Similar results 
were obtained for both dividing and differentiated C2C12 cells infected with the vectors, 
where the cells infected with the integrating vector express more transgene than with the 
episomal vectors NILV and AAV. 
Since the formation of DNA is different for the vectors studied, and the rate of 
second-strand  synthesis  for  AAV  vectors  is  slow,  it  is  also  important  to  compare  the 
number of vector copies obtained in dividing C2C12 cells (which were assessed two days 
after infection) and in  differentiated C2C12 cells  (which were measured 12 days  after 
infection). The copy number in cells infected with the same concentration of integrating 
lentiviral vectors decreased two fold. Similarly, the number of AAV vectors was also two 
fold lower in differentiated C2C12 cells. The copy number obtained in cells infected with 
the NILV also decreased, but at the higher rate of 14 fold. 
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Figure 6.5: Relation between expression and vector DNA concentration in vitro 
293T (A) and dividing (B) and differentiated (C) C2C12 cells were infected with different 
concentrations of integrating and episomal viral vectors expressing eGFP from the SFFV 
promoter.  Two  days  after  infection,  293T  and  dividing  C2C12  cells  were  harvested. 
Differentiated C2C12 cells were harvested 12 days after infection. A sample was used to 
assess  transgene  production  by  measuring  the  MFI  of  eGFP  expressing  cells  by  flow 
cytometry. The value obtained was then normalised against the MFI of untransduced cells 
analysed  at  the  same  time.  Total  DNA  was  also  extracted  and  used  as  a  template  to 
measure  vector  genomes.  The  concentration  of  DNA  obtained  was  compared  with 
standards to evaluate the number of cells in each sample and then used to normalise the 
number of genomes obtained by qPCR. 
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 6.3 – Comparison of expression from lentiviral vectors and transfected 
DNA 
 
  The  comparison  of  NILV  and  AAV  vectors  revealed  that  both  have  similar 
expression patterns, and that the level of protein produced is 4-5 fold lower compared with 
an integrating lentiviral vector. It was then decided to extend this study by analysing the 
expression from lentivectors and a transfected plasmid. 
   
In order to compare expression from these systems, it is necessary to have a similar 
expression  cassette.  Therefore,  the  transfected  plasmid  DNA  chosen  (SEW)  was  the 
lentivector plasmid used in the production of integrating and NILVs, that contains eGFP 
being expressed from the SFFV promoter and all the cis elements used in the lentivectors. 
293T cells were used as a model for this study. The transfection reagent chosen to 
deliver  the  plasmid  DNA  to  the  cells  was  Lipofectamine  2000.  This  is  a  commercial 
reagent that complexes with the DNA and allows an efficient delivery of the plasmid to the 
target  cell  nucleus,  when  cells  are  dividing.  To  investigate  the  expression  from  the 
transfected plasmid, the DNA-Lipofectamine complexes were diluted before transfection 
of the cells. 293T cells were also infected with different concentration of integrating and 
non-integrating  lentiviral  vectors.  Two  days  after  infection  or  transfection,  cells  were 
harvested and expression levels assessed by measuring the MFI of eGFP expressing cells 
by flow cytometry. Total  DNA was  also extracted from  the cells  and the vector copy 
number was assessed by qPCR. As described in the section 6.4, the MFI was standardised 
with the negative control and the vector copy number with the DNA concentration. 
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Figure 6.6: Expression comparison between integrating lentivectors, NILVs and 
transfected DNA in 293T cells 
293T cells were infected with different concentrations of integrating (Int +) and NILVs or 
transfected with serial dilutions of DNA-Lipofectamine complexes (SEW). Two days after 
infection, cells were harvested the MFI of eGFP expressing cells was assessed by flow 
cytometry. The value obtained was then normalised against the MFI of untransduced cells 
analysed  at  the  same  time.  Total  DNA  was  also  extracted  and  used  as  a  template  to 
measure vector DNA. The concentration of DNA obtained was compared with standards to 
evaluate the number of cells in each sample and then used to normalise the number of 
genomes obtained by qPCR. 
 
 
The transfection of a plasmid delivers large quantities of plasmids to cells, whereas 
lentiviral vectors mediate the transfer of genomes at low copy numbers. Therefore, the 
comparison of the results obtained with these systems may not be accurate. Figure 6.6 
indicates that the expression from  a transfected plasmid is  higher compared with  both 
integrating and non-integrating vectors. When similar concentration of DNA was delivered 
to  the cells,  the transfected plasmid expressed  2 fold more protein compared with  the 
integrating lentivector and 2-5 fold more compared with the NILV. 
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6.4 – Discussion 
 
  In  this  work,  NILVs  were  developed  and  applied  in  the  gene  therapy  context, 
showing that these vectors are able to sustain prolonged expression in non-dividing cells, 
both  in  vitro and  in vivo.  It  was  also  shown that  the vector particle production is  not 
affected, that it is possible to achieve high infectious titres, and that viral DNA kinetics are 
similar to the integrating vectors. These results imply that infectivity, reverse transcription 
and nuclear entry of viral DNA are not altered by the introduced mutations. Nevertheless, 
it  was  also  apparent  that  NILVs  have  lower  expression  levels  compared  with  the 
integrating counterpart. 
  When the vector expression cassette used had the p5 promoter driving eGFP as a 
transgene, the expression levels were within the same range, although there was a 2 fold 
difference  in  293T  cells  infected  with  integrating  and  non-integrating  vectors.  This 
difference became more apparent when the expression cassette was changed into the hFIX 
transgene being expressed from the SFFV promoter. In vivo, muscle cells infected with the 
DNW Δatt vector expressed and secreted the transgene into the blood  stream,  but  the 
concentration of plasma hFIX was more than 10 fold lower compared with mice injected 
with the integrating vector. 
  Therefore, in order to optimise expression from the NILVs, it was necessary to 
determine why there was a difference in expression. The previous experiments suggested 
that there was a difference of expression when different promoters were used. Thus, an 
experiment designed to compare expression of the vectors from different promoters was 
performed. Figure 6.1 shows that, regardless of the promoter used, NILVs expressed lower 
concentrations of the transgene. Comparing the differences of expression of eGFP from 
integrating and non-integrating vectors, it becomes apparent that the highest difference 
arises when the SFFV promoter is used (3.4 fold) and the lowest when the p5 promoter is 
used (1.7 fold). Interestingly, the difference of expression of the vectors containing the 
UCOE promoter is similar to the p5 promoter (2 fold). The SFFV promoter is derived from 
the spleen focus-forming virus. It is regularly used in vectors since it is a strong promoter 
producing  high  concentrations  of  the  transgene.  The  spleen  focus-forming  virus  is  a 
replication-defective murine type C virus, and it is incorporated into the target genome   140 
(Ruscetti et al., 1980). On the contrary, the p5 promoter is derived from the AAV, an 
episomal virus. Although the AAV can be found integrated in the target genome, it is 
commonly found in the episomal form.  It is possible that both promoters have different 
characteristics that influence expression when integrated or not into a genome. Hence, it is 
plausible to assume that the p5 promoter would produce similar quantities of RNA whether 
or not it is integrated into the host genome, contrarily to the SFFV promoter. This would 
explain the reason for the observed difference between these promoters in the context of 
integrating  and  non-integrating  vectors.  The  SFFV  promoter  was  then  used  in  further 
experiments to determine the reason for such discrepancies of expression because of the 
larger difference between integrated and non-integrating vectors. 
  In order to investigate why there is a difference of expression between integrating 
and non-integrating lentiviral vectors, it was necessary to determine at which level there 
was an impairment of the expression from NILVs. 293T cells were then infected with both 
vectors  and  viral  DNA,  RNA  and  produced  transgene  were  quantified.  Figure  6.2 
demonstrates that the reduced expression from NILVs is due to a lower transcription level. 
When similar quantities of viral DNA are delivered into the cells, less RNA is produced 
when the viral DNA is episomal, and consequently less protein is detected.  
There are several hypotheses to explain why NILVs have a lower transcription 
activity. There could be a faster promoter methylation in the episomal forms preventing the 
promoter  to  produce  high  concentration  of  RNA  over  time.  Although  valid,  this 
explanation is unlikely. Experiments performed with different promoters were done 48h 
after transduction, a very early time point, where episomal promoters are unlikely to have 
become methylated. Also the UCOE promoter is not easily silenced (Zhang et al., 2007a). 
It is possible that the episomal DNA is not located in an optimal place within the nucleus 
for  access  by  the  transcription  machinery.  Another  explanation  is  the  contribution  of 
surrounding  sequences  when  the  vector  is  integrated  into  the  genome.  Although  the 
integration of lentiviral vectors is not the same for each individual DNA, the vectors tend 
to integrate within highly expressed regions of the genome (Mitchell et al., 2003; Schroder 
et al., 2002). It is therefore possible that on average, the integrated forms of the vectors 
produce more RNA due to the enhancement of the promoter from nearby regions.   141 
It was important to extend this study and compare expression with other episomal 
vectors. The AAV vector is a promising vector for gene therapy, and it has been also used 
to deliver FIX cDNA to muscle cells. Therefore, this natural episomal vector was chosen 
to  evaluate  expression  between  integrating  and  episomal  viral  vectors.  To  compare 
expression between these systems, it is necessary to have the same expression cassette, so 
the SFFV promoter, eGFP and WPRE sequences used in the lentivectors were cloned in 
the AAV vector. The vectors were produced and first titred in 293T cells by measuring the 
concentration  of  transducing  units.  This  was  performed  by  analysing  eGFP  expressing 
cells two days after infection.  
293T cells, dividing and differentiated C2C12 cells were used as models for the 
expression  comparison.  293T  cells  were  chosen,  as  they  are  permissive  for  both  viral 
vectors. The expression of AAV vector may be delayed due to the slow second strand 
synthesis process. Therefore, differentiated C2C12 cells were transduced with the vectors 
and  analysed  12  days  after  and  for  comparison,  infected  dividing  C2C12  cells  were 
assessed  2  days  after  infection.  It  is  important  to  mention  that  to  achieve  a  similar 
percentage of expression positive cells, it was necessary to infect C2C12 cells with 5 fold 
more lentiviral vectors than with AAV vectors. This result indicates that these cells are 
more permissive towards the AAV vectors. 
Cells  were  then  infected  with  serial  dilutions  of  the  vectors.  Expression  was 
evaluated by measuring the MFI of eGFP positive cells. Vector genomes delivered to the 
cells were also quantified in the same samples. From the Figures 6.3 and 6.5, it is possible 
to identify a positive relation between the concentration of transduced vectors or the vector 
copies delivered to the cells and the protein being produced and accumulated in the cells. 
This result is similar in all cells and for all vectors tested. The data suggests that the level 
of vector concentration used in the experiments did not saturate the production of eGFP. 
The cells were then infected with the vectors to obtain a population of 20-40% of 
eGFP expressing cells. By comparing the MFI of the eGFP positive cells, it is possible to 
see that the level of expression from both episomal vectors AAV and NILV is similar and 
lower compared with the integrating vector (Figure 6.4). Most important, the expression 
per copy of DNA delivered by the integrating lentiviral vector is 3-5 fold higher compared 
with both episomal vectors NILV and AAV, regardless of the target cells (Figure 6.5).   142 
The comparison of the concentration of vector copies obtained in C2C12 cells two 
and 12 days after infection shows that there is a reduction of 14 fold for the NILVs but 
only two fold for the integrating lentiviral vectors. The differentiated C2C12 cells are a 
mixed population of terminally differentiated cells and a minority of dividing cells that 
may still undergo cellular division over time. The integrating vector will not be diluted out 
with cell division as the NILV, so this may explain the reduction of the amount of vector 
DNA. The AAV vector is also episomal so, if the rate of dilution due to cell division is 
similar to the NILV, the concentration of AAV vector should also be reduced in the same 
proportion. Nonetheless, the reduction of DNA concentration is similar to the integrating 
vector and not to the NILV. This data implies that although some of the ssDNA delivered 
to the cells may have been lost due to cell division, second-strand synthesis has happened 
and possibly, concatemers and higher order concatemer circles (through a rolling circle 
replication process) have also been formed. Taken together, these results suggest that the 
different sequences necessary and used in the production of both NILV and AAV vectors 
do not influence expression. 
Expression from the integrating and NILVs was also compared with a transfected 
plasmid. Results indicate that the expression from the transfected plasmid is higher than 
from  the integrating and NILVs.  However, the vector  copy number delivered by  each 
system is very different and a comparison may not be accurate as only the highest dilution 
of plasmid transfection and the highest concentration of vector transduction resulted in 
comparable copy numbers being delivered to the cells. 
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7 – Protein Delivery with Lentiviral Vectors 
7.1 – Introduction 
 
The correction of genetic diseases relies mainly in the addition of a correct gene to 
target cells. However, this method has several disadvantages. Viral vectors have a limited 
packaging capacity, restricting the size of the transgene. An example is the dystrophin 
gene, one of the longest genes known, covering 2.4 megabases. Mutations in this gene give 
rise  to  Duchenne  muscular  dystrophy.  However,  the  incorporation  of  such  gene  is 
impossible in the available viral vectors. Another disadvantage is the control of transgene 
expression. The transcription of a gene can be heavily regulated by surrounding sequences. 
An example that demonstrates the importance of such sequences is locus control region of 
the  β-globin,  which  is  involved  in  the  β-thalassemia  genetic  disease.  This  anaemic 
condition  arises  from  the  lack  of  β-globin  protein  and  can  be  caused  by  deletions  or 
mutations of the coding region or its promoter (Grosveld et al., 1987; Van Der Ploeg et al., 
1980). A different approach to the sub-optimal gene addition strategy is gene repair. In this 
technique,  the  mutation  or  deletion  of  a  specific  sequence  is  repaired  by  a  defined 
replacement with a correct sequence, by a process called homologous recombination (HR). 
This enables the production of a correct gene with the control of expression maintained 
from the endogenous regulatory sequences. 
Homologous recombination events are rare. Early reports show that there are 1-10 
events in 10
6 cells transfected with a substrate plasmid (Finn et al., 1989; Thyagarajan et 
al., 1995). However, this process can be enhanced by introducing a double strand break 
(DSB) in the chromosomal target. There are several ways to achieve a targeted DSB, such 
as the use of modified triplex-forming oligonucleotides (shown to increase HR events 3 to 
10 fold, (Faruqi et al., 1996; Sandor and Bredberg, 1995), modified peptide nucleic acid 
(shown to increase HR events 10 to 60 fold, (Faruqi et al., 1998; Rogers et al., 2002), 
modified homing endonucleases or zinc finger nucleases (ZFN). 
NILVs can be used to transiently express homing nucleases or ZFN enhancing HR 
events.  In  one  report,  two  NILVs  were  used  to  deliver  the  template  and  the  homing 
nuclease  I-Sce  I,  resulting  in  gene  correction  in  12%  of  the  target  cells  (Cornu  and   145 
Cathomen, 2007). Using a similar approach, Lombardo and colleagues have shown that 
combining one vector providing the template and two other NILVs to transiently express 
the two required ZFN (the endonuclease used is only active as a dimmer) resulted in up to 
39% of gene editing, with HR accounting for 74% of those events (Lombardo et al., 2007). 
The  strategy  presented  in  both  reports  relies  on  the  infection  of  one  cell  with  all  the 
required vectors. One important aspect to improve the technology would be to decrease the 
number of vectors required to carry the template and the enzymes necessary to increase 
HR events, thus improving the probability of gene repair. This chapter is going to focus on 
the development of a new approach to deliver the template and an enzyme to enhance HR 
within the same vector. The goal of this vector is the delivery to the target cell of a protein 
contained in the viral particle and the template within the vector genome. 
  There have been several reports about the incorporation of foreign proteins into the 
lentiviral particle. Vpr is incorporated into the virion by the interaction with the gag P6 
region during assembly (Paxton et al., 1993). It was shown that a Vpr-GFP fusion protein 
could be efficiently incorporated into viral particles (McDonald et al., 2002). Other fusion 
proteins that allow the incorporation of foreign proteins into the virion particles were also 
constructed, such as Nef-GFP (Welker et al., 1998), several gag-GFP fusions (Sandefur et 
al., 1998; Sherer et al., 2003) and E.coli lex A repressor fused to integrase (Holmes-Son 
and Chow, 2002). The work presented here relies on the insertion of a foreign protein in 
gag by fusion with the P2 protein. This is a 14 amino acid protein that separates capsid 
(CA) and nucleocapsid (NC). During maturation, the viral protease (Pro) cleaves gag and 
gag-pol generating the structural proteins matrix (MA), CA, NC and P6 that assemble and 
form  the  virion  particle,  also  producing  the  spacer  proteins  P1  and  P2.  It  has  been 
hypothesised that P2 has a role in the regulation of the proteolytic process. Nevertheless, 
the deletion of this protein had little effect on particle release (Krausslich et al., 1995; 
Pettit et al., 1994). Also, when 5 amino acids of the P2 protein were deleted (aa 6-10), 
virion particle production was similar to the wild type virus although viral replication was 
delayed (Accola et al., 1998).  
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7.2 – Production of vectors for delivery of proteins 
 
  In order to maximise the number of foreign protein molecules within the virion, the 
strategy adopted here was to incorporate the foreign protein within gag, fusing it in the 
middle  of  the  viral  protein  P2  (Figure  7.1  –  P2mut).  The  hypothesis  is  that  during 
maturation, the viral protease will cleave gag releasing the foreign protein inside the virion. 
However, it has been proposed that the P2 protein is necessary for the correct maturation 
of  the  virion  particles.  Therefore,  a  different  strategy  was  also  planned  in  order  to 
introduce the foreign protein in gag but leaving an intact P2 protein. In this approach, the 
amino acid sequence necessary for the recognition and cleavage of gag in the boundary of 
P2 and NC proteins  was  duplicated in  the P2-NC  region  (Figure 7.1  -  P2ins) and the 
foreign protein will then be incorporated between P2 and NC. During maturation, the viral 
protease may recognise and cleavage gag between CA and P2 and the junctions P2-X and 
X-NC will potentially be recognised and cleaved as a normal P2-NC boundary, releasing 
the foreign protein (X) and the native P2 protein.  Therefore, in  the P2mut vector, the 
foreign  protein  will  carry  the  extra  amino  acids  AEAMSS  in  the  c-terminus  and 
GTNPATIM in the n-terminus resulting from the fusion with the P2 protein. In the P2ins 
vector, the cleaved protein will carry IQNGNS in the c-terminus and GPATIM in the n-
terminus. 
The packaging plasmid of the lentiviral vector was then mutated to facilitate the 
cloning  of  the  foreign  protein.  Since  there  was  no  BspE  I  restriction  site  within  the 
plasmid, amino acids 6 and 7 of the P2 protein where mutated from valine and glutamine 
to serine and glycine to produce a unique restriction sequence within gag in the region of 
P2,  creating  the  packaging  plasmid  P2mut.  For  the  second  strategy,  several  sequential 
rounds of site directed mutatagenesis were done in the packaging plasmid to introduce the 
required sequences in gag to create the packaging plasmid P2ins. The packaging plasmids 
were then sequenced to confirm the correct mutations or nucleotide insertions. 
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Figure 7.1: Schematic representation of the strategy adopted to insert a foreign protein in 
the P2 region of gag. 
 
 
  Lentiviral  vectors were  produced using the native P2 (P2wt), P2mut and P2ins 
packaging plasmids and an expression cassette containing eGFP being driven by the p5 
promoter.  Vectors  carrying  normal  and  mutated  forms  of  gag  were  also  produced  by 
transfecting the produced cells with a 1:1 ratio of normal packaging plasmid P2wt, and the 
P2mut  or  P2ins  packaging  plasmids.  Production  was  assessed  by  measuring  the 
concentration of RT in the vector preparations. Infectivity was measured by infecting 293T 
cells with 50ng(RT) of vectors and assessing the percentage of eGFP positive cells by flow 
cytometry 3 days after transduction. 
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Figure 7.2: Infectivity of vectors harbouring mutations in the P2 region of gag. 
The P2 region of gag was mutated in order to introduce a unique restriction site (P2mut) or 
to introduce a second P2/NC protease cleavage site (P2ins). Vectors were produced with 
these packaging plasmids or with a combination of the packaging plasmids expressing a 
native gag protein, in a ratio 1:1. All vector expressed eGFP from the p5 promoter. 293T 
cells  were  infected  with  the  same  RT  concentration  of  each  vector  (50ng(RT)).  The 
percentage  of  cells  expressing  eGFP  was  assessed  by  flow  cytometry  3  days  after 
infection. 
 
 
All of the vectors produced with P2mut or P2ins (or with a combination with P2wt) 
had similar levels of RT (between 4.5 – 7.2ng(RT)/µL), which were 10 fold lower compared 
with an integrating vector produced with the P2wt, implicating that the vectors could be 
produced, although at a lower concentration. Figure 7.2 demonstrates that all the vectors 
are able to infect 293T cells, but with different efficiencies. When the vectors contain only 
the mutant gag protein, the percentage of eGFP expressing cells was much lower than 
when the vector contained the native gag protein. The percentage of eGFP positive cells 
was 79% in cells infected with the P2wt vector and only 2.7% and 0.1% in cells infected 
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with  the  P2mut  and  P2ins  vectors,  respectively.  Nevertheless,  infectivity  of  vectors 
produced from cells transfected with a mixture of native gag and mutated gag was almost 
restored to P2wt levels, as cells infected with these vectors were 59-66% eGFP positive. In 
this  experiment,  no  major  differences  were  discovered  between  the  two  different 
approaches to incorporate a foreign protein into the lentiviral vectors. Therefore, it was 
decided to carry the study with only one of the developed vectors. The P2ins vector was 
chosen as the P2 protein would still be contained in the virion. eGFP was then cloned in 
the restriction site of P2ins, by PCR cloning. The atg start codon was introduced just after 
serine, and the stop codon of eGFP was mutated to glycine. 
 
In order to determine if the eGFP protein was processed correctly within the viral 
particles, the vectors P2insGFP and P2wt-P2insGFP (proportion of 1:1 between native gag 
and eGFP fused to gag) were produced and a western blot was done to the viral particles to 
detect eGFP. Total protein in the viral stocks was determined and similar quantities of 
protein were loaded in the gel. As a positive control, cells stably infected with a lentivector 
expressing eGFP were also contained in the western blot. 
 
Figure 7.3 demonstrates that the processed eGFP protein can be detected in both 
vectors. As expected, the eGFP protein contained in the viral particles was slightly heavier 
than eGFP produced in the cells. This shift in the eGFP weight was due to the extra 10 
amino acids that the protein now carries as result of the fusion with gag. The eGFP protein 
in the produced vectors is well processed, as there are little heavier eGFP containing bands 
(unprocessed gag containing eGFP) being detected. Also,  it is possible to  see that the 
vector  containing  only  gag-eGFP  has  more  eGFP  protein  compared  with  the  vector 
carrying a mixture of both native gag and gag-eGFP fusion. 
 
 
   150 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Western blot of lentiviral vectors carrying eGFP protein 
The  eGFP  sequence  was  introduced  in  the  packaging  plasmid  P2ins  in  the  BspE  I 
restriction  site.  Vectors  were produced  with  this  packaging  plasmid or with  a mixture 
containing the P2ins and P2wt packaging plasmids in a proportion 1:1. A western blot was 
then performed to 10μL of concentrated viral lysates (50ng(RT)) and 12μg of total protein 
extracted from cells expressing eGFP. eGFP was detected using an antibody that binds to 
that protein.  
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7.2 – Protein delivery to cells by lentiviral vectors 
 
It was established that it is possible to incorporate a foreign protein within gag, by 
fusion  with  the  P2  protein,  with  good  protease  processing.  Also,  the  two  strategies 
designed to fuse the foreign protein with P2 were similar, so it was decided to use only one 
of the developed packaging plasmids (P2ins) to test protein delivery. 
Vectors were then produced with DsRed as a transgene and tested in vitro in 293T 
cells  to  study  protein  delivery  to  cells.  Since  the  fluorescent  protein  eGFP  would  be 
transported in the viral particle, a pilot experiment was performed to determine at which 
time after infection it would be best to assess protein delivery. Hence, 293T cells were 
infected with 10μL of concentrated vectors and harvested at several time points to assess 
eGFP positive cells by flow cytometry. 
 
 
 
  Figure 7.4 shows that it was possible to detect green cells as early as six hours, but 
the percentage of eGFP positive cells diminishes afterwards, for the vector produced with a 
mixture of the native and mutated gag protein  - P2wt:P2insGFP (in a 1:1 proportion). 
Conversely,  DsRed  positive  cells  were  only  detected  24h  after  transduction,  and  the 
percentage of DsRed positive cells increased in the 48h time point. Therefore, the best time 
to assess protein delivery is less than 24h after infection. However, to test infectivity, it is 
better to wait at least 48h following transduction with the vectors. 
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Figure 7.4: Protein delivery to cells from vectors carrying eGFP 
293T cells were infected with 50ng(RT) of vectors carrying eGFP and expressing DsRed as 
a  transgene.  The  percentage  of  eGFP  and  DsRed  positive  cells  was  assessed  by  flow 
cytometry at several time points after infection. Graphs with the data obtained over time 
were generated (B). A dot blot of a sample analysed is shown as an example (A) 
B 
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In  order  to  study  if  the  vector  is  able  to  achieve  protein  delivery  into  the  cell 
cytoplasm, an experiment was designed to visualise cells infected with vector carrying 
eGFP  fused  to  gag.  293T  cells  were  infected  with  50ng(RT)  of  P2insGFP  and 
P2wt:P2insGFP vectors expressing Ds-Red as a transgene. Twenty hours after infection, 
cells were fixed with PFA, washed and stained with phalloidin. This peptide binds actin 
and can be conjugated with fluorescent analogs permitting the visualisation of actin in the 
cells by confocal microscopy. Actin is a protein found in the cytoplasm of cells. Therefore, 
actin was used as a marker to delimit the cytoplasm of cells in confocal microscopy. The 
infected cells were then visualised in a confocal microscope. 
 
Figure 7.5 shows that it was possible to detect green spots, with a fluorescence 
intensity well above the background. These spots may correspond to viral particles, viral 
aggregates or VSVg vesicles carrying the eGFP protein. The vectors are probably able to 
attach the cells but internalisation may be poor as the majority of green spots were detected 
outside the cells. Green dots were seen inside cells but, this event was rare. It is possible 
that  the  concentration  of  eGFP  delivered  to  cells  is  not  sufficient  to  allow  efficient 
detection of the protein in the cytoplasm of target cells.   154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5: Visualisation of cells infected with a lentiviral vector carrying eGFP protein. 
293T cells were infected with 50ng(RT) of lentiviral vectors produced with a packaging 
plasmid containing eGFP protein inserted in the P2 region of the gag protein and a plasmid 
with wt gag protein, in a proportion 1:1 (P2wt-P2insGFP). Twenty hours after infection, 
the cells were fixed. β-actin was stained with phalloidin conjugated with Alexa Fluor 488 
and  the  genetic  material  with  Dapi.  The  cells  were  then  visualised  using  a  confocal 
microscope. An example of pictures taken at different z sections (height) of cells infected 
with the P2wt-P2insGFP vector and a picture taken to untransduced cells are shown. In the 
image,  red  represents  β-actin,  blue  the  DNA,  green  the  eGFP  and  arrows  indicate 
intracellular eGFP. 
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(Top section) 
Neg Ctr 
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7.3 – Discussion 
 
  The aim of the work presented in this chapter was the improvement of vectors for 
gene repair. Gene repair can be accomplished in cells by homologous recombination, a rare 
event in cells that can be increased by introducing double strand breaks in the target gene. 
Recent reports have shown that it is possible to increase gene repair by delivery to the cells 
with a donor sequence and introducing a specific DSB using a zinc finger nuclease or a 
homing endonuclease. Nevertheless, both donor sequence and enzyme to increase HR have 
been delivered to cells  in  different  vectors, thus  relying on chance for the cells  to  be 
infected  with  all  the  vectors  necessary  to  achieve  gene  repair.  Here,  a  vector  was 
engineered  to  achieve  protein  delivery.  The  developed  vector  would  deliver  a  foreign 
protein within the viral particle, and the vector genome would be able to supply the donor 
sequence for homologous recombination. To incorporate the protein into the viral particle, 
there have been several reports that fuse foreign proteins with Vpr and other structural 
proteins of the virions. This is a novel vector where a foreign protein would be fused to 
gag in the P2 region. 
  Two approaches were conceived to achieve the goal. In one, the foreign protein 
would be fused in the middle of the viral P2 protein. In this case, the P2 protein would be 
disrupted and the foreign protein would be released in the virion upon cleavage by the viral 
protease in the maturation stage of the vector production. It has been shown that P2 is 
involved in correct maturation of the virus particle. However, deletion of 6 amino acids 
was well tolerated, and virus produced with this deletion had only delayed infectivity. In a 
second  approach,  the  foreign  protein  was  incorporated  also  in  the  P2  region,  without 
disruption  of  this  small  protein.  The  protease  cleavage  site  between  P2  and  NC  was 
duplicated, and the foreign protein was introduced in gag between these protease cleavage 
sites. Therefore, during maturation, the foreign protein would be released by cleavage of 
gag, but an intact P2 protein would be present in the virion for correct maturation of the 
viral particle. 
  It was shown that when the P2 protein was mutated in order to introduce a unique 
restriction site, to easily clone the foreign protein in gag, the infectivity of the vector was   156 
diminished (Figure 7.2). Also, when the P2-NC protease cleavage site was duplicated and 
the unique restriction site was introduced between the duplicated cleavage sites, the vector 
lost infectivity. Nevertheless, infectivity was restored almost to wild type levels when the 
production of vector was made with a mixture of wt gag and mutated gag. Since both 
approaches had similar results, it was opted to continue the study with only one of the 
developed vectors. The P2ins vector was chosen, as there are no deletions of viral proteins, 
minimising possible problems in maturation related to the lack of P2 protein in the virion. 
  eGFP was then fused as a model to study protein delivery with this vector. It was 
demonstrated that the eGFP is well processed as almost all the eGFP contained in the 
virions was cleaved (Figure 7.3). It was seen that when a mixture of wt gag and gag-eGFP 
fusion was used to produce the vectors, the quantity of eGFP in the virions was lower 
compared when virions were produced with only gag-eGFP fusion. 
  Protein delivery was then assessed by infecting 293T cells with vectors carrying 
eGFP protein in the viral particle. It was determined that the best time to assess protein 
delivery would be less than 24h after infection, as after this time point, the percentage of 
eGFP positive cells diminished (Figure 7.4). Protein delivery was studied in more detail, to 
determine if the vectors were able to efficiently deliver eGFP into the cytoplasm of cells. 
Cells were infected with viral particles carrying eGFP and visualised under a confocal 
microscope. The eGFP protein was easily detected, as the fluorescence level was well 
above the background. It was hypothesised that the fluorescence spots may correspond to 
vectors carrying the eGFP protein. Most of the eGFP spots were detected outside the cells, 
and only in some rare events, spots were detected in the cytoplasm. It is possible that the 
concentration of eGFP delivered to cells is not sufficient to distinguish fluorescent cells 
from background, so the result is inconclusive. However, it supports the hypothesis that the 
concentration of protein delivered to cells is not very high. Therefore, these vectors may 
not be efficient enough to be used as tools for gene repair. The measurement of gene repair 
efficiency with this system may elucidate this question. 
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8 – Final Discussion 
 
Gene therapy is a technique where a DNA sequence is introduced into a cell by the 
use  of  a  vector.  There  have  been  enormous  advances  in  the  development  vectors  to 
optimise gene delivery. Vectors based on adenoviruses, adeno-associated viruses (AAV), 
retroviruses and lentiviruses among others, have been used to exploit the natural properties 
of  infection.  It  has  been  demonstrated  that  gene  delivery  by  such  vectors  is  high  and 
efficient,  although  with  different  levels  of  success,  depending  on  the  models  used. 
Recently,  results  from  clinical  trials  were  reported,  demonstrating  efficient  disease 
correction  by  gene  therapy  (Cavazzana-Calvo  et  al.,  2000;  Gaspar  et  al.,  2004). 
Nevertheless, it was later reported that one of the patients had developed a monoclonal 
lymphoproliferative disease and since then, other patients have developed similar forms of 
leukaemia  (Hacein-Bey-Abina  et  al.,  2003a).  The  T-cell  clones  from  the  patient  were 
analysed  revealing  the  integration  of  the  vector  in  the  proximity  of  the  LMO2  proto-
oncogene promoter, leading to aberrant transcription and translation of the gene product 
(Hacein-Bey-Abina et al., 2003b). The leukaemias in this trial represented the first reports 
of insertional mutagenesis in humans by gene therapy vectors and prompted a detailed 
research to study how integration by viral vectors occurs. It has been shown that lentiviral 
vectors  integrate  preferentially  within  highly  expressed  genes,  and  gammaretroviruses 
integrate preferentially near transcription start sites (Mitchell et al., 2004; Schroder et al., 
2002; Wu et al., 2003), demonstrating that the integration preferences of these vectors are 
different and thus, the safety profile may also differ. 
Integration  is  an  important  feature  of  retroviral  and  lentiviral  vectors,  enabling 
transgene expression in dividing cells infected with the vectors. Nevertheless, when only 
transient expression in dividing cells or stable expression in non-dividing cells is required, 
integration from the vectors may not be necessary. Therefore, the development of non-
integrating lentiviral vectors may prove to be an important and safer tool for gene therapy. 
In  a  previous  report,  mutations  in  the  viral  HIV  integrase  produced  replication 
defective viruses. Although the mutant virus production was similar to the wild type virus, 
the viral gene expression was impaired (Wiskerchen and Muesing, 1995). Furthermore, the   159 
development of non-integrating lentiviral vectors (NILVs) by the mutation of the viral 
integrase  in  first  generation  lentiviral  vectors  demonstrated  that  normal  levels  of  viral 
DNA  could  be  detected  after  infection  of  target  cells  (Leavitt  et  al.,  1996).  However, 
expression from these vectors was negligible (Blomer et al., 1997).  
A  major  improvement  towards  the  safety  of  vectors  for  gene  therapy  was  the 
development of self inactivating (SIN) vectors (Zufferey et al., 1998). In these vectors, a 
large part of the U3 region in the 3’LTR was deleted, abolishing the viral promoter activity 
and allowing transgene expression to be controlled by the incorporation of an internal 
promoter. Recently, it was demonstrated that the viral DNA generated by non-integrating 
lentiviral vectors using the SIN version is capable of efficient expression (Yanez-Munoz et 
al., 2006). Another report demonstrated that use of non-SIN or SIN vectors is the reason 
for the discrepancy in expression from these non-integrating vectors, possibly due to a 
sequence element within the U3 region of the viral LTR that reduces expression (Bayer et 
al., 2008). 
The aim of the work presented in this thesis was to further develop the research in 
this new field of viral vectors for gene therapy. In order to produce NILVs, there are two 
possible approaches. The enzyme responsible for integration can be mutated, or the viral 
sequence  for  integrase  recognition  can  be  altered.  In  this  context,  the  combination  of 
several mutations may improve the safety of the developed vectors. Several mutations in 
integrase have been published in the literature where, although integration of the vector is 
impaired,  infectivity  is  not  affected.  Any  mutation  in  the  catalytic  motif  of  integrase 
(DD35E) impairs integration (Leavitt et al., 1996). The vector used by Yanez-Munoz and 
colleagues to demonstrate that NILVs are able to sustain expression in cells has a mutation 
in  the  D64  residue.  Other  mutations  have  been  suggested  to  affect  specific  steps  of 
integration and were therefore chosen to be studied here. N120L and W235E mutations do 
not impair integration in vitro. Vectors harbouring these mutations are not able to complete 
integration in cells upon infection, but it was postulated that these residues are related to 
host DNA recognition (Leavitt et al., 1996). The mutation Q148A blocks integration and 
has been implicated in the recognition of viral DNA (Esposito and Craigie, 1998; Gerton et 
al.,  1998).  Also,  the  mutations  K264,266,273R  have  been  shown  to  reduce  integrase 
activity due to the lack of acetylation on those residues. Additionally, the mutation of the   160 
conserved dinucleotides CA (attachment sites) to TG in the vector genome has been shown 
to impair integration (Masuda et al., 1998). 
All  of  the  mutations  detailed  were  introduced  in  the  lentiviral  vectors  by  site 
directed mutagenesis. Vector production was then assessed by the measurement of viral 
particles  (by  quantifying  the  concentration  of  p24  protein)  and  infectivity  by  the 
measurement of transducing units. All vectors produced had similar concentrations of p24, 
indicating that vector production was not affected, as previously published. High titres 
were achieved for all mutant vectors, demonstrating that infectivity was also not altered. 
Dividing cells were then infected with the vectors and expression was assessed over time. 
If the viral DNA does not become integrated, the DNA is lost over time due to dilution or 
degradation of the DNA and thus, expression is transient. Expression from all the vectors 
was detected in 293T cells at an early time point but it decreased afterwards for all NILVs. 
In contrast, the cells infected with the integrating vector maintained expression throughout 
the  course  of  the  experiment.  These  results  suggested  that  the  mutations  introduced 
impaired viral integration. 
It was necessary to assess integration in more detail, so an assay was established to 
measure  background  integration  enabling  the  quantification  of  integration  and  the 
comparison with the integrating vector. This assay relied on the expression of a transgene 
that confers resistance to G148. The dividing cells that have the vector integrated in the 
genome stably express the transgene and survive over time, but in contrast, cells that lost 
the viral  DNA would die. The results  from  this  experiment  show that the background 
integration  was  different  among  the  vectors.  The  D64V,  N120L  and  W235E  vectors 
exhibit the lowest level of integration, being 10
3 fold lower compared with the integrating 
vector. The Q148A, K264R and K264,266,273R vectors integrated the viral DNA 13, 3 
and 14 fold lower, respectively, than the integrating vector. The vector carrying the att 
mutation had a 100 fold difference in integration compared with the integrating vector. All 
these results are in accordance with previous studies (Cereseto et al., 2005; Esposito and 
Craigie, 1998; Gerton et al., 1998; Leavitt et al., 1996; Masuda et al., 1998). Therefore, it 
is possible to conclude that the produced vectors are integration defective. These results 
correlate well with the expression data collected over time from infected cells. Transgene 
expression in cells infected with the low integrating NILVs D64V, N120L and W235E   161 
could  not  be  distinguished  from  background  15  days  after  infection.  However,  cells 
infected with the vectors Q148A, K264R and K264,266,273R were still expressing the 
transgene  at  that  time  point,  although  the  percentage  of  expressing  cells  was  lower 
compared with cells infected with the integrating vector. 
The  mutations  that  had  the  highest  impact  on  integration  (D64V,  N120L  and 
W235E) were then combined and vectors harbouring the 3 mutations in integrase with or 
without  the  mutant  att  sites  were  produced.  As  with  the  previously  tested  NILVs, 
production and infectivity of these vectors was similar to the integrating vector, and 293T 
cells infected with these vectors expressed the transgene transiently. The quantification of 
the background integration revealed that the DNW mutant vector integrates on average 
1.4x10
3  fold  lower  than  the  integrating  vector  and  in  combination  with  the  att  sites 
integration is lowered 3x10
3 fold on average. Although this represents a decrease of 1.4 to 
3 fold of the background integration compared with the single mutant vectors, it is not 
statistically different, so it is not possible to infer that the combination of the mutations has 
a synergetic or additive effect on integration impairment. This is in accordance with a 
previous study where the mutant att sites were combined with the D64V integrase mutation 
(Nightingale et al., 2006). These multiple mutant vectors present an advantage in safety, 
compared  with  single  mutant  NILVs.  Mutations  may  occur  in  the  packaging  plasmid 
during viral production or plasmid preparation. One of such mutations may restore the 
enzymatic activity of integrase. Therefore, the multiple mutation combination may reduce 
the potential for reversion back to an integrative phenotype. Also, the mutation in the att 
site has the advantage to prevent rescue of the vector if the target cell becomes infected 
with a wild type virus. 
Viral DNA accumulation in cells infected with the lentivectors was also studied. It 
was shown that viral DNA could be detected as early as three hours post infection and that 
the formation of viral DNA circles occurs after that for both integrating and NILVs. Total 
viral  DNA  was  quantified  in  cells,  48h  after  infection.  Results  demonstrate  that  the 
concentration of viral DNA is similar for all integrating and non-integrating vectors, so it is 
possible to conclude that the studied integrase defective vectors do not have an impact on 
reverse transcription.   162 
It  was  shown  that  NILVs  are  able  to  deliver  viral  DNA  to  target  cells  but 
expression is transient. There are several applications for such vectors. An example is the 
temporary expression of HoxB4 in haematopoietic stem cells. This protein has been shown 
to increase self-renewal and promote expansion of these cells (Antonchuk et al., 2002). 
However, the permanent production of such protein can have adverse effects on the cells 
(Zhang et al., 2007b; Krosl et al., 1998). Due to the capacity of lentiviruses to infect such 
cells, NILVs would make very good vector candidates to accomplish this task. Another 
interesting  application  of  such  vectors  is  vaccination.  Lentiviral  vectors  efficiently 
stimulate cell-mediated and humoral immunity, following subcutaneous and intramuscular 
immunization. Indeed, NILVs have been shown to be efficient immunogens with long-
lasting  immune  responses  (Karwacz  et  al.,  2009;  Negri  et  al.,  2007).  If  prolonged 
transgene  expression  is  required,  the  NILVs  could  also  be  modified.  One  interesting 
development  would  be  the  incorporation  of  a  replication  signal  or  a  scaffold/matrix 
associating region (S/MAR). In such a vector, the risk of insertional mutagenesis would 
not be present but the transgene would be stably expressed both in dividing and non-
dividing cells. It has been previously shown that it is possible to incorporate the simian 
virus  40  (SV40)  oriT  into  NILVs  allowing  the  maintenance  of  the  episomal  DNA  in 
dividing  cells,  without  reversion  back  to  an  integrative  phenotype.  Replication  and 
expression from that vector was sustained for up to 56 days in cells that express the T-
antigen, but in cells that do not express the T-antigen, stable expression was not seen (Lu 
et al., 2004; Vargas, Jr. et al., 2008). Nonetheless, these vectors would carry a risk of 
mutagenesis due to the presence of the SV40 oriT. Up until now, no NILV incorporating 
an S/MAR that is retained in dividing cells has been reported. NILVs are able to deliver 
DNA to the cells without integration into the genome, so a different strategy for stable 
expression in dividing cells would be the integration of the vector genome in a safer way, 
such as the use of a different enzyme to mediate this process. One example is the Rep 
protein from AAV. This protein can site-specifically integrate DNA substracts into the 
human genome, including circular DNA (Kotin  et  al., 1990). Therefore, an interesting 
development would be the combination of this enzyme with the delivery of the target DNA 
mediated by NILVs. Other examples include the phage ʦC31 integrase, the Cre and Flp 
recombinases and the Sleeping Beauty transposase. The DNA delivered by NILVs may   163 
also be used as a template for homologous recombination. This strategy has been used by 
combining  several  NILVs  to  deliver  the  DNA  template  and  enzymes  to  enhance 
homologous  recombination  demonstrating  the  potential  of  these  vectors  in  gene  repair 
(Cornu and Cathomen, 2007; Lombardo et al., 2007). However, if the target cells are not 
dividing then the episomal DNA may be maintained in the cells. Indeed, NILVs have been 
previously tested in retina and brain tissues. It was demonstrated that cells in these post-
mitotic tissues infected with  NILVs display stable and prolonged transgene expression 
(Philippe et al., 2006; Yanez-Munoz et al., 2006). Here, it was decided to extent this work 
and study the application of NILVs for gene delivery to muscle cells. 
The developed NILVs were first tested in C2C12 muscle cells in vitro. In contrast 
with  dividing  cells,  differentiated  C2C12  cells  maintained  expression  over  time, 
demonstrating that these vectors can stably express a transgene in non-dividing cells. The 
vectors were then tested in vivo, by injecting mice in the tibialis anterior muscle. It was 
demonstrated that the vectors are able to infect muscle cells in vivo. Most importantly, it 
was shown that the vectors are able to sustain transgene expression over time for up to 
eight months post injection. The quantification of transgene expression revealed that all 
vectors  expressed  the  transgene  at  high  levels  (0.01-0.1%  of  total  protein).  The 
quantification of viral DNA in non-dividing cells revealed that the episomal vectors are not 
degraded over time and also that 2LTR circles levels were higher for NILVs, compared 
with the integrating vector. These results were well documented both in vitro and in vivo. 
This may be explained by assuming that the newly transcribed viral DNA, which does not 
serve as a template for integration, is therefore more available for circularisation. This 
result also indicates that the mutations in the vectors did not impair the viral DNA nuclear 
entry. 
NILVs were then tested in a disease model. The model chosen was haemophilia B, 
due to the low immunogenicity of the vectors and the requirement of a relatively low 
protein production for disease amelioration. Also, it has been proven that it is possible to 
achieve disease amelioration by the production of FIX from muscle cells (Herzog et al., 
1997). Therefore, the aim of this work was to evaluate disease correction of haemophiliac 
mice by integrating and non-integrating lentiviral vectors injected intramuscularly.   164 
It was demonstrated that it is possible to quantify FIX from the supernatant of 
infected  293T  and  C2C12  cells  and  also  in  the  blood  of  injected  mice.  However,  the 
concentration of circulating FIX obtained with the injection of the integrating vector in 
mice was low. It was then necessary to improve vector expression. To achieve that, a 
codon optimised version of hFIX was used. Also, this cDNA was mutated in order to 
decrease the binding of the secreted transgene to collagen IV. The results demonstrate that 
the mutations introduced to FIX increased the concentration of plasma FIX, but it was not 
clear if the codon optimisation had a positive effect  on  transgene  expression.  In mice 
injected with NILVs, the values of plasma FIX remained very low even using the best 
expressed  and  secreted  transgene  with  the  highest  vector  concentration.  However,  the 
levels of hFIX produced in mice infected with the integrating lentiviral vector were always 
above the therapeutic threshold, indicating that gene therapy with this vector may achieve 
disease amelioration. Muscle cells may not be very permissive towards lentiviral vectors 
pseudotyped with VSVg. An indication for this was the necessity to infect C2C12 cells 
with MOI 10 to obtain 30% of transgene expressing cells. Therefore, the use of a more 
suitable envelope may increase vector infectivity thus enhancing protein production from 
these cells. Another possibility to improve protein production would be the repetition of 
vector  injection.  Therefore,  integrating  lentiviral  vectors  may  be  useful  tools  for  the 
treatment of haemophilia B. 
Taking all the results obtained in vivo together, it was possible to conclude that the 
integrating vector expresses more transgene than the NILVs. This prompted a new project 
to  study  the  reason  for  lower  expression  from  NILVs  compared  with  the  integrating 
lentiviral vectors. The expression obtained from integrating and non-integrating vectors 
using different promoters to drive transgene expression was evaluated in 293T cells. The 
promoters  chosen  for  this  study  were  the  strong  viral  promoter  SFFV,  the  weak  p5 
promoter from the natural episomal virus AAV, and the UCOE element, an enhancerless 
promoter involved in chromatin organisation. The results obtained show that, regardless of 
the promoter used, NILVs express less transgene than the integrating vector. Nevertheless, 
the  differences  in  expression  were  different.  There  was  a  3.4  fold  difference  between 
integrating and NILVs using the SFFV promoter and only a 1.7 fold difference with the p5 
promoter. As the first is derived from an integrating virus and the second from an episomal   165 
virus, a hypothesis to explain the difference is that the p5 promoter may be less susceptible 
to influences from nearby sequences if the vector is integrated in the host genome, in 
contrast to the SFFV promoter. On the other side, it is possible to assume that the p5 
promoter may be less affected than the SFFV promoter if the DNA is episomal and not in 
an optimal location for expression. 
In order to investigate the reason for the lower expression from NILVs, DNA, RNA 
and transgene produced in cells were measured and compared with the integrating vector. 
It was demonstrated that when similar concentrations of DNA are delivered to cells, the 
levels  of  RNA  produced  from  the  episomal  NILVs  were  lower  compared  with  the 
concentrations  obtained  for  the  integrating  counterpart.  This  lower  RNA  concentration 
related to the lower protein concentration being produced. Then, it is possible to conclude 
that  NILVs  display  lower  transcription  activity  compared  with  integrating  lentiviral 
vectors. 
This study was further developed by comparing expression from integrating and 
NILVs with AAV vectors and transfected DNA. Since these systems are very divergent, a 
comparison is difficult. The experiment had to be designed in order to take into account 
several differences. The lentivector genome is RNA and needs to be reverse transcribed 
upon cell entry whereas the AAV vector delivers a ssDNA that, upon a slow process of 
second-strand  synthesis,  forms  a  transcriptionally  active  DNA  molecule.  Both  vectors 
infect  dividing  and  non-dividing  cells,  but  a  plasmid  DNA  molecule  is  not  efficiently 
transfected in terminally differentiated cells. Also, target  cells can be more permissive 
towards one of the vector systems. Another difference between the viral vectors is the need 
of particular cis sequences. The AAV vector only requires the inverted terminal repeats 
(ITRs).  Apart  from  the  long  terminal  repeats  (LTRs),  packaging  signal,  PPT  and  the 
central  polypurine  tract  (cPPT),  lentivectors  also  use  a  sequence  (WPRE)  to  export 
unspliced RNA to the cell cytoplasm. This element is used to increase the vector titre and 
is located between the transgene and the 5’LTR. Therefore, the SSFV promoter, eGFP and 
the  WPRE  sequence  were  cloned  into  an  AAV  vector.  The  plasmid  chosen  to  be 
transfected was the lentivector so that all vectors had the same expression cassette. 
Expression was compared in 293T cells, as these dividing cells are permissive for 
all  the  vector  systems.  Cells  were  transfected  or  infected  with  serial  dilutions  of  the   166 
vectors. Two days after, expression and vector copy number were assessed. Data shows 
that, when similar quantities of DNA are delivered into cells, both episomal viral vectors 
AAV and NILV had similar levels of expression, but 4-5 fold lower compared with the 
integrating lentivector. Cells transfected with a plasmid had a 2 fold higher expression 
compared with the integrating lentiviral vector. However, plasmid transfection delivers a 
very large quantity of DNA to cells, so the comparison may not be appropriate. 
The expression was also compared between integrating and episomal viral vectors 
in  C2C12  cells.  These  cells  were  analysed  2  days  (dividing  cells)  and  12  days 
(differentiated cells) after infection in  order to compensate  for  a possible delay of the 
expression from the AAV vector due to the slow second-strand synthesis. Regardless of 
the time point, expression from the AAV vector was similar to the NILV and both were 
lower compared with  expression from  the integrating lentiviral  vector. The  viral  DNA 
concentration in cells, 12 days after infection with the NILV, diminished 14 fold compared 
to cells tested 2 days after infection. Possibly, this happened due to dilution by some cell 
division. However, for the AAV vectors, the DNA concentration was only two fold lower 
in the last time point. If the rate of dilution due to cell division is similar between NILV 
and AAV vectors, then it is possible to infer that the AAV vector DNA has completed the 
second-strand process and may even have formed concatemers (or higher order concatemer 
circles by rolling circle replication). Therefore, the lower expression levels compared with 
the integrating vector cannot be explained by a lack of second-strand synthesis. 
AAV vectors are natural episomal vectors nonetheless, the results demonstrate that 
these vectors do not possess any advantage in expression over NILVs and even have a 
lower expression compared with the integrating lentivectors. Therefore, it is possible to 
conclude that the sequences present in the AAV vector, namely, the ITRs, do not influence 
expression.  The  discrepancy  in  expression  between  integrating  and  NILVs  may  be 
explained by the influence of sequences nearby the insertion sites of the integrating vectors 
or  the  chromatin  structure,  as  it  is  known  that  lentiviral  vectors  tend  to  integrate 
preferentially within highly transcribed regions of the genome. It is important to mention 
that C2C12 cells are more permissive towards AAV vectors than to lentiviral vectors, as it 
was necessary to infect cells with 5 fold more lentivectors to obtain the same percentage of 
transgene expressing cells. This result implies that muscle cells may be more permissive   167 
towards  AAV  vectors,  which  in  turn  may  explain  the  lower  levels  of  FIX  obtained 
injecting the lentivectors intramuscularly in mice, compared with the FIX concentration 
achieved by injection of AAV vectors (Herzog et al., 1997). 
  A different application of NILVs is the enhancement of gene repair. This strategy 
relies on homologous recombination (HR) events between similar sequences using the host 
cell mechanisms.  These events  are rare, but  can be increased by introducing a double 
strand break (DSB) in the target sequence which can be achieved by zinc finger nucleases 
or homing endonucleases. As aforementioned, the approaches published until now rely on 
the  transient  expression  of  such  proteins  using  NILVs  (Cornu  and  Cathomen,  2007; 
Lombardo et al., 2007). Two or more NILVs are necessary to achieve the goal of gene 
repair enhancement. Therefore, these approaches rely on the infection of the target cell 
with all the vectors. Here a new approach where only one NILV would be necessary to 
achieve  enhanced  HR  was  presented.  This  vector  was  designed  to  carry  a  protein  to 
enhance  HR  inside  the  virion.  Several  reports  have  previously  demonstrated  that  it  is 
possible to incorporate additional proteins within the viral particles, by fusing the foreign 
protein to a viral protein such as Vpr, Nef, gag or integrase (Holmes-Son and Chow, 2002; 
McDonald et al., 2002; Sandefur et al., 1998; Sherer et al., 2003; Welker et al., 1998). A 
new approach was developed where the foreign protein would be fused to the viral P2 
protein. Two strategies were designed. In one, the P2 protein was mutated so that a unique 
restriction site would be introduced in the middle of the P2 sequence facilitating the fusion 
of the foreign protein to gag. In a second approach, the native P2 protein in gag would be 
maintained. In this vector, the cleavage site between P2 and NC was duplicated so that the 
foreign protein could be inserted within these sites. Upon maturation, viral protease would 
cleave gag, releasing the foreign protein within the virion. The viral vector would supply 
the  DNA  template  upon  reverse  transcription  of  the  vector  genome,  and  the  protein 
necessary for HR augmentation (a meganuclease, such as I-Sce I) would be carried within 
the viral particle and delivered in the target cell after infection. 
The  two  developed  packaging  plasmids  were  used  to  produce  vectors  carrying 
eGFP as a transgene. Additionally, a mixture of native gag and mutated gag in a proportion 
of  1:1  were  used  to  produce  vectors.  293T  cells  were  infected  with  the  vectors  and 
infectivity  was  assessed  by  measuring  the  percentage  of  eGFP  positive  cells.  It  was   168 
demonstrated  that  the  vectors  produced  from  mutated  gag  plasmids  lost  infectivity. 
Although the concentration of the vector particles produced was similar to the wt levels 
(assessed by measuring the p24 protein), it is possible that the vectors produced were not 
able to incorporate the genomic viral RNA, or that another step in the viral life cycle would 
be impaired, such as reverse transcription or nuclear entry. A report has been published 
implicating that the P2 region may be important for viral RNA recognition, supporting the 
first hypothesis (Kaye and Lever, 1998). Nevertheless, the vectors produced with a mixture 
of wt and mutated gag were almost as infectious as the wt vectors. If the mutated gag 
proteins are not being specifically excluded from the viral particles, it is possible to assume 
that these vectors would be able to achieve protein delivery without disrupting infectivity. 
Since  both  strategies  had  similar  results,  the  P2ins  vector  was  chosen  to  study 
protein delivery to cells. In this context, eGFP was inserted in gag. Vectors were produced 
and protein incorporation in the virions was assessed by western blot. It was shown that the 
eGFP is incorporated in the virion particles and that the protein is well processed by the 
viral protease since most of the eGFP present in the vectors is cleaved. Cells infected with 
the  vector  transporting  the  fluorescent  protein  were  eGFP  positive  (assessed  by  flow 
cytometry).  In order to  study protein delivery  in more detail,  cells  were infected with 
vectors carrying eGFP and visualised by confocal microscopy. It was shown that green 
spots, which may correspond to vectors carrying eGFP, remain mostly in the periphery of 
the cells probably attached to the cellular membrane. It is important to refer that eGFP was 
detected within the cytoplasm of some cells, but this event was rare. The fact that cells 
infected with the eGFP carrying vectors were positive by flow cytometry may be explained 
by the inability of the machine to differentiate between cells that have the protein within 
the cell or only attached to them. Nevertheless, it is also possible that the concentration of 
delivered  eGFP  was  not  sufficient  to  be  above  background  in  order  to  allow  the 
visualisation  of  intracellular  eGFP  by  confocal  microscopy.  This  implies  that  the 
concentration of delivered protein is low and thus, these vectors may not deliver enough 
protein to enhance homologous recombination. It is possible that the developed vectors are 
just not able to infect cells, so a different strategy could be developed. One approach could 
be the fusion of the foreign protein in the end of the viral integrase with the introduction of 
an  extra  protease  cleavage  site  between  IN  and  the  enzyme.  In  conclusion,  the   169 
development of such vectors would potentially create the ideal tool for the treatment of 
genetic  diseases.  These  vectors  would  alleviate  the  risk  of  mutagenesis  correcting 
mutations regardless of whether the target cells were dividing or not. In addition, the target 
gene  would  still  be  expressed  from  the  endogenous  promoter  with  all  the  cellular 
regulatory mechanisms. 
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